0000819118-23-000139.txt : 20230720 0000819118-23-000139.hdr.sgml : 20230720 20230720112923 ACCESSION NUMBER: 0000819118-23-000139 CONFORMED SUBMISSION TYPE: N-CSRS PUBLIC DOCUMENT COUNT: 7 CONFORMED PERIOD OF REPORT: 20230531 FILED AS OF DATE: 20230720 DATE AS OF CHANGE: 20230720 EFFECTIVENESS DATE: 20230720 FILER: COMPANY DATA: COMPANY CONFORMED NAME: FIDELITY CONCORD STREET TRUST CENTRAL INDEX KEY: 0000819118 IRS NUMBER: 000000000 STATE OF INCORPORATION: MA FISCAL YEAR END: 0228 FILING VALUES: FORM TYPE: N-CSRS SEC ACT: 1940 Act SEC FILE NUMBER: 811-05251 FILM NUMBER: 231098686 BUSINESS ADDRESS: STREET 1: 245 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 617-563-7000 MAIL ADDRESS: STREET 1: 245 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: FIDELITY INSTITUTIONAL TRUST DATE OF NAME CHANGE: 19920703 0000819118 S000055366 Fidelity Nasdaq Composite Index Fund C000174185 Fidelity Nasdaq Composite Index Fund FNCMX N-CSRS 1 filing6650.htm PRIMARY DOCUMENT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549



FORM N-CSR

CERTIFIED SHAREHOLDER REPORT OF REGISTERED

MANAGEMENT INVESTMENT COMPANIES



Investment Company Act file number    811-05251



Fidelity Concord Street Trust

 (Exact name of registrant as specified in charter)



245 Summer St., Boston, MA 02210

 (Address of principal executive offices)       (Zip code)



Margaret Carey, Secretary

245 Summer St.

Boston, Massachusetts  02210

(Name and address of agent for service)





Registrant's telephone number, including area code:

617-563-7000





Date of fiscal year end:

November 30





Date of reporting period:

May 31, 2023



Item 1.

Reports to Stockholders







Fidelity® Nasdaq Composite Index® Fund
 
 
Semi-Annual Report
May 31, 2023

Contents

Investment Summary

Schedule of Investments

Financial Statements

Notes to Financial Statements

Shareholder Expense Example

Board Approval of Investment Advisory Contracts

Liquidity Risk Management Program

To view a fund's proxy voting guidelines and proxy voting record for the 12-month period ended June 30, visit http://www.fidelity.com/proxyvotingresults or visit the Securities and Exchange Commission's (SEC) web site at http://www.sec.gov.
You may also call 1-800-544-8544 to request a free copy of the proxy voting guidelines.
The NASDAQ OMXGroup, Inc. (which with its Affiliates are the Corporations) and are licensed for use by Fidelity. The product has not been passed on by the Corporations as to its legality or suitability. The product is not issued, endorsed or sold by the Corporations. The Corporations make no warranties and bear no liability with respect to shares of the product.
Standard & Poor's, S&P and S&P 500 are registered service marks of The McGraw-Hill Companies, Inc. and have been licensed for use by Fidelity Distributors Corporation.
Other third-party marks appearing herein are the property of their respective owners.
All other marks appearing herein are registered or unregistered trademarks or service marks of FMR LLC or an affiliated company. © 2023 FMR LLC. All rights reserved.
This report and the financial statements contained herein are submitted for the general information of the shareholders of the Fund. This report is not authorized for distribution to prospective investors in the Fund unless preceded or accompanied by an effective prospectus.
A fund files its complete schedule of portfolio holdings with the SEC for the first and third quarters of each fiscal year on Form N-PORT. Forms N-PORT are available on the SEC's web site at http://www.sec.gov. A fund's Forms N-PORT may be reviewed and copied at the SEC's Public Reference Room in Washington, DC. Information regarding the operation of the SEC's Public Reference Room may be obtained by calling 1-800-SEC-0330.
For a complete list of a fund's portfolio holdings, view the most recent holdings listing, semiannual report, or annual report on Fidelity's web site at http://www.fidelity.com, http://www.institutional.fidelity.com, or http://www.401k.com, as applicable.
NOT FDIC INSURED •MAY LOSE VALUE •NO BANK GUARANTEE
Neither the Fund nor Fidelity Distributors Corporation is a bank.
 
Top Holdings (% of Fund's net assets)
 
Apple, Inc.
13.3
 
Microsoft Corp.
11.6
 
Amazon.com, Inc.
5.9
 
NVIDIA Corp.
4.5
 
Alphabet, Inc. Class C
3.5
 
Alphabet, Inc. Class A
3.5
 
Tesla, Inc.
3.1
 
Meta Platforms, Inc. Class A
2.8
 
Broadcom, Inc.
1.6
 
PepsiCo, Inc.
1.2
 
 
51.0
 
 
Market Sectors (% of Fund's net assets)
 
Information Technology
46.5
 
Communication Services
14.5
 
Consumer Discretionary
13.7
 
Health Care
8.4
 
Industrials
4.8
 
Consumer Staples
4.4
 
Financials
4.3
 
Utilities
0.9
 
Real Estate
0.9
 
Energy
0.7
 
Materials
0.3
 
 
Asset Allocation (% of Fund's net assets)
Futures - 0.6%
 
 
Showing Percentage of Net Assets
Common Stocks - 99.4%
 
 
Shares
Value ($)
 
COMMUNICATION SERVICES - 14.5%
 
 
 
Diversified Telecommunication Services - 0.1%
 
 
 
Anterix, Inc. (a)
 
15,055
491,546
AST SpaceMobile, Inc. (a)(b)
 
27,143
147,115
ATN International, Inc.
 
9,505
356,723
Bandwidth, Inc. (a)
 
15,411
183,391
Charge Enterprises, Inc. (a)
 
120,637
110,154
Cogent Communications Group, Inc.
 
25,499
1,568,698
Consolidated Communications Holdings, Inc. (a)
 
76,045
277,564
Cuentas, Inc. (a)(b)
 
515
2,467
EchoStar Holding Corp. Class A (a)(b)
 
23,662
373,150
Frontier Communications Parent, Inc. (a)(b)
 
136,361
2,029,052
Iridium Communications, Inc.
 
74,721
4,486,249
Liberty Global PLC:
 
 
 
 Class A (a)
 
86,386
1,408,092
 Class B (a)
 
327
5,284
 Class C (a)
 
165,419
2,815,431
Liberty Latin America Ltd.:
 
 
 
 Class A (a)
 
1,495
10,943
 Class C (a)
 
139,788
1,020,452
Nextplat Corp. (a)(b)
 
37,686
81,402
Radius Global Infrastructure, Inc. (a)
 
57,547
851,696
Sify Technologies Ltd. sponsored ADR (a)(b)
 
13,702
19,320
Telesat Corp. (a)(b)
 
5,704
39,871
 
 
 
16,278,600
Entertainment - 1.8%
 
 
 
Activision Blizzard, Inc.
 
439,189
35,222,958
Anghami, Inc. (a)
 
17,135
18,506
Bilibili, Inc. ADR (a)(b)
 
67,925
1,063,706
Blue Hat Interactive Entertainment Technology (a)(b)
 
1,312
1,325
Chicken Soup For The Soul Entertainment, Inc. (a)(b)
 
4,574
5,809
Cineverse Corp. (a)(b)
 
80,948
23,783
CuriosityStream, Inc. Class A (a)(b)
 
14,288
13,109
Dolphin Entertainment, Inc. (a)(b)
 
1,963
3,730
DoubleDown Interactive Co. Ltd. ADR (a)(b)
 
2,770
24,099
DouYu International Holdings Ltd. ADR (a)
 
88,468
85,407
Electronic Arts, Inc.
 
155,081
19,850,368
Gaia, Inc. Class A (a)
 
13,031
32,578
Gamesquare Holdings, Inc. (a)(b)
 
5,889
22,319
Genius Brands International, Inc. (a)(b)
 
16,029
37,989
GigaMedia Ltd. (a)
 
1,957
2,799
Gravity Co. Ltd. ADR (a)(b)
 
3,536
194,940
Grom Social Enterprises, Inc. (a)(b)
 
1,101
381
iQIYI, Inc. ADR (a)
 
210,107
853,034
Liberty Media Corp. Liberty Braves:
 
 
 
 Class A (a)(b)
 
14,692
549,040
 Class C (a)
 
16,026
587,834
Liberty Media Corp. Liberty Formula One:
 
 
 
 Class A (a)
 
14,368
907,339
 Series C (a)
 
117,797
8,292,909
Liquid Media Group Ltd. (a)(b)
 
14,232
2,088
LiveOne, Inc. (a)
 
40,255
45,086
Lizhi, Inc. ADR (a)(b)
 
12,605
10,589
Lytus Technologies Holdings PTV Ltd. (a)(b)
 
40,712
22,396
Mobile Global Esports, Inc. (b)
 
9,224
4,981
Motorsport Games, Inc. Class A (a)(b)
 
564
2,453
MultiMetaVerse Holdings Ltd. Class A (a)(b)
 
2,807
2,779
NetEase, Inc. ADR
 
73,870
6,284,860
Netflix, Inc. (a)
 
250,619
99,052,147
Playstudios, Inc. Class A (a)
 
64,251
291,057
Playtika Holding Corp. (a)(b)
 
214,417
2,150,603
Reading International, Inc. Class A (a)
 
19,966
55,306
Reservoir Media, Inc. (a)
 
32,035
208,548
Roku, Inc. Class A (a)
 
68,831
4,005,964
Scienjoy Holding Corp. (a)(b)
 
17,909
73,964
Sciplay Corp. (A Shares) (a)
 
15,425
299,091
Take-Two Interactive Software, Inc. (a)
 
94,886
13,068,649
The9 Ltd. sponsored ADR (a)(b)
 
8,161
5,223
Versus Systems, Inc. (a)(b)
 
1,207
711
Vivid Seats, Inc. Class A (a)(b)
 
51,717
378,051
Warner Bros Discovery, Inc. (a)
 
1,374,501
15,504,371
Warner Music Group Corp. Class A
 
76,992
1,882,454
 
 
 
211,145,333
Interactive Media & Services - 10.1%
 
 
 
36Kr Holdings, Inc. ADR (a)
 
1,078
1,058
9F, Inc. ADR (a)(b)
 
2,127
10,912
AcuityAds Holdings, Inc. (a)
 
23,024
41,213
Alphabet, Inc.:
 
 
 
 Class A (a)
 
3,362,143
413,106,510
 Class C (a)
 
3,373,209
416,152,794
Angi, Inc. (a)
 
45,307
138,639
Antelope Enterprise Holdings L (a)(b)
 
13,809
17,261
Baidu, Inc. sponsored ADR (a)
 
86,034
10,569,277
Bumble, Inc. (a)
 
70,092
1,072,408
BuzzFeed, Inc. (a)(b)
 
65,219
41,760
CarGurus, Inc. Class A (a)
 
54,988
1,033,225
Enthusiast Gaming Holdings, Inc. (a)(b)
 
110,249
45,202
EverQuote, Inc. Class A (a)
 
16,480
150,133
Fangdd Network Group Ltd. ADR (a)(b)
 
2,821
1,975
FaZe Holdings, Inc. Class A (a)(b)
 
58,712
29,450
Glory Star New Media Group Holdings Ltd. (a)
 
45,347
25,848
Hello Group, Inc. ADR
 
99,348
801,738
IAC, Inc. (a)
 
46,666
2,605,829
Izea Worldwide, Inc. (a)(b)
 
31,302
23,627
JOYY, Inc. ADR
 
32,344
802,131
Kanzhun Ltd. ADR (a)
 
153,348
2,126,937
Kubient, Inc. (a)(b)
 
6,524
4,606
Liberty TripAdvisor Holdings, Inc. (a)(b)
 
115,325
72,978
Luokung Technology Corp. (a)(b)
 
7,006
9,808
Match Group, Inc. (a)
 
143,972
4,967,034
Meta Platforms, Inc. Class A (a)
 
1,256,550
332,633,916
Oriental Culture Holding Ltd. (a)
 
19,230
12,500
Outbrain, Inc. (a)
 
28,607
132,450
QuinStreet, Inc. (a)
 
29,776
274,535
Rumble, Inc. (a)(b)
 
69,664
687,584
So-Young International, Inc. ADR (a)
 
55,629
116,265
Society Pass, Inc. (a)(b)
 
9,864
5,921
Sohu.Com Ltd. ADR (a)
 
24,154
273,423
Spark Networks SE ADR (a)
 
5,776
4,797
Super League Gaming, Inc. (a)(b)
 
17,381
9,629
Taboola.com Ltd. (a)
 
139,702
381,386
Travelzoo, Inc. (a)
 
6,862
60,866
TripAdvisor, Inc. (a)
 
69,482
1,081,140
Trivago NV ADR (a)
 
43,707
51,574
TrueCar, Inc. (a)
 
56,073
126,725
Vimeo, Inc. (a)
 
92,858
340,789
Vinco Ventures, Inc. (a)(b)
 
6,308
13,751
Weibo Corp. sponsored ADR
 
47,363
661,661
Wejo Group Ltd. (a)(b)
 
49,881
4,240
Yandex NV Series A (a)(c)
 
178,045
1,459,969
Ziff Davis, Inc. (a)
 
25,582
1,510,361
Zoominfo Technologies, Inc. (a)
 
225,551
5,577,876
 
 
 
1,199,273,711
Media - 1.6%
 
 
 
AdTheorent Holding Co., Inc. Class A (a)(b)
 
47,329
82,826
Advantage Solutions, Inc. Class A (a)(b)
 
181,240
344,356
AirNet Technology, Inc. ADR (a)
 
1,367
1,504
AMC Networks, Inc. Class A (a)
 
16,028
181,277
Baosheng Media Group Holding Ltd. (a)(b)
 
164
945
Beasley Broadcast Group, Inc. Class A (a)
 
282,190
296,300
Cardlytics, Inc. (a)(b)
 
18,394
95,097
Charter Communications, Inc. Class A (a)
 
87,698
28,602,703
Comcast Corp. Class A
 
2,368,909
93,216,569
comScore, Inc. (a)(b)
 
21,501
19,351
Criteo SA sponsored ADR (a)
 
32,862
1,047,969
Cumulus Media, Inc. (a)
 
11,565
37,239
Daily Journal Corp. (a)
 
1,070
315,415
DISH Network Corp. Class A (a)
 
161,033
1,035,442
E.W. Scripps Co. Class A (a)
 
39,165
308,620
Fluent, Inc. (a)(b)
 
46,702
29,067
Fox Corp.:
 
 
 
 Class A (b)
 
169,445
5,286,684
 Class B
 
126,638
3,699,096
Gambling.com Group Ltd. (a)
 
16,409
166,387
Harte-Hanks, Inc. (a)
 
5,634
31,607
iClick Interactive Asia Group Ltd. (A Shares) ADR (a)
 
3,435
9,755
iHeartMedia, Inc. (a)(b)
 
66,104
156,666
Insignia Systems, Inc. (a)
 
1,817
13,591
Integral Ad Science Holding Corp. (a)
 
86,987
1,644,924
Lee Enterprises, Inc. (a)(b)
 
2,469
33,578
Liberty Broadband Corp.:
 
 
 
 Class A (a)
 
8,972
662,762
 Class C (a)
 
73,860
5,473,026
Liberty Media Corp. Liberty SiriusXM:
 
 
 
 Series A (a)
 
56,558
1,582,493
 Series C (a)
 
114,035
3,188,419
Loyalty Ventures, Inc. (a)(b)
 
32,234
258
Magnite, Inc. (a)
 
74,029
879,465
Marchex, Inc. Class B (a)
 
34,542
67,011
Mediaco Holding, Inc. (a)
 
9,137
10,690
Mobiquity Technologies, Inc. (a)
 
5,950
1,022
Moxian (BVI), Inc. (a)(b)
 
15,637
15,012
National CineMedia, Inc. (b)
 
42,414
11,978
News Corp.:
 
 
 
 Class A
 
212,559
3,891,955
 Class B
 
111,410
2,058,857
Nexstar Broadcasting Group, Inc. Class A
 
20,923
3,157,699
Nextplay Technologies, Inc. (a)(b)
 
3,569
4,283
Paramount Global:
 
 
 
 Class A (b)
 
10,752
188,913
 Class B (b)
 
371,076
5,644,066
Perion Network Ltd. (a)(b)
 
27,171
836,323
PubMatic, Inc. (a)
 
20,605
361,618
Saga Communications, Inc. Class A
 
1,486
28,977
Salem Communications Corp. Class A (a)(b)
 
18,198
16,926
Scholastic Corp.
 
19,973
848,453
Sinclair Broadcast Group, Inc. Class A (b)
 
23,228
357,247
Sirius XM Holdings, Inc. (b)
 
2,177,119
7,750,544
Stagwell, Inc. (a)
 
74,881
464,262
Starbox Group Holdings Ltd. (b)
 
17,852
51,414
Stran & Co., Inc. (a)
 
1,570
2,198
TechTarget, Inc. (a)
 
15,882
551,741
The Trade Desk, Inc. (a)
 
250,755
17,572,910
Thryv Holdings, Inc. (a)(b)
 
18,106
421,870
Tremor International Ltd. ADR (a)(b)
 
6,260
43,069
Troika Media Group, Inc. (a)(b)
 
26,445
3,229
TuanChe Ltd. ADR (A Shares) (a)(b)
 
5,969
3,044
Urban One, Inc.:
 
 
 
 Class A (a)
 
4,568
28,550
 Class D (non-vtg.) (a)
 
21,932
125,232
WiMi Hologram Cloud, Inc. ADR (a)(b)
 
28,988
26,669
Xcel Brands, Inc. (a)
 
4,288
3,731
ZW Data Action Technologies, Inc. (a)(b)
 
2,547
3,438
 
 
 
192,996,322
Wireless Telecommunication Services - 0.9%
 
 
 
FingerMotion, Inc. (a)(b)
 
25,594
40,950
Gogo, Inc. (a)
 
75,352
1,134,048
Millicom International Cellular SA (a)
 
100,983
1,690,455
NII Holdings, Inc. (a)(c)
 
5,182
0
Shenandoah Telecommunications Co.
 
28,888
548,294
Spok Holdings, Inc.
 
20,912
246,762
SurgePays, Inc. (a)(b)
 
15,080
103,449
T-Mobile U.S., Inc. (a)
 
686,918
94,279,496
uCloudlink Group, Inc. ADR (a)(b)
 
12,409
44,548
VEON Ltd. sponsored ADR (a)
 
39,649
758,882
Vodafone Group PLC sponsored ADR
 
229,790
2,178,409
 
 
 
101,025,293
TOTAL COMMUNICATION SERVICES
 
 
1,720,719,259
CONSUMER DISCRETIONARY - 13.7%
 
 
 
Automobile Components - 0.2%
 
 
 
China Automotive Systems, Inc. (a)
 
19,314
89,231
Dorman Products, Inc. (a)
 
18,379
1,507,997
ECARX Holdings, Inc. Class A (a)(b)
 
72,806
534,396
Foresight Autonomous Holdings Ltd. ADR (a)
 
361
823
Fox Factory Holding Corp. (a)
 
24,073
2,140,571
Garrett Motion, Inc. (a)(b)
 
45,018
372,749
Gentex Corp.
 
134,536
3,532,915
Gentherm, Inc. (a)
 
18,806
1,033,578
Kandi Technologies Group, Inc. (a)(b)
 
39,238
137,725
Luminar Technologies, Inc. (a)(b)
 
141,016
960,319
Mobileye Global, Inc. (b)
 
28,320
1,262,222
Motorcar Parts of America, Inc. (a)
 
12,691
69,927
Patrick Industries, Inc.
 
12,945
848,286
REE Automotive Ltd. (a)(b)
 
118,453
44,953
Solid Power, Inc. (a)(b)
 
104,800
229,512
Strattec Security Corp. (a)
 
2,491
46,158
Sypris Solutions, Inc. (a)(b)
 
6,622
12,582
The Goodyear Tire & Rubber Co. (a)
 
153,215
2,103,642
Visteon Corp. (a)
 
15,401
2,057,266
XPEL, Inc. (a)(b)
 
15,505
1,067,829
 
 
 
18,052,681
Automobiles - 3.3%
 
 
 
Arcimoto, Inc. (a)(b)
 
1,160
1,833
Arrival SA (a)(b)
 
10,035
37,631
AYRO, Inc. (a)(b)
 
18,733
10,490
Canoo, Inc. (a)(b)
 
211,555
117,625
Cenntro Electric Group Ltd. (a)(b)
 
208,899
63,046
ElectraMeccanica Vehicles Corp. (a)(b)
 
157,533
89,148
Ezgo Technologies Ltd. (a)(b)
 
2,944
4,298
Faraday Future Intelligent Electric, Inc. (a)(b)
 
464,584
114,566
Gogoro, Inc. (a)(b)
 
138,974
408,584
Li Auto, Inc. ADR (a)
 
153,624
4,462,777
Lordstown Motors Corp. Class A (a)(b)
 
7,493
25,476
Lucid Group, Inc. Class A (a)(b)
 
1,074,597
8,338,873
Mullen Automotive, Inc. (a)(b)
 
37,375
27,134
Niu Technologies ADR (a)
 
26,584
93,310
NWTN, Inc. (a)(b)
 
110,125
1,157,414
Phoenix Motor, Inc.
 
8,319
6,572
Polestar Automotive Holding UK PLC (a)(b)
 
38,751
132,141
Rivian Automotive, Inc. (a)(b)
 
480,451
7,077,043
Tesla, Inc. (a)
 
1,789,927
365,019,813
Volcon, Inc. (a)
 
14,272
9,851
Workhorse Group, Inc. (a)(b)
 
124,046
104,285
Zapp Electric Vehicles Group Ltd. (a)(b)
 
22,298
61,542
 
 
 
387,363,452
Broadline Retail - 6.6%
 
 
 
1stDibs.com, Inc. (a)(b)
 
17,092
64,779
Amazon.com, Inc. (a)
 
5,792,368
698,443,733
Baozun, Inc. sponsored ADR (a)
 
27,489
108,032
ContextLogic, Inc. (a)(b)
 
12,240
85,802
D-MARKET Electronic Services & Trading ADR (a)(b)
 
42,209
44,319
eBay, Inc.
 
305,326
12,988,568
Etsy, Inc. (a)
 
70,514
5,715,160
Global-e Online Ltd. (a)
 
88,077
3,154,918
Groupon, Inc. (a)(b)
 
12,293
66,382
Hour Loop, Inc. (a)(b)
 
19,584
37,797
iMedia Brands, Inc. (a)(b)
 
4,159
790
JD.com, Inc. sponsored ADR
 
261,634
8,529,268
MercadoLibre, Inc. (a)
 
28,311
35,077,329
Nogin, Inc. (a)(b)
 
691
1,057
Ollie's Bargain Outlet Holdings, Inc. (a)
 
35,458
1,954,445
Ozon Holdings PLC ADR (a)(b)(c)
 
50,413
433,552
PDD Holdings, Inc. ADR (a)
 
336,165
21,958,298
Qurate Retail, Inc. (a)(b)
 
62,930
332,900
Qurate Retail, Inc. Series A (a)
 
108,182
89,802
Secoo Holding Ltd. ADR (a)(b)
 
2,632
2,237
Yunji, Inc. ADR (a)
 
42,417
8,611
 
 
 
789,097,779
Distributors - 0.1%
 
 
 
Educational Development Corp. (a)
 
7,081
8,639
Funko, Inc. (a)(b)
 
24,268
296,070
GigaCloud Technology, Inc. Class A (b)
 
17,953
121,183
Kaival Brands Innovations Group, Inc. (a)(b)
 
31,106
17,422
LKQ Corp.
 
148,469
7,831,740
Pool Corp. (b)
 
21,914
6,929,864
Weyco Group, Inc. (b)
 
6,799
184,525
 
 
 
15,389,443
Diversified Consumer Services - 0.1%
 
 
 
17 Education & Technology Group, Inc. ADR (a)(b)
 
24,088
23,247
2U, Inc. (a)
 
55,243
220,972
Afya Ltd. (a)
 
26,135
306,564
American Public Education, Inc. (a)
 
10,578
52,996
Amesite, Inc. (a)(b)
 
1,845
8,210
Arco Platform Ltd. Class A (a)(b)
 
16,151
191,874
ATA Creativity Global ADR (a)
 
4,528
6,747
China Liberal Education Holdings Ltd. (a)
 
48,266
30,306
Color Star Technology Co. Ltd. (a)(b)
 
1,380
1,808
Duolingo, Inc. (a)
 
17,400
2,602,518
E-Home Household Service Holdings Ltd. (a)(b)
 
94
16
EpicQuest Education Group International Ltd. (a)(b)
 
1,797
3,360
European Wax Center, Inc. (b)
 
23,645
409,768
Frontdoor, Inc. (a)
 
47,662
1,469,419
Golden Sun Education Group Ltd. (b)
 
6,190
6,685
Grand Canyon Education, Inc. (a)
 
18,800
1,969,488
Laureate Education, Inc. Class A
 
102,949
1,245,683
Lincoln Educational Services Corp. (a)(b)
 
24,123
154,146
Meten EdtechX Education Group Ltd. (a)(b)
 
7,857
1,483
OneSpaWorld Holdings Ltd. (a)
 
45,861
478,330
Perdoceo Education Corp. (a)
 
46,741
551,076
Rover Group, Inc. Class A (a)
 
107,567
500,187
Skillful Craftsman Education Technology Ltd. (a)(b)
 
6,452
9,678
Strategic Education, Inc. (b)
 
14,254
1,124,783
Tarena International, Inc. ADR (a)(b)
 
8,570
27,510
Udemy, Inc. (a)
 
81,254
812,540
Vasta Platform Ltd. (a)
 
9,735
30,179
Visionary Education Technology Holdings Group, Inc. (b)
 
22,075
9,934
Vitru Ltd. (a)(b)
 
16,255
246,263
Wag! Group Co. (a)
 
8,539
19,725
Wah Fu Education Group Ltd. (a)
 
9,305
20,099
WW International, Inc. (a)
 
45,720
299,923
Xwell, Inc. (a)(b)
 
121,824
28,275
Zhongchao, Inc. (a)(b)
 
5,917
6,095
 
 
 
12,869,887
Hotels, Restaurants & Leisure - 2.1%
 
 
 
Airbnb, Inc. Class A (a)
 
231,789
25,443,479
Allied Esports Entertainment, Inc. (a)(b)
 
17,647
18,176
Atour Lifestyle Holdings Ltd. ADR (a)(b)
 
8,087
130,686
BJ's Restaurants, Inc. (a)(b)
 
13,822
411,619
Bloomin' Brands, Inc.
 
47,329
1,130,690
Booking Holdings, Inc. (a)
 
21,206
53,200,977
Bragg Gaming Group, Inc. (a)
 
6,633
22,619
BurgerFi International, Inc. (a)(b)
 
9,417
11,960
Caesars Entertainment, Inc. (a)
 
119,498
4,900,613
Canterbury Park Holding Co. (b)
 
422
9,672
Carrols Restaurant Group, Inc. (a)
 
24,770
136,235
Century Casinos, Inc. (a)
 
16,194
109,957
Churchill Downs, Inc.
 
41,452
5,630,011
Chuy's Holdings, Inc. (a)
 
9,648
355,432
Codere Online Luxembourg SA (a)(b)
 
3,157
10,102
Cracker Barrel Old Country Store, Inc. (b)
 
13,041
1,278,279
Dave & Buster's Entertainment, Inc. (a)(b)
 
26,022
836,607
Denny's Corp. (a)
 
38,087
421,623
Draftkings Holdings, Inc. (a)
 
258,700
6,038,058
Ebet, Inc. (a)
 
9,638
2,227
El Pollo Loco Holdings, Inc.
 
18,467
168,788
Elys Game Technology Corp. (a)(b)
 
11,486
5,582
Esports Entertainment Group, Inc. (a)
 
102
194
Expedia, Inc. (a)
 
84,617
8,098,693
FAT Brands, Inc. Class B (b)
 
53,810
291,650
Fiesta Restaurant Group, Inc. (a)
 
12,322
88,595
First Watch Restaurant Group, Inc. (a)
 
32,731
577,702
Full House Resorts, Inc. (a)
 
16,206
115,063
GAN Ltd. (a)(b)
 
11,149
13,936
Golden Entertainment, Inc. (a)
 
16,184
681,994
Good Times Restaurants, Inc. (a)
 
9,092
26,276
H World Group Ltd. ADR (a)
 
98,434
3,604,653
Hall of Fame Resort & Entertainment Co. (a)(b)
 
2,602
17,199
Inspirato, Inc. (a)(b)
 
59,945
56,708
Inspired Entertainment, Inc. (a)
 
15,862
217,785
Jack in the Box, Inc. (b)
 
11,357
983,062
Krispy Kreme, Inc. (b)
 
91,265
1,363,499
Kura Sushi U.S.A., Inc. Class A (a)(b)
 
4,711
383,899
Light & Wonder, Inc. Class A (a)
 
53,198
3,100,911
Lindblad Expeditions Holdings (a)
 
29,723
281,774
MakeMyTrip Ltd. (a)
 
37,977
990,060
Marriott International, Inc. Class A
 
172,045
28,867,431
Melco Crown Entertainment Ltd. sponsored ADR (a)
 
122,393
1,352,443
Monarch Casino & Resort, Inc.
 
10,263
665,966
Mondee Holdings, Inc. (a)(b)
 
46,163
535,491
Muscle Maker, Inc. (a)(b)
 
84,646
92,264
Nathan's Famous, Inc.
 
3,678
262,168
NeoGames SA (a)
 
14,676
400,215
Noodles & Co. (a)
 
27,889
93,428
Papa John's International, Inc.
 
19,976
1,400,517
Penn Entertainment, Inc. (a)
 
87,489
2,190,725
Playa Hotels & Resorts NV (a)
 
89,710
797,522
Portillo's, Inc. (a)(b)
 
22,092
443,386
Potbelly Corp. (a)
 
13,678
106,415
Rave Restaurant Group, Inc. (a)(b)
 
5,714
9,771
RCI Hospitality Holdings, Inc.
 
5,507
397,771
Red Robin Gourmet Burgers, Inc. (a)(b)
 
10,497
132,997
Red Rock Resorts, Inc.
 
32,133
1,464,943
Ruth's Hospitality Group, Inc.
 
22,375
479,496
Sabre Corp. (a)(b)
 
179,819
557,439
Selina Hospitality PLC (a)(b)
 
60,296
50,058
SharpLink Gaming Ltd. (a)(b)
 
2,080
6,490
Sonder Holdings, Inc. (a)(b)
 
146,334
103,868
Sportradar Holding AG (a)(b)
 
117,810
1,420,789
Starbucks Corp.
 
646,694
63,143,202
Target Hospitality Corp. (a)
 
55,616
785,854
Texas Roadhouse, Inc. Class A
 
36,905
3,982,050
TH International Ltd. (a)(b)
 
72,190
191,304
The Cheesecake Factory, Inc. (b)
 
27,723
868,562
The ONE Group Hospitality, Inc. (a)(b)
 
17,098
120,712
Trip.com Group Ltd. ADR (a)
 
245,712
7,759,585
Tuniu Corp. Class A sponsored ADR (a)(b)
 
24,726
27,446
Vacasa, Inc. Class A (a)(b)
 
142,077
109,001
Wendy's Co. (b)
 
114,306
2,515,875
Wingstop, Inc.
 
16,550
3,299,408
Wynn Resorts Ltd.
 
64,119
6,328,545
Yatra Online, Inc. (a)(b)
 
14,712
30,895
 
 
 
252,161,077
Household Durables - 0.1%
 
 
 
Aterian, Inc. (a)(b)
 
29,386
17,164
Bassett Furniture Industries, Inc.
 
4,416
59,660
Cavco Industries, Inc. (a)
 
5,108
1,271,790
Cricut, Inc. (b)
 
25,101
236,702
Dixie Group, Inc. (a)
 
9,905
9,429
Flexsteel Industries, Inc.
 
3,070
56,181
GoPro, Inc. Class A (a)
 
68,957
289,619
Helen of Troy Ltd. (a)(b)
 
13,259
1,276,577
Hooker Furnishings Corp.
 
6,220
92,367
iRobot Corp. (a)
 
15,616
553,587
Koss Corp. (a)(b)
 
4,327
16,659
Landsea Homes Corp. (a)
 
27,139
195,401
Legacy Housing Corp. (a)
 
15,043
286,419
LGI Homes, Inc. (a)(b)
 
13,233
1,505,518
Lifetime Brands, Inc. (b)
 
13,509
66,194
Live Ventures, Inc. (a)
 
1,687
40,033
Lovesac (a)(b)
 
8,426
177,620
Nephros, Inc. (a)
 
3,085
4,936
Newell Brands, Inc. (b)
 
230,165
1,912,671
Nova LifeStyle, Inc. (a)(b)
 
1,383
3,596
Purple Innovation, Inc. (b)
 
48,510
167,845
Singing Machine Co., Inc. (b)
 
2,438
3,218
Snap One Holdings Corp. (a)(b)
 
42,683
376,891
Sonos, Inc. (a)
 
69,375
1,008,019
United Homes Group, Inc. (a)(b)
 
20,014
220,354
Universal Electronics, Inc. (a)
 
7,603
61,356
Viomi Technology Co. Ltd. ADR Class A (a)(b)
 
21,467
18,462
VOXX International Corp. (a)(b)
 
13,480
130,486
Vuzix Corp. (a)(b)
 
34,442
172,899
ZAGG, Inc. rights (a)(c)
 
14,972
0
 
 
 
10,231,653
Leisure Products - 0.1%
 
 
 
American Outdoor Brands, Inc. (a)(b)
 
7,566
54,929
AMMO, Inc. (a)(b)
 
66,715
117,418
BRP, Inc. (b)
 
20,842
1,492,496
Clarus Corp. (b)
 
18,975
156,923
Escalade, Inc. (b)
 
7,721
89,718
Hasbro, Inc. (b)
 
77,045
4,572,621
JAKKS Pacific, Inc. (a)
 
6,809
140,606
Johnson Outdoors, Inc. Class A (b)
 
5,547
314,848
Latham Group, Inc. (a)(b)
 
38,705
139,338
Malibu Boats, Inc. Class A (a)
 
11,640
610,518
MasterCraft Boat Holdings, Inc. (a)
 
12,347
327,196
Mattel, Inc. (a)
 
198,055
3,448,138
Peloton Interactive, Inc. Class A (a)(b)
 
198,054
1,441,833
Smith & Wesson Brands, Inc. (b)
 
28,528
334,633
Vision Marine Technologies, Inc. (a)(b)
 
5,949
21,714
 
 
 
13,262,929
Specialty Retail - 0.8%
 
 
 
1-800-FLOWERS.com, Inc. Class A (a)
 
24,871
201,953
Academy Sports & Outdoors, Inc.
 
43,562
2,132,796
America's Car Mart, Inc. (a)
 
3,745
305,330
Arhaus, Inc. (a)(b)
 
33,484
236,732
Arko Corp. (b)
 
74,889
542,945
Betterware de Mexico SAPI de CV (b)
 
23,570
285,433
Big 5 Sporting Goods Corp. (b)
 
11,818
89,344
Brilliant Earth Group, Inc. Class A (a)(b)
 
5,550
18,593
CarParts.com, Inc. (a)
 
33,968
141,647
Citi Trends, Inc. (a)
 
5,929
86,682
Conn's, Inc. (a)(b)
 
16,366
66,446
Destination XL Group, Inc. (a)
 
32,101
133,540
Digital Brands Group, Inc. (a)(b)
 
145
106
Duluth Holdings, Inc. (a)
 
20,657
111,548
EVgo, Inc. Class A (a)(b)
 
38,018
150,551
Five Below, Inc. (a)
 
30,513
5,264,103
Franchise Group, Inc. (b)
 
22,084
642,644
GrowGeneration Corp. (a)(b)
 
43,987
162,752
Hibbett, Inc. (b)
 
7,367
265,359
JOANN, Inc. (b)
 
23,229
36,237
Jowell Global Ltd. (a)(b)
 
14,581
2,776
Kaixin Auto Holdings (a)(b)
 
90,645
22,117
Kidpik Corp. (a)(b)
 
2,938
1,596
Kirkland's, Inc. (a)(b)
 
7,395
21,224
Lands' End, Inc. (a)(b)
 
21,391
134,122
Lazydays Holdings, Inc. (a)(b)
 
6,139
73,668
Leslie's, Inc. (a)(b)
 
104,964
995,059
Lulu's Fashion Lounge Holdings, Inc. (a)(b)
 
23,329
56,689
Monro, Inc. (b)
 
17,865
739,075
NaaS Technology, Inc. ADR (a)(b)
 
9,484
67,621
National Vision Holdings, Inc. (a)
 
45,468
1,148,067
Newegg Commerce, Inc. (a)(b)
 
206,350
216,668
O'Reilly Automotive, Inc. (a)
 
35,150
31,751,347
OneWater Marine, Inc. Class A (a)(b)
 
7,834
217,707
Overstock.com, Inc. (a)(b)
 
23,881
447,291
Petco Health & Wellness Co., Inc. (a)(b)
 
125,762
960,822
PetMed Express, Inc. (b)
 
10,954
162,448
Rent the Runway, Inc. Class A (a)(b)
 
29,385
59,064
Ross Stores, Inc.
 
195,143
20,220,718
RumbleON, Inc. Class B (a)(b)
 
8,320
90,854
Shift Technologies, Inc. Class A (a)(b)
 
21,797
34,003
Shoe Carnival, Inc. (b)
 
16,794
328,659
Sleep Number Corp. (a)(b)
 
13,605
246,795
Smart Share Global Ltd. ADR (a)(b)
 
5,917
4,615
Sportsman's Warehouse Holdings, Inc. (a)
 
25,040
113,431
Stitch Fix, Inc. (a)(b)
 
68,949
247,527
The Children's Place, Inc. (a)(b)
 
8,107
121,848
The ODP Corp. (a)
 
26,983
1,080,939
The RealReal, Inc. (a)(b)
 
84,330
107,521
thredUP, Inc. (a)(b)
 
33,528
69,403
Tile Shop Holdings, Inc. (a)(b)
 
26,904
141,515
Tractor Supply Co. (b)
 
62,207
13,037,965
Ulta Beauty, Inc. (a)
 
28,464
11,665,401
Upbound Group, Inc.
 
34,141
1,021,157
Urban Outfitters, Inc. (a)(b)
 
54,234
1,671,492
Uxin Ltd. ADR (a)(b)
 
17,215
24,101
Vroom, Inc. (a)(b)
 
133,383
106,480
Winmark Corp.
 
2,004
653,284
Zumiez, Inc. (a)(b)
 
11,506
184,901
 
 
 
99,124,711
Textiles, Apparel & Luxury Goods - 0.3%
 
 
 
Allbirds, Inc. Class A (a)(b)
 
51,562
60,843
Charles & Colvard Ltd. (a)(b)
 
22,010
20,593
Columbia Sportswear Co. (b)
 
35,660
2,632,778
Crocs, Inc. (a)
 
34,414
3,864,004
Crown Crafts, Inc.
 
9,628
49,584
Dogness (International) Corp. (a)
 
20,518
14,670
Fossil Group, Inc. (a)
 
29,540
59,966
G-III Apparel Group Ltd. (a)
 
27,453
441,444
Lakeland Industries, Inc.
 
4,914
53,808
lululemon athletica, Inc. (a)
 
68,913
22,874,292
PLBY Group, Inc. (a)(b)
 
20,215
30,525
Rocky Brands, Inc.
 
4,879
93,238
Steven Madden Ltd.
 
45,830
1,430,354
Superior Group of Companies, Inc. (b)
 
10,737
93,412
Toughbuilt Industries, Inc. (a)(b)
 
2,250
1,815
Vera Bradley, Inc. (a)
 
17,686
84,009
 
 
 
31,805,335
TOTAL CONSUMER DISCRETIONARY
 
 
1,629,358,947
CONSUMER STAPLES - 4.4%
 
 
 
Beverages - 1.9%
 
 
 
Alkaline Water Co., Inc. (a)(b)
 
3,068
5,461
Celsius Holdings, Inc. (a)
 
43,099
5,410,217
Coca-Cola Bottling Co. Consolidated
 
4,832
3,197,528
Coca-Cola European Partners PLC
 
257,530
16,067,297
Eastside Distilling, Inc. (a)(b)
 
308
1,109
Keurig Dr. Pepper, Inc.
 
802,641
24,978,188
MGP Ingredients, Inc. (b)
 
12,465
1,184,923
Monster Beverage Corp.
 
589,360
34,548,283
National Beverage Corp. (a)(b)
 
53,052
2,621,830
PepsiCo, Inc.
 
774,823
141,288,974
The Vita Coco Co., Inc. (a)(b)
 
31,559
841,994
Vintage Wine Estates, Inc. (a)(b)
 
37,368
42,226
Willamette Valley Vineyards, Inc. (a)
 
1,065
6,294
 
 
 
230,194,324
Consumer Staples Distribution & Retail - 1.5%
 
 
 
111, Inc. ADR (a)
 
33,100
82,419
Andersons, Inc.
 
20,649
805,517
Bit Brother Ltd. (a)(b)
 
1,005
829
Casey's General Stores, Inc.
 
20,433
4,610,706
Chefs' Warehouse Holdings (a)
 
21,604
672,100
China Jo-Jo Drugstores Holdings, Inc. (a)(b)
 
3,930
2,900
Costco Wholesale Corp.
 
250,877
128,338,638
Dada Nexus Ltd. ADR (a)
 
54,718
254,986
Dollar Tree, Inc. (a)
 
124,753
16,826,685
G Willi-Food International Ltd.
 
5,646
72,833
Grocery Outlet Holding Corp. (a)(b)
 
54,795
1,573,712
HF Foods Group, Inc. (a)
 
38,952
140,227
Ingles Markets, Inc. Class A
 
8,837
709,346
MedAvail Holdings, Inc. (a)(b)
 
18,459
4,450
Meiwu Technology Co. Ltd. (a)(b)
 
41,954
7,136
Missfresh Ltd. ADR (a)(b)
 
625
331
PriceSmart, Inc.
 
18,216
1,320,296
SpartanNash Co.
 
22,023
504,327
Sprouts Farmers Market LLC (a)
 
62,788
2,169,953
Village Super Market, Inc. Class A
 
6,605
137,087
Walgreens Boots Alliance, Inc.
 
486,544
14,776,341
 
 
 
173,010,819
Food Products - 0.9%
 
 
 
AgriFORCE Growing Systems Ltd. (a)(b)
 
17,646
6,882
Alico, Inc. (b)
 
5,485
126,978
AppHarvest, Inc. (a)(b)
 
53,353
24,542
Arcadia Biosciences, Inc. (a)
 
93
427
Barfresh Food Group, Inc. (a)(b)
 
3,883
4,737
Beyond Meat, Inc. (a)(b)
 
36,004
365,441
Bridgford Foods Corp. (a)(b)
 
3,580
42,674
Cal-Maine Foods, Inc.
 
24,897
1,183,852
Calavo Growers, Inc. (b)
 
11,772
380,589
Cresud S.A.C.I.F. y A. sponsored ADR (b)
 
31,238
197,424
Farmer Brothers Co. (a)(b)
 
13,797
24,559
Farmmi, Inc. (a)(b)
 
4,169
1,898
Forafric Global PLC (a)(b)
 
12,774
137,576
Freshpet, Inc. (a)(b)
 
28,067
1,677,284
Hostess Brands, Inc. Class A (a)
 
69,302
1,724,234
J&J Snack Foods Corp. (b)
 
11,277
1,736,094
John B. Sanfilippo & Son, Inc.
 
5,270
612,532
Lancaster Colony Corp.
 
16,021
3,149,408
Lifecore Biomedical (a)(b)
 
22,245
182,187
Lifeway Foods, Inc. (a)(b)
 
9,131
54,786
Limoneira Co. (b)
 
11,551
185,740
MamaMancini's Holdings, Inc. (a)
 
12,805
32,013
Mission Produce, Inc. (a)(b)
 
38,524
469,993
Mondelez International, Inc.
 
771,742
56,653,580
Moolec Science SA (a)(b)
 
12,378
36,268
Nuzee, Inc. (a)(b)
 
12,436
128,091
Oatly Group AB ADR (a)(b)
 
142,119
224,548
Origin Agritech Ltd. (a)(b)
 
9,462
44,661
Pilgrim's Pride Corp. (a)
 
134,622
2,988,608
Pingtan Marine Enterprise Ltd. (a)(b)(c)
 
62,069
18,621
RiceBran Technologies (a)(b)
 
2,042
1,695
Rocky Mountain Chocolate Factory, Inc. (a)
 
1,651
8,470
S&W Seed Co. (a)(b)
 
18,677
19,798
Seneca Foods Corp. Class A (a)
 
5,752
265,972
Sovos Brands, Inc. (a)
 
55,871
1,060,990
Steakholder Foods Ltd. ADR (a)
 
3,942
3,232
Stryve Foods, Inc. (a)(b)
 
15,166
11,262
SunOpta, Inc. (a)
 
66,843
449,853
Tattooed Chef, Inc. (a)(b)
 
50,860
27,780
TDH Holdings, Inc. (a)(b)
 
1,828
2,157
The Hain Celestial Group, Inc. (a)
 
48,663
594,175
The Kraft Heinz Co.
 
693,118
26,490,970
The Simply Good Foods Co. (a)
 
54,832
1,984,370
Village Farms International, Inc. (a)(b)
 
42,308
25,046
Vital Farms, Inc. (a)
 
21,819
316,157
Westrock Coffee Holdings (a)
 
32,256
355,945
Whole Earth Brands, Inc. Class A (a)(b)
 
19,675
56,861
 
 
 
104,090,960
Household Products - 0.1%
 
 
 
Central Garden & Pet Co. Class A (non-vtg.) (a)
 
32,387
1,112,493
Reynolds Consumer Products, Inc.
 
120,924
3,318,155
WD-40 Co. (b)
 
7,823
1,483,632
 
 
 
5,914,280
Personal Care Products - 0.0%
 
 
 
DSwiss, Inc. (a)(d)
 
7,648
612
Flora Growth Corp. (a)(b)
 
20,412
4,791
Guardion Health Sciences, Inc. (a)(b)
 
527
3,167
Inter Parfums, Inc.
 
18,677
2,345,831
Jupiter Wellness, Inc. (a)(b)
 
21,368
7,808
LifeVantage Corp.
 
9,383
43,725
Mannatech, Inc.
 
1,514
18,955
Natural Alternatives International, Inc. (a)
 
4,379
32,930
Natural Health Trends Corp. (b)
 
3,553
19,542
Nature's Sunshine Products, Inc. (a)
 
13,052
145,921
Neptune Technologies & Bioressources, Inc. (a)(b)
 
898
153
Olaplex Holdings, Inc. (a)
 
365,095
1,153,700
Paranovus Entertainment Techno (a)(b)
 
306
900
Shineco, Inc. (a)(b)
 
3,572
1,928
The Beauty Health Co. (a)(b)
 
84,249
677,362
The Honest Co., Inc. (a)
 
85,048
125,021
Thorne HealthTech, Inc. (a)
 
16,107
71,193
United-Guardian, Inc. (b)
 
2,521
21,731
Upexi, Inc. (a)(b)
 
8,773
27,196
Veru, Inc. (a)(b)
 
45,307
44,854
Waldencast PLC (a)
 
11,211
109,868
Zivo Bioscience, Inc. (a)(b)
 
3,401
9,353
 
 
 
4,866,541
Tobacco - 0.0%
 
 
 
22nd Century Group, Inc. (a)(b)
 
102,993
63,948
TOTAL CONSUMER STAPLES
 
 
518,140,872
ENERGY - 0.7%
 
 
 
Energy Equipment & Services - 0.2%
 
 
 
Baker Hughes Co. Class A
 
569,054
15,506,722
Championx Corp.
 
111,772
2,823,361
CSI Compressco LP
 
68,170
73,624
DMC Global, Inc. (a)
 
9,930
161,065
ENGlobal Corp. (a)(b)
 
35,026
14,851
Geospace Technologies Corp. (a)(b)
 
17,265
142,436
Gulf Island Fabrication, Inc. (a)(b)
 
18,749
60,747
KLX Energy Services Holdings, Inc. (a)(b)
 
8,196
65,076
Mammoth Energy Services, Inc. (a)(b)
 
29,614
104,834
MIND Technology, Inc. (a)
 
28,716
18,091
NCS Multistage Holdings, Inc. (a)
 
2,198
36,817
Patterson-UTI Energy, Inc. (b)
 
125,863
1,225,906
Profire Energy, Inc. (a)
 
47,414
57,845
ProFrac Holding Corp. (b)
 
27,996
314,115
Recon Technology Ltd. (a)(b)
 
15,122
6,124
Smart Sand, Inc. (a)
 
22,511
33,316
Weatherford International PLC (a)
 
38,962
2,199,015
 
 
 
22,843,945
Oil, Gas & Consumable Fuels - 0.5%
 
 
 
Aemetis, Inc. (a)(b)
 
18,211
86,866
Alliance Resource Partners LP
 
70,985
1,213,844
American Resources Corp. (a)(b)
 
86,855
123,334
Amplify Energy Corp. warrants 5/4/22 (a)(c)
 
717
0
APA Corp.
 
180,168
5,725,739
Berry Corp.
 
49,459
311,592
Bitnile Metaverse, Inc. (a)
 
442
517
Brooge Energy Ltd. (a)(b)
 
37,918
185,040
Calumet Specialty Products Partners LP (a)
 
49,250
772,733
Chesapeake Energy Corp.
 
74,952
5,640,138
Chord Energy Corp.
 
23,623
3,379,034
Clean Energy Fuels Corp. (a)(b)
 
121,128
486,935
Diamondback Energy, Inc.
 
105,176
13,373,128
Dorchester Minerals LP
 
21,696
626,364
Epsilon Energy Ltd.
 
6,275
30,810
EzFill Holdings, Inc. (a)(b)
 
3,573
7,325
Gevo, Inc. (a)(b)
 
109,249
140,931
Golar LNG Ltd.
 
59,599
1,225,951
Green Plains Partners LP
 
16,394
197,220
Green Plains, Inc. (a)(b)
 
31,051
900,479
Hallador Energy Co. (a)(b)
 
23,353
181,920
Hammerhead Energy, Inc. Class A (a)(b)
 
19,641
141,415
HighPeak Energy, Inc. (b)
 
63,170
779,518
Imperial Petroleum, Inc. (a)(b)
 
5,999
20,097
Lightbridge Corp. (a)(b)
 
12,328
53,750
Marine Petroleum Trust
 
339
2,532
Martin Midstream Partners LP
 
33,068
67,789
New Fortress Energy, Inc.
 
118,176
3,104,484
Nextdecade Corp. (a)(b)
 
167,292
928,471
OPAL Fuels, Inc. (a)
 
17,077
109,122
PDC Energy, Inc.
 
52,236
3,584,434
Plains All American Pipeline LP
 
390,987
5,051,552
Plains GP Holdings LP Class A
 
107,827
1,466,447
PrimeEnergy Corp. (a)
 
938
85,827
Ranger Oil Corp.
 
12,018
441,662
Stabilis Solutions, Inc. (a)(b)
 
5,194
19,114
StealthGas, Inc. (a)
 
39,172
119,475
Top Ships, Inc. (a)(b)
 
2,008
1,446
TORM PLC (b)
 
45,179
1,120,891
U.S. Energy Corp. (b)
 
15,098
21,439
Uranium Royalty Corp. (a)(b)
 
42,856
82,284
Verde Clean Fuels, Inc. (a)(b)
 
3,630
42,616
Vertex Energy, Inc. (a)(b)
 
41,719
269,922
Viper Energy Partners LP
 
40,566
1,045,791
 
 
 
53,169,978
TOTAL ENERGY
 
 
76,013,923
FINANCIALS - 4.3%
 
 
 
Banks - 1.2%
 
 
 
1895 Bancorp of Wisconsin, Inc. (a)(b)
 
3,059
20,373
1st Source Corp.
 
12,820
527,287
ACNB Corp.
 
4,529
133,379
Amalgamated Financial Corp.
 
18,900
268,758
Amerant Bancorp, Inc. Class A
 
21,076
371,991
American National Bankshares, Inc.
 
6,531
187,636
Ameris Bancorp
 
41,511
1,310,087
Ames National Corp. (b)
 
6,067
111,147
Arrow Financial Corp.
 
10,317
188,182
Auburn National Bancorp., Inc.
 
551
12,122
BancFirst Corp.
 
18,889
1,597,443
Bancorp, Inc., Delaware (a)
 
33,605
1,037,050
Bank First National Corp. (b)
 
5,614
427,338
Bank of Marin Bancorp
 
11,894
192,326
Bank OZK (b)
 
64,274
2,222,595
Bank7 Corp.
 
3,616
82,445
BankFinancial Corp.
 
14,628
108,247
Bankwell Financial Group, Inc.
 
4,285
97,912
Banner Corp.
 
18,237
789,115
BayCom Corp.
 
3,947
63,981
BCB Bancorp, Inc.
 
9,394
99,670
Blue Foundry Bancorp (a)
 
14,520
135,036
Bogota Financial Corp. (a)
 
8,810
69,599
BOK Financial Corp.
 
38,544
3,134,398
Bridgewater Bancshares, Inc. (a)
 
13,282
114,358
Broadway Financial Corp. (a)
 
16,771
15,599
Brookline Bancorp, Inc., Delaware
 
50,034
411,279
Business First Bancshares, Inc.
 
8,715
126,978
C & F Financial Corp.
 
2,765
140,324
California Bancorp, Inc. (a)
 
2,203
31,944
Cambridge Bancorp
 
2,788
140,906
Camden National Corp.
 
8,189
241,657
Capital Bancorp, Inc.
 
5,877
99,850
Capital City Bank Group, Inc.
 
16,718
502,710
Capitol Federal Financial, Inc.
 
85,642
512,139
Capstar Financial Holdings, Inc.
 
13,933
167,893
Carter Bankshares, Inc. (a)
 
17,756
250,360
Carver Bancorp, Inc. (a)
 
7,032
24,682
Cathay General Bancorp
 
43,472
1,271,121
CB Financial Services, Inc.
 
591
11,424
Central Valley Community Bancorp
 
8,707
125,642
Chemung Financial Corp.
 
4,490
158,946
ChoiceOne Financial Services, Inc. (b)
 
2,947
61,445
Citizens & Northern Corp.
 
4,121
79,041
Citizens Community Bancorp, Inc.
 
6,202
52,779
Citizens Financial Services, Inc. (b)
 
198
14,874
Citizens Holding Co. (b)
 
2,179
27,129
City Holding Co.
 
8,728
752,266
Civista Bancshares, Inc.
 
12,037
180,314
CNB Financial Corp., Pennsylvania
 
11,686
194,104
Coastal Financial Corp. of Washington (a)
 
7,239
247,646
Codorus Valley Bancorp, Inc.
 
7,465
132,728
Colony Bankcorp, Inc.
 
7,282
67,723
Columbia Banking Systems, Inc. (b)
 
119,023
2,384,031
Columbia Financial, Inc. (a)(b)
 
68,761
1,110,490
Commerce Bancshares, Inc.
 
70,761
3,392,990
Community Financial Corp. (b)
 
4,047
105,910
Community Trust Bancorp, Inc.
 
8,039
270,914
ConnectOne Bancorp, Inc.
 
23,646
321,113
CrossFirst Bankshares, Inc. (a)
 
29,438
283,782
Cullman Bancorp, Inc.
 
1,695
18,086
CVB Financial Corp.
 
76,652
920,591
Dime Community Bancshares, Inc.
 
22,773
368,923
Eagle Bancorp Montana, Inc.
 
2,880
36,058
Eagle Bancorp, Inc.
 
17,724
353,239
East West Bancorp, Inc.
 
77,433
3,705,169
Eastern Bankshares, Inc.
 
100,469
1,090,089
Enterprise Bancorp, Inc.
 
7,478
198,765
Enterprise Financial Services Corp.
 
22,406
910,132
Esquire Financial Holdings, Inc.
 
4,195
177,574
Farmers & Merchants Bancorp, Inc.
 
8,160
162,302
Farmers National Banc Corp. (b)
 
18,770
221,111
Fidelity D & D Bancorp, Inc. (b)
 
2,330
88,062
Fifth Third Bancorp
 
383,552
9,308,807
Financial Institutions, Inc.
 
9,689
152,214
First Bancorp, North Carolina
 
21,088
634,749
First Bancshares, Inc.
 
9,721
253,135
First Bank Hamilton New Jersey
 
14,532
149,098
First Busey Corp.
 
27,899
521,711
First Business Finance Services, Inc.
 
4,740
126,890
First Capital, Inc. (b)
 
2,233
55,200
First Citizens Bancshares, Inc. (b)
 
7,554
9,421,349
First Community Bankshares, Inc.
 
10,669
284,436
First Community Corp. (b)
 
3,875
64,713
First Financial Bancorp, Ohio
 
55,952
1,060,850
First Financial Bankshares, Inc. (b)
 
80,098
2,074,538
First Financial Corp., Indiana
 
8,773
284,596
First Financial Northwest, Inc.
 
9,975
101,246
First Foundation, Inc.
 
30,319
117,638
First Guaranty Bancshares, Inc. (b)
 
8,053
106,300
First Hawaiian, Inc.
 
72,880
1,201,791
First Internet Bancorp
 
8,345
102,477
First Interstate Bancsystem, Inc.
 
63,592
1,402,204
First Merchants Corp.
 
31,340
828,943
First Mid-Illinois Bancshares, Inc.
 
11,244
269,744
First Northwest Bancorp
 
7,546
84,666
First of Long Island Corp.
 
15,039
153,548
First Savings Financial Group, Inc.
 
2,781
35,041
First U.S. Bancshares, Inc. (b)
 
3,641
26,434
First Western Financial, Inc. (a)
 
3,616
61,544
Five Star Bancorp
 
9,325
178,294
Flushing Financial Corp.
 
19,436
226,429
FNCB Bancorp, Inc.
 
3,698
20,635
Franklin Financial Services Corp.
 
854
22,161
FS Bancorp, Inc.
 
6,150
174,660
Fulton Financial Corp.
 
96,952
1,081,984
FVCBankcorp, Inc. (a)
 
7,292
74,524
German American Bancorp, Inc.
 
16,332
450,763
Great Southern Bancorp, Inc.
 
7,786
378,633
Greene County Bancorp, Inc.
 
10,452
279,591
Grupo Financiero Galicia SA sponsored ADR (b)
 
29,288
347,649
Hancock Whitney Corp.
 
49,885
1,822,299
Hanmi Financial Corp.
 
18,233
262,555
HarborOne Bancorp, Inc.
 
36,797
301,735
Hawthorn Bancshares, Inc. (b)
 
2,866
51,588
HBT Financial, Inc.
 
16,600
292,160
Heartland Financial U.S.A., Inc.
 
29,421
811,725
Heritage Commerce Corp.
 
41,991
305,694
Heritage Financial Corp., Washington
 
21,942
358,752
Hingham Institution for Savings (b)
 
1,454
280,360
HMN Financial, Inc.
 
3,382
61,316
Home Bancorp, Inc.
 
7,434
228,893
Home Federal Bancorp, Inc. (b)
 
813
11,106
HomeStreet, Inc. (b)
 
11,829
61,984
HomeTrust Bancshares, Inc.
 
11,346
222,268
Hope Bancorp, Inc.
 
64,741
519,223
Horizon Bancorp, Inc. Indiana
 
24,746
219,992
Huntington Bancshares, Inc.
 
812,958
8,381,597
Independent Bank Corp.
 
26,861
1,185,645
Independent Bank Corp.
 
10,908
178,346
Independent Bank Group, Inc.
 
23,847
795,774
Inter & Co., Inc. Class A (a)(b)
 
144,994
365,385
International Bancshares Corp.
 
38,617
1,649,718
Investar Holding Corp.
 
8,715
95,865
John Marshall Bankcorp, Inc.
 
7,918
161,369
Kearny Financial Corp.
 
43,102
294,387
Lakeland Bancorp, Inc.
 
32,751
426,091
Lakeland Financial Corp.
 
14,621
734,413
Landmark Bancorp, Inc.
 
3,064
62,965
LCNB Corp.
 
12,147
165,078
Logistics Innovation Technologies Corp. Class A (a)
 
22,127
227,466
Luther Burbank Corp.
 
22,484
193,362
Macatawa Bank Corp.
 
20,908
182,318
Magyar Bancorp, Inc.
 
3,540
35,825
Mainstreet Bancshares, Inc.
 
1,715
36,135
Mercantile Bank Corp.
 
10,866
282,842
Meridian Corp.
 
3,732
35,976
Metrocity Bankshares, Inc.
 
11,608
190,719
Mid Penn Bancorp, Inc.
 
7,980
176,996
Middlefield Banc Corp. (b)
 
1,133
28,586
Midland States Bancorp, Inc.
 
11,372
219,934
MidWestOne Financial Group, Inc.
 
11,723
221,330
MVB Financial Corp.
 
5,314
94,377
National Bankshares, Inc.
 
4,034
109,604
NBT Bancorp, Inc.
 
24,469
820,935
Northeast Bank
 
7,547
270,484
Northeast Community Bancorp, Inc.
 
1,901
25,302
Northfield Bancorp, Inc.
 
31,683
324,117
Northrim Bancorp, Inc.
 
5,057
191,711
Northwest Bancshares, Inc. (b)
 
56,561
594,456
Norwood Financial Corp.
 
3,432
82,780
Oak Valley Bancorp Oakdale California
 
5,385
124,340
OceanFirst Financial Corp.
 
33,684
478,313
Oconee Federal Financial Corp. (b)
 
878
14,083
Old National Bancorp, Indiana
 
158,691
1,970,942
Old Point Financial Corp.
 
2,955
47,191
Old Second Bancorp, Inc.
 
25,984
307,651
OP Bancorp (b)
 
5,419
42,485
OptimumBank Holdings, Inc. (a)
 
3,813
10,676
Orange County Bancorp, Inc.
 
1,297
41,634
Orrstown Financial Services, Inc.
 
7,486
135,497
Pacific Premier Bancorp, Inc.
 
54,299
1,022,450
PacWest Bancorp
 
65,272
421,004
Parke Bancorp, Inc.
 
4,103
65,894
Partners Bancorp
 
4,331
23,474
Pathward Financial, Inc.
 
17,376
763,501
Patriot National Bancorp, Inc. (a)(b)
 
1,781
12,574
PB Bankshares, Inc. (a)(b)
 
871
10,835
PCB Bancorp
 
9,838
138,617
Peapack-Gladstone Financial Corp.
 
10,114
266,908
Penns Woods Bancorp, Inc.
 
4,912
118,035
Peoples Bancorp of North Carolina (b)
 
3,497
60,218
Peoples Bancorp, Inc.
 
19,099
490,271
Peoples Financial Services Corp.
 
4,449
176,091
Pinnacle Financial Partners, Inc.
 
43,693
2,125,664
Pioneer Bancorp, Inc. (a)
 
10,879
92,907
Plumas Bancorp
 
1,764
58,089
Ponce Financial Group, Inc. (a)
 
13,052
98,934
Popular, Inc.
 
40,429
2,311,730
Preferred Bank, Los Angeles
 
7,653
352,956
Premier Financial Corp.
 
24,001
334,574
Primis Financial Corp. (b)
 
16,511
121,686
Princeton Bancorp, Inc.
 
4,666
115,204
Provident Bancorp, Inc.
 
14,544
110,680
QCR Holdings, Inc.
 
8,225
316,005
RBB Bancorp
 
8,755
91,402
Red River Bancshares, Inc.
 
3,386
166,320
Renasant Corp.
 
30,122
786,787
Republic Bancorp, Inc., Kentucky Class A
 
10,388
437,750
Republic First Bancorp, Inc. (a)(b)
 
41,243
54,441
Richmond Mutual Bancorp., Inc.
 
1,852
20,816
Riverview Bancorp, Inc.
 
15,015
70,270
S&T Bancorp, Inc.
 
26,065
699,063
Salisbury Bancorp, Inc. (b)
 
3,260
79,218
Sandy Spring Bancorp, Inc.
 
26,534
555,622
SB Financial Group, Inc.
 
4,710
58,969
Seacoast Banking Corp., Florida (b)
 
42,413
877,101
Shore Bancshares, Inc.
 
11,308
127,328
Sierra Bancorp
 
9,675
154,703
Simmons First National Corp. Class A (b)
 
79,631
1,295,596
SmartFinancial, Inc.
 
10,154
214,249
Sound Financial Bancorp, Inc.
 
1,189
43,066
South Plains Financial, Inc.
 
9,325
206,642
Southern First Bancshares, Inc. (a)
 
4,670
107,270
Southern Missouri Bancorp, Inc.
 
6,368
236,571
Southern States Bancshares, Inc. (b)
 
3,439
68,780
Southside Bancshares, Inc. (b)
 
16,588
439,582
Southstate Corp.
 
42,169
2,636,406
Stellar Bancorp, Inc.
 
32,804
763,021
Sterling Bancorp, Inc. (a)
 
23,636
117,944
Stock Yards Bancorp, Inc. (b)
 
19,408
813,195
Summit Financial Group, Inc. (b)
 
11,557
220,276
Summit State Bank (b)
 
3,743
55,471
TC Bancshares, Inc. (b)
 
3,351
45,272
Territorial Bancorp, Inc.
 
4,189
44,990
Texas Capital Bancshares, Inc. (a)
 
28,669
1,356,044
The First Bancorp, Inc.
 
6,787
160,852
Third Coast Bancshares, Inc. (a)
 
9,897
160,232
Timberland Bancorp, Inc./Washington
 
5,704
134,386
TowneBank
 
42,448
986,492
Trico Bancshares
 
18,864
614,212
Triumph Bancorp, Inc. (a)(b)
 
13,714
712,031
Trustco Bank Corp., New York
 
10,680
295,088
Trustmark Corp.
 
33,488
699,229
UMB Financial Corp.
 
26,643
1,509,060
Union Bankshares, Inc. (b)
 
2,283
49,792
United Bankshares, Inc., West Virginia (b)
 
74,900
2,203,558
United Community Bank, Inc.
 
58,004
1,311,470
United Security Bancshares, California
 
1,456
9,100
Unity Bancorp, Inc.
 
6,284
142,961
Univest Corp. of Pennsylvania
 
13,955
247,422
USCB Financial Holdings, Inc. (a)
 
3,294
32,676
Valley National Bancorp
 
291,362
2,150,252
Veritex Holdings, Inc.
 
33,332
575,644
VersaBank (b)
 
1,224
8,592
Virginia National Bankshares C
 
1,549
44,023
Washington Federal, Inc.
 
37,556
976,832
Washington Trust Bancorp, Inc.
 
8,141
207,270
WesBanco, Inc.
 
35,638
860,301
West Bancorp., Inc.
 
9,814
164,875
Westamerica Bancorp.
 
15,600
590,148
Western New England Bancorp, Inc.
 
19,217
108,768
William Penn Bancorp, Inc. (b)
 
6,289
61,884
Wintrust Financial Corp.
 
31,710
2,015,805
WSFS Financial Corp.
 
38,651
1,292,489
Zions Bancorp NA
 
82,930
2,263,160
 
 
 
138,451,914
Capital Markets - 1.3%
 
 
 
AGM Group Holdings, Inc. (a)
 
12,918
22,348
Alti Global, Inc. Class A (a)(b)
 
37,389
162,642
ARYA Sciences Acquisition Corp. IV Class A (a)(b)
 
7,820
81,641
ARYA Sciences Acquisition Corp. V (a)
 
3,281
33,860
Avantax, Inc. (a)
 
30,712
649,866
B. Riley Financial, Inc. (b)
 
15,733
569,220
Belong Acquisition Corp. (a)
 
2,319
23,538
BGC Partners, Inc. Class A
 
186,493
759,027
Capital Southwest Corp.
 
11,251
205,893
Carlyle Group LP (b)
 
200,455
5,494,472
Chavant Capital Acquisition Corp. (a)
 
3,004
32,083
CME Group, Inc.
 
203,035
36,292,506
Coinbase Global, Inc. (a)(b)
 
105,416
6,556,875
Coliseum Acquisition Corp. Class A (a)
 
1,078
11,136
Compass Digital Acquisition Corp. (a)
 
13,835
141,947
CONX Corp. Class A (a)
 
52,880
539,905
Crescent Capital BDC, Inc. (b)
 
12,883
173,663
Diamond Hill Investment Group, Inc.
 
1,539
244,347
Focus Financial Partners, Inc. Class A (a)
 
36,546
1,903,681
Forum Merger IV Corp. (a)
 
20,165
207,296
Freedom Holding Corp. (a)(b)
 
34,184
2,822,573
Frontier Investment Corp. Class A (a)
 
2,054
21,177
Futu Holdings Ltd. ADR (a)(b)
 
39,748
1,465,111
GCM Grosvenor, Inc. Class A (b)
 
32,247
222,504
Golden Arrow Merger Corp. Class A (a)
 
14,830
152,897
Good Works II Acquisition Corp. (a)(c)
 
1,091
0
Hamilton Lane, Inc. Class A (b)
 
20,275
1,376,875
Hennessy Advisors, Inc. (b)
 
4,729
34,474
Heritage Global, Inc. (a)
 
28,350
98,942
Horizon Technology Finance Corp.
 
7,992
93,187
Hywin Holdings Ltd. ADR (a)(b)
 
6,913
42,861
Interactive Brokers Group, Inc.
 
57,514
4,441,806
Investcorp Credit Management BDC, Inc.
 
16,938
64,364
Jaguar Global Growth Corp. I Class A (a)
 
17,091
179,541
Kernel Group Holdings, Inc. (a)
 
21,554
225,239
Khosla Ventures Acquisition Co. (a)
 
24,911
255,836
Lion Group Holding Ltd. ADR (a)(b)
 
11,889
1,148
Logan Ridge Finance Corp. (b)
 
3,628
73,467
LPL Financial
 
44,972
8,759,646
Magic Empire Global Ltd. (b)
 
8,293
15,508
MarketAxess Holdings, Inc.
 
21,449
5,842,922
MarketWise, Inc. Class A (b)
 
17,442
39,419
Morningstar, Inc.
 
23,892
4,890,692
NASDAQ, Inc.
 
275,691
15,259,497
New Mountain Finance Corp.
 
53,270
637,642
Northern Trust Corp.
 
116,815
8,401,335
Open Lending Corp. (a)
 
64,281
651,809
Patria Investments Ltd.
 
31,353
462,457
Perella Weinberg Partners Class A
 
23,081
180,724
PhenixFIN Corp. (b)
 
762
25,984
Portage Fintech Acquisition Corp. Class A (a)
 
11,581
119,516
Puyi, Inc. ADR (a)(b)
 
12,308
62,402
Quadro Acquisition One Corp. (a)
 
7,900
81,686
Robinhood Markets, Inc. (a)(b)
 
433,638
3,868,051
Runway Growth Finance Corp. (b)
 
18,253
209,544
SEI Investments Co.
 
73,307
4,147,710
Senior Connect Acquisition Corp. I Class A (a)
 
50,774
508,248
Siebert Financial Corp. (a)(b)
 
14,080
32,947
Silvercrest Asset Management Group Class A (b)
 
8,360
163,605
StepStone Group, Inc. Class A
 
38,064
818,757
StoneX Group, Inc. (a)
 
10,664
856,213
T. Rowe Price Group, Inc.
 
125,056
13,401,001
Top Financial Group Ltd.
 
19,596
180,479
TPG, Inc. (b)
 
39,979
1,031,458
Tradeweb Markets, Inc. Class A
 
62,060
4,154,917
Trinity Capital, Inc. (b)
 
14,443
182,560
Twelve Seas Investment Co. II (a)(b)
 
11,364
117,390
U.S. Global Investors, Inc. Class A
 
8,407
22,194
Up Fintech Holdings Ltd. ADR (a)(b)
 
68,253
206,807
Value Line, Inc. (b)
 
5,984
274,666
Victory Capital Holdings, Inc.
 
40,656
1,259,116
Vinci Partners Investments Ltd. (b)
 
27,294
219,171
Virtu Financial, Inc. Class A
 
59,093
1,039,446
Virtus Investment Partners, Inc.
 
4,472
853,168
XP, Inc. Class A (a)
 
255,544
4,510,352
 
 
 
149,166,987
Consumer Finance - 0.2%
 
 
 
7GC & Co. Holdings, Inc. Class A (a)
 
32,674
341,770
Atlanticus Holdings Corp. (a)(b)
 
8,115
283,700
Consumer Portfolio Services, Inc. (a)(b)
 
11,397
132,319
Credit Acceptance Corp. (a)(b)
 
7,272
3,240,985
Encore Capital Group, Inc. (a)(b)
 
13,454
579,464
EZCORP, Inc. (non-vtg.) Class A (a)(b)
 
28,924
241,226
FirstCash Holdings, Inc.
 
27,125
2,672,898
Jiayin Group, Inc. ADR (a)
 
5,761
35,430
Katapult Holdings, Inc. (a)(b)
 
46,564
22,872
LendingTree, Inc. (a)
 
11,859
216,901
LexinFintech Holdings Ltd. ADR (a)
 
76,837
154,442
Medallion Financial Corp. (b)
 
10,141
64,294
Mogo, Inc. (a)(b)
 
22,529
16,212
Navient Corp.
 
77,284
1,170,853
NerdWallet, Inc. (a)
 
28,927
271,914
Nicholas Financial, Inc. (a)(b)
 
5,880
27,166
Oportun Financial Corp. (a)(b)
 
16,861
96,614
Pintec Technology Holdings Ltd. ADR (a)(b)
 
4,579
3,892
PRA Group, Inc. (a)
 
22,082
412,933
Qifu Technology, Inc. ADR
 
75,999
1,044,986
Senmiao Technology Ltd. (a)
 
1,673
1,271
SLM Corp.
 
144,139
2,199,561
SoFi Technologies, Inc. (a)(b)
 
516,239
3,582,699
Upstart Holdings, Inc. (a)(b)
 
42,938
1,169,631
World Acceptance Corp. (a)(b)
 
3,875
430,861
 
 
 
18,414,894
Financial Services - 1.1%
 
 
 
10X Capital Venture Acquisition Corp. II (a)
 
12,375
126,225
26 Capital Acquisition Corp. Class A (a)
 
15,170
161,561
A SPAC I Acquisition Corp. (a)
 
1,374
14,386
A SPAC II Acquisition Corp. (a)
 
13,668
143,514
A-Mark Precious Metals, Inc.
 
13,443
455,314
Acacia Research Corp. (a)
 
26,315
108,944
Accretion Acquisition Corp. (a)
 
31,080
321,989
Ace Global Business Acquisition Ltd. (a)
 
1,698
19,086
Achari Ventures Holdings Corp. I (a)(b)
 
6,078
64,305
Aequi Acquisition Corp. Class A (a)
 
19,142
194,866
Aetherium Acquisition Corp. Class A (a)
 
2,757
29,059
Affirm Holdings, Inc. (a)(b)
 
84,838
1,260,693
Agba Group Holding Ltd. (a)(b)
 
13,625
22,073
Ahren Acquisition Corp. Class A (a)
 
20,270
213,849
Alerus Financial Corp. (b)
 
9,517
158,648
Alpha Healthcare Acquisition Corp. III Class A (a)
 
1,017
10,424
Alpha Partners Technology Merger Corp. (a)
 
7,353
75,809
AltEnergy Acquisition Corp. Class A (a)
 
6,664
68,706
Altitude Acquisition Corp. Class A (a)
 
41,617
419,499
American Acquisition Opportunity, Inc. Class A (a)
 
2,024
20,665
Anzu Special Acquisition Corp. I Class A (a)
 
19,079
192,889
AppTech Payments Corp. (a)(b)
 
8,070
14,365
APx Acquisition Corp. I (a)
 
4,358
46,391
Armada Acquisition Corp. I (a)
 
5,183
53,281
Arogo Capital Acquisition Corp. Class A (a)
 
1,679
17,529
Arrowroot Acquisition Corp. Class A (a)
 
14,007
146,373
Artemis Strategic Investment Corp. (a)
 
10,298
107,923
Atlantic Coastal Acquisition Corp. Class A (a)
 
24,695
250,407
Atlantic Coastal Acquisition Corp. II (a)
 
27,493
288,677
Aurora Acquisition Corp. Class A (a)(b)
 
11,702
122,871
Aurora Technology Acquisition Corp. Class A (a)
 
9,115
96,072
Avalon Acquisition, Inc. Class A (a)
 
27,934
295,542
AvidXchange Holdings, Inc. (a)
 
108,324
1,049,660
AxonPrime Infrastructure Acquisition Corp. (a)
 
3,754
38,441
Better World Acquisition Corp. (a)
 
3,600
39,060
Bilander Acquisition Corp. Class A (a)(b)
 
4,788
48,550
BioPlus Acquisition Corp. (a)
 
6,657
70,431
Bleuacacia Ltd. Class A (a)
 
50,133
512,861
Blockchain Coinvestors Acquisition Corp. I Class A (a)
 
8,779
93,496
Blue Whale Acquisition Corp. I (a)
 
12,116
122,372
Blue World Acquisition Corp. (a)
 
1,613
17,146
Breeze Holdings Acquisition Corp. (a)
 
4,436
47,643
Bridgetown Holdings Ltd. Class A (a)
 
70,587
718,576
Brilliant Acquisition Corp. (a)(b)
 
4,918
54,590
Bullpen Parlay Acquisition Co. (a)
 
3,726
38,937
Burtech Acquisition Corp. (a)
 
3,639
37,263
byNordic Acquisition Corp. (a)
 
9,284
97,761
BYTE Acquisition Corp. Class A (a)(b)
 
22,411
242,711
Cactus Acquisition Corp. 1 Ltd. (a)
 
6,618
69,555
Canna-Global Acquisition Corp. (a)
 
10,398
110,427
Cantaloupe, Inc. (a)
 
40,019
246,117
Cartesian Growth Corp. II (a)
 
5,956
63,312
Cascadia Acquisition Corp. Class A (a)
 
2,973
31,692
Cass Information Systems, Inc.
 
9,021
348,391
CF Acquisition Corp. IV Class A (a)
 
47,181
493,513
CF Acquisition Corp. VII Class A (a)
 
4,271
44,418
CF Acquisition Corp. VIII Class A (a)(b)
 
11,894
127,861
Chain Bridge I Class A (a)
 
13,927
145,259
Clean Earth Acquisitions Corp. Class A (a)
 
13,802
143,541
ClimateRock Class A (a)
 
1,009
10,695
Conyers Park III Acquisition Corp. Class A (a)
 
11,482
117,002
Corner Growth Acquisition Corp. (a)
 
56,198
583,897
Corner Growth Acquisition Corp. 2 Class A (a)
 
11,847
126,644
Crescera Capital Acquisition Corp. Class A (a)
 
2,264
24,791
Crixus BH3 Acquisition Co. (a)
 
4,612
47,411
DA32 Life Science Tech Acquision Corp. (a)
 
2,365
24,170
Data Knights Acquisition Corp. Class A (a)
 
4,680
50,825
Deep Medicine Acquisition Corp. Class A (a)
 
21,476
228,719
Denali Capital Acquisition Corp. Class A (a)
 
1,252
14,204
DHC Acquisition Corp. (a)
 
12,386
128,195
Digital Health Acquisition Corp. (a)
 
1,431
16,356
Digital Transformation Opportunities Corp. (a)
 
13,139
135,857
Digital World Acquisition Corp. (a)
 
17,141
220,776
Disruptive Acquisition Corp. I (a)
 
16,328
166,056
Dlocal Ltd. (a)
 
90,228
1,050,254
DP Cap Acquisition Corp. I Class A (a)
 
13,527
141,898
Dune Acquisition Corp. (a)
 
26,599
264,394
East Resources Acquisition Co. (a)
 
9,378
96,687
Edify Acquisition Corp. (a)
 
21,442
224,498
Edoc Acquisition Corp. Class A (a)
 
1,542
16,839
EdtechX Holdings Acquisition Corp. II (a)
 
600
6,534
Enact Holdings, Inc.
 
94,039
2,288,909
Energem Corp. Class A (a)
 
2,351
25,203
Enterprise 4.0 Technology Acquisition Corp. (a)
 
6,380
67,692
ESGEN Acquisition Corp. Class A (a)
 
19,076
204,876
Euronet Worldwide, Inc. (a)
 
27,816
3,098,702
ExcelFin Acquisition Corp. Class A (a)
 
12,469
128,680
Fat Projects Acquisition Corp. (a)
 
20,151
218,638
Feutune Light Acquisition Corp. Class A (a)
 
6,342
66,654
FG Merger Corp. (a)
 
1,007
10,584
Fifth Wall Acquisition Corp. III Class A (a)
 
52,330
575,107
Finnovate Acquisition Corp. Class A (a)
 
10,151
106,484
FinServ Acquisition Corp. II Class A (a)
 
23,391
237,419
Fintech Ecosystem Development Corp. Class A (a)
 
6,729
70,991
Fiserv, Inc. (a)
 
358,046
40,169,181
FlexShopper, Inc. (a)(b)
 
15,072
16,579
Flywire Corp. (a)
 
58,767
1,765,361
Focus Impact Acquisition Corp. Class A (a)
 
6,444
67,791
Forbion European Acquisition Corp. Class A (a)
 
201
2,137
FTAC Zeus Acquisition Corp. Class A (a)
 
42,674
442,956
Future FinTech Group, Inc. (a)(b)
 
9,290
11,427
Future Health ESG Corp. (a)
 
3,358
33,916
Future Health ESG Corp. warrants 12/31/28 (a)(c)
 
3,358
0
Genesis Growth Tech Acquisition Corp. (a)
 
712
8,088
Global Blockchain Acquisition Corp. (a)
 
5,501
57,045
Global Partner Acquisition Corp. II Class A (a)
 
17,671
185,722
Global Systems Dynamics, Inc. (a)
 
3,884
41,365
Global Technology Acquisition Corp. I Class A (a)
 
10,407
108,129
Globalink Investment, Inc. (a)
 
3,677
38,572
Goal Acquisitions Corp. (a)
 
28,701
295,620
Gores Holdings IX, Inc. (a)
 
17,849
181,881
Growth For Good Acquisition Corp. (a)
 
9,242
95,932
GSR II Meteora Acquisition Corp. Class A (a)
 
10,323
106,843
HCM Acquisition Corp. (a)
 
2,102
22,218
Healthcare AI Acquisition Corp. (a)
 
12,820
135,123
Healthwell Acquisition Corp. I (a)
 
6,406
65,469
Hennessy Capital Investment Corp. VI Class A (a)
 
15,376
156,989
HHG Capital Corp. (a)
 
1,448
15,204
Home Plate Acquisition Corp. (a)
 
6,074
61,408
Home Point Capital, Inc.
 
64,166
148,223
i3 Verticals, Inc. Class A (a)
 
11,916
272,281
Inception Growth Acquisition Ltd. (a)
 
16,315
168,045
Industrial Tech Acquisitions II, Inc. (a)
 
3,192
33,069
Innovative International Acquisition Corp. Class A (a)
 
9,297
101,151
Integral Acquisition Corp. 1 (a)
 
1,063
11,087
International Media Acquisition Corp. (a)
 
6,960
74,681
International Money Express, Inc. (a)
 
54,542
1,270,829
Investcorp Europe Acquisition Corp. I (a)
 
11,247
119,443
Investcorp India Acquisition Corp. (a)
 
1,467
15,565
Iris Acquisition Corp. Class A (a)
 
29,112
294,322
IX Acquisition Corp. Class A (a)
 
10,419
109,087
Jack Henry & Associates, Inc.
 
40,992
6,267,267
Jaws Hurricane Acquisition Corp. Class A (a)
 
21,452
219,883
Jaws Juggernaut Acquisition Corp. Class A (a)
 
6,008
61,942
Jupiter Acquisition Corp. (a)
 
5,254
53,591
Keyarch Acquisition Corp. (a)
 
1,883
19,659
L Catterton Asia Acquisition Corp. Class A (a)
 
13,075
135,196
LAMF Global Ventures Corp. I (a)
 
13,867
144,355
Landcadia Holdings IV, Inc. Class A (a)
 
43,419
439,400
LatAmGrowth SPAC (a)
 
4,041
42,915
Lesaka Technologies, Inc. (a)(b)
 
31,755
120,987
LF Capital Acquisition Corp. II (a)
 
48,609
515,741
Liberty Resources Acquisition Corp. Class A (a)
 
3,303
35,309
LIV Capital Acquisition Corp. II (a)
 
1,805
19,043
LM Funding America, Inc. (a)
 
6,078
4,376
Malacca Straits Acquisition Co. Ltd. Class A (a)
 
6,813
72,082
Maquia Capital Acquisition Corp. Class A (a)
 
23,638
251,745
Marblegate Acquisition Corp. (a)
 
13,895
141,034
Marqeta, Inc. Class A (a)
 
222,385
1,065,224
MedTech Acquisition Corp. Class A (a)
 
17,239
179,458
MELI Kaszek Pioneer Corp. (a)(b)
 
15,932
164,578
Mercato Partners Acquisition Corp. Class A (a)
 
3,381
35,501
Merchants Bancorp
 
24,579
561,876
Metal Sky Star Acquisition Corp. (a)
 
10,593
111,332
Minority Equality Opportunities Acquisition, Inc. Class A (a)(c)
 
1,582
41,986
MoneyGram International, Inc. (a)
 
51,548
566,513
Monterey Bio Acquisition Corp. (a)
 
13,454
143,554
Moringa Acquisition Corp. Class A (a)
 
5,285
54,647
Mountain & Co. I Acquisition Corp. (a)
 
6,280
68,075
Mountain Crest Acquisition Corp. IV (a)
 
2,322
24,265
Mountain Crest Acquisition Corp. V (a)(b)
 
17,855
185,692
Mr. Cooper Group, Inc. (a)
 
40,845
1,889,490
New Providence Acquisition Corp. II Class A (a)
 
5,325
55,433
Newbury Street Acquisition Corp. (a)
 
6,961
72,325
Newcourt Acquisition Corp. Class A (a)
 
10,488
115,683
Newtekone, Inc. (b)
 
13,878
170,838
NMI Holdings, Inc. (a)
 
48,402
1,217,310
Nocturne Acquisition Corp. (a)
 
17,571
193,632
Northern Revival Acquisition C Class A (a)
 
11,942
123,003
Nova Vision Acquisition Corp. (a)
 
150
1,620
Nuvei Corp. (a)(d)
 
37,066
1,163,502
OCA Acquisition Corp. Class A (a)
 
8,868
92,316
OceanTech Acquisitions I Corp. Class A (a)
 
1,749
18,959
OmniLit Acquisition Corp. Class A (a)
 
2,506
25,912
Onyx Acquisition Co. I Class A (a)
 
10,960
116,834
OPY Acquisition Corp. I Class A (a)
 
1,750
17,868
Oxbridge Acquisition Corp. Class A (a)
 
7,561
83,247
Oxus Acquisition Corp. (a)
 
8,028
85,418
Payoneer Global, Inc. (a)
 
190,331
789,874
PayPal Holdings, Inc. (a)
 
641,925
39,792,931
Paysign, Inc. (a)
 
29,027
69,665
PepperLime Health Acquisition Corp. Class A (a)
 
7,163
74,424
Perception Capital Corp. II Class A (a)
 
6,893
74,444
Phoenix Biotech Acquisition Corp. (a)
 
10,588
113,927
PHP Ventures Acquisition Corp. Class A (a)
 
1,807
19,082
Plum Acquisition Corp. I Class A (a)
 
6,545
68,592
Pono Capital Two, Inc. (a)
 
1,883
19,169
Power & Digital Infrastructure Acquisition II Corp. (a)
 
13,806
142,892
PowerUp Acquisition Corp. Class A (a)
 
5,490
57,316
Prime Number Acquisition I Corp. (a)
 
1,128
11,872
Priority Technology Holdings, Inc. (a)
 
38,686
138,496
Priveterra Acquisition Corp. (a)
 
14,763
152,059
Prospector Capital Corp. Class A (a)
 
31,408
328,685
Redwoods Acquisition Corp. (a)
 
11,252
117,583
Relativity Acquisition Corp. Class A (a)(c)
 
3,558
43,692
Remitly Global, Inc. (a)
 
99,757
1,829,543
Repay Holdings Corp. (a)
 
52,937
335,091
Revelstone Capital Acquisition Corp. (a)
 
3,211
33,138
RF Acquisition Corp. (a)
 
385
4,008
RMG Acquisition Corp. III Class A (a)
 
23,202
234,340
ROC Energy Acquisition Corp. (a)
 
6,729
55,178
Rose Hill Acquisition Corp. Class A (a)
 
5,199
55,889
Rosecliff Acquisition Corp. I (a)
 
14,419
152,265
Roth CH Acquisition V Co. (a)
 
9,625
98,656
Ryvyl, Inc. (a)(b)
 
21,290
13,843
Schultze Special Purpose Acquisition Corp. II Class A (a)
 
1,986
20,754
Screaming Eagle Acquisition Corp. (a)
 
39,390
403,748
SEALSQ Corp. (a)(b)
 
71
852
Security National Financial Corp. Class A
 
7,773
61,718
Semper Paratus Acquisition Corp. Class A (a)
 
5,967
61,162
SEP Acquisition Corp. Class A (a)
 
3,822
37,991
SHUAA Partners Acquisition Corp. I Class A (a)
 
3,561
37,711
SILVERspac, Inc. Class A (a)
 
5,375
55,631
Sizzle Acquisition Corp. (a)
 
10,451
111,199
SK Growth Opportunities Corp. (a)
 
11,427
120,326
Slam Corp. (a)
 
29,043
305,532
Social Capital Suvretta Holdings Corp. II (a)
 
6,600
68,046
Social Capital Suvretta Holdings Corp. IV (a)
 
6,040
62,272
Sound Point Acquisition Corp. I Ltd. (a)
 
601
6,407
SportsMap Tech Acquisition Corp. (a)
 
7,111
74,666
Springwater Special Situations Corp. (a)
 
13,177
135,064
Springwater Special Situations Corp. rights (a)(c)
 
13,177
0
StoneBridge Acquisition Corp. (a)
 
7,553
81,346
StoneCo Ltd. Class A (a)
 
160,026
2,005,126
Stratim Cloud Acquisition Corp. (a)
 
3,529
36,349
Sustainable Development Acquisition I Corp. Class A (a)
 
22,589
230,634
Swiftmerge Acquisition Corp. Class A (a)
 
2,517
26,152
SWK Holdings Corp. (a)(b)
 
5,279
89,479
Talon 1 Acquisition Corp. Class A (a)
 
2,685
28,891
Target Global Acquisition I Corp. (a)
 
2,760
29,049
Tastemaker Acquisition Corp. Class A (a)
 
22,661
239,074
TFS Financial Corp. (b)
 
171,062
1,934,711
TG Venture Acquisition Corp. (a)
 
5,333
55,410
The OLB Group, Inc. (a)
 
1,982
1,260
Thunder Bridge Capital Partner IV, Inc. (a)
 
4,969
50,932
Thunder Bridge Capital Partners III, Inc. Class A (a)
 
19,136
197,101
Tigo Energy, Inc. (a)(b)
 
4,724
55,365
TKB Critical Technologies 1 Class A (a)
 
29,046
305,273
TLGY Acquisition Corp. (a)
 
1,607
17,050
TradeUP Acquisition Corp. (a)
 
1,582
16,927
Usio, Inc. (a)
 
12,705
25,791
UTA Acquisition Corp. Class A (a)
 
12,234
128,702
Vahanna Tech Edge Acquisition I Corp. (a)
 
2,626
27,626
Valuence Merger Corp. I Class A (a)
 
960
10,166
Vector Acquisition Corp. II Class A (a)
 
40,000
408,400
Vision Sensing Acquisition Corp. Class A (a)
 
3,608
37,956
Waterstone Financial, Inc.
 
16,746
226,406
Welsbach Technology Metals Acquisition Corp. (a)
 
1,791
18,788
Western Acquisition Ventures Corp. (a)
 
1,125
11,520
WinVest Acquisition Corp. (a)
 
1,876
20,129
Worldwide Webb Acquisition Corp. Class A (a)
 
4,207
43,332
XPAC Acquisition Corp. (a)
 
1,680
17,237
Yotta Acquisition Corp. (a)
 
5,156
53,622
Zimmer Energy Transition Acquisition Corp. (a)
 
12,820
131,213
 
 
 
138,216,265
Insurance - 0.5%
 
 
 
Amerisafe, Inc.
 
9,587
489,512
Arch Capital Group Ltd. (a)
 
207,200
14,441,840
Atlantic American Corp. (a)
 
8,809
18,499
Brighthouse Financial, Inc. (a)
 
36,700
1,477,542
BRP Group, Inc. (a)
 
37,986
761,999
Cincinnati Financial Corp.
 
89,345
8,621,793
Conifer Holdings, Inc. (a)(b)
 
3,312
5,266
Donegal Group, Inc. Class A
 
18,229
262,133
eHealth, Inc. (a)
 
14,424
96,497
Enstar Group Ltd. (a)
 
9,493
2,234,462
Erie Indemnity Co. Class A
 
26,740
5,725,034
Fanhua, Inc. ADR (a)
 
18,931
151,448
FG Financial Group, Inc. (a)(b)
 
3,213
5,687
GoHealth, Inc. (a)(b)
 
3,981
75,878
Goosehead Insurance (a)(b)
 
12,415
685,060
Greenlight Capital Re, Ltd. (a)
 
7,844
75,381
Hallmark Financial Services, Inc. (a)
 
824
3,502
Huize Holding Ltd. ADR (a)(b)
 
8,820
10,055
International General Insurance Holdings Ltd. (b)
 
24,436
225,056
Investors Title Co.
 
1,165
154,421
James River Group Holdings Ltd. (b)
 
24,967
477,868
Kingstone Companies, Inc.
 
5,340
6,835
Maiden Holdings Ltd. (a)(b)
 
52,310
106,712
Midwest Holding, Inc. (a)(b)
 
1,575
40,210
National Western Life Group, Inc.
 
1,743
650,209
NI Holdings, Inc. (a)
 
13,483
184,717
Oxbridge Re Holdings Ltd. (a)
 
5,511
6,944
Palomar Holdings, Inc. (a)
 
14,396
786,885
Principal Financial Group, Inc.
 
135,553
8,873,299
Reliance Global Group, Inc. (a)(b)
 
213
969
Root, Inc. (a)(b)
 
3,480
16,739
Safety Insurance Group, Inc.
 
8,823
642,491
Selective Insurance Group, Inc.
 
35,297
3,414,279
Skyward Specialty Insurance Group, Inc. (b)
 
16,719
394,736
Tian Ruixiang Holdings Ltd. (a)(b)
 
301
467
Tiptree, Inc.
 
21,813
287,713
Trupanion, Inc. (a)(b)
 
22,228
499,463
Unico American Corp. (a)
 
851
945
United Fire Group, Inc.
 
16,750
359,790
United Insurance Holdings Corp. (a)(b)
 
16,071
84,533
Vericity, Inc. (a)
 
6,650
44,888
Willis Towers Watson PLC
 
60,674
13,278,505
 
 
 
65,680,262
Mortgage Real Estate Investment Trusts - 0.0%
 
 
 
AGNC Investment Corp. (b)
 
373,201
3,429,717
Manhattan Bridge Capital, Inc.
 
8,746
41,981
New York Mortgage Trust, Inc.
 
71,130
694,940
Seven Hills Realty Trust (b)
 
921
8,602
 
 
 
4,175,240
TOTAL FINANCIALS
 
 
514,105,562
HEALTH CARE - 8.4%
 
 
 
Biotechnology - 4.7%
 
 
 
180 Life Sciences Corp. (a)
 
844
962
2seventy bio, Inc. (a)
 
27,817
331,300
4D Molecular Therapeutics, Inc. (a)
 
19,051
349,776
4D Pharma PLC ADR (a)(b)(c)
 
2,099
3,463
89Bio, Inc. (a)(b)
 
26,832
489,147
Aadi Bioscience, Inc. (a)
 
11,601
92,808
Abcam PLC ADR (a)
 
106,049
1,712,691
Abeona Therapeutics, Inc. (a)(b)
 
3,435
10,614
ABVC BioPharma, Inc. (a)(b)
 
49,915
33,947
AC Immune SA (a)
 
37,118
80,917
ACADIA Pharmaceuticals, Inc. (a)
 
95,418
2,242,323
Acelyrin, Inc. (a)
 
40,000
724,000
Achieve Life Sciences, Inc. (a)(b)
 
10,358
64,220
Achilles Therapeutics PLC ADR (a)
 
21,590
21,590
Acorda Therapeutics, Inc. (a)(b)
 
6,110
3,666
Acrivon Therapeutics, Inc. (a)
 
9,052
106,633
Acumen Pharmaceuticals, Inc. (a)(b)
 
21,758
107,267
Acurx Pharmaceuticals, Inc. (a)
 
8,683
26,917
Adagene, Inc. ADR (a)
 
10,309
13,814
Adamas Pharmaceuticals, Inc.:
 
 
 
 rights (a)(c)
 
26,195
6,549
 rights (a)(c)
 
26,195
2,881
Adaptimmune Therapeutics PLC sponsored ADR (a)(b)
 
105,910
108,028
Adicet Bio, Inc. (a)
 
21,229
116,335
Aditxt, Inc. (a)(b)
 
1,779
1,085
ADMA Biologics, Inc. (a)(b)
 
115,355
469,495
Adverum Biotechnologies, Inc. (a)(b)
 
11,628
14,302
Aeglea BioTherapeutics, Inc. (a)
 
34,317
4,458
Aerovate Therapeutics, Inc. (a)(b)
 
13,597
220,951
Aeterna Zentaris, Inc. (a)(b)
 
3,659
10,062
Affimed NV (a)
 
135,947
119,593
Agenus, Inc. (a)
 
174,976
272,963
Agios Pharmaceuticals, Inc. (a)(b)
 
32,726
827,313
Aileron Therapeutics, Inc. (a)(b)
 
4,039
5,978
Akebia Therapeutics, Inc. (a)
 
81,930
85,207
Akero Therapeutics, Inc. (a)
 
27,027
1,204,864
Akouos, Inc. (CVR) (c)
 
22,594
17,397
Alaunos Therapeutics, Inc. (a)(b)
 
133,508
66,607
Albireo Pharma, Inc. rights (a)(c)
 
10,788
0
Aldeyra Therapeutics, Inc. (a)
 
30,129
285,924
Alector, Inc. (a)
 
43,832
326,110
Aligos Therapeutics, Inc. (a)(b)
 
30,622
34,603
Alkermes PLC (a)
 
93,120
2,693,962
Allakos, Inc. (a)(b)
 
41,210
205,226
Allogene Therapeutics, Inc. (a)(b)
 
79,583
417,811
Allovir, Inc. (a)(b)
 
63,966
241,152
Alnylam Pharmaceuticals, Inc. (a)
 
69,905
12,933,124
Alpine Immune Sciences, Inc. (a)
 
21,624
215,375
Alterity Therapeutics Ltd. ADR (a)(b)
 
1,212
3,478
Altimmune, Inc. (a)(b)
 
64,125
259,065
Alvotech SA (a)(b)
 
25,558
215,454
ALX Oncology Holdings, Inc. (a)
 
22,550
150,409
Alzamend Neuro, Inc. (a)(b)
 
40,587
29,474
Amarin Corp. PLC ADR (a)(b)
 
214,385
250,830
Amgen, Inc.
 
300,558
66,318,123
Amicus Therapeutics, Inc. (a)
 
168,225
1,894,214
AnaptysBio, Inc. (a)(b)
 
15,023
286,939
Anavex Life Sciences Corp. (a)(b)
 
53,320
492,677
Anika Therapeutics, Inc. (a)
 
7,769
210,462
Anixa Biosciences, Inc. (a)
 
24,102
73,752
Annexon, Inc. (a)(b)
 
25,755
77,007
Apellis Pharmaceuticals, Inc. (a)
 
67,413
5,787,406
Apexigen, Inc. (a)(b)
 
21,401
11,467
Apollomics, Inc. (a)(b)
 
13,427
54,379
Applied Therapeutics, Inc. (a)(b)
 
23,060
29,747
Aptevo Therapeutics, Inc. (a)(b)
 
7,524
11,737
Aptorum Group Ltd. (a)
 
2,413
7,577
Aptose Biosciences, Inc. (a)(b)
 
32,455
13,307
AquaBounty Technologies, Inc. (a)
 
39,718
19,275
Aravive, Inc. (a)(b)
 
23,256
39,535
Arbutus Biopharma Corp. (a)
 
118,928
296,131
ARCA Biopharma, Inc. (a)(b)
 
25,116
52,995
Arcellx, Inc. (a)
 
25,227
1,113,772
Arcturus Therapeutics Holdings, Inc. (a)
 
15,029
410,893
Arcutis Biotherapeutics, Inc. (a)(b)
 
33,142
248,896
Ardelyx, Inc. (a)
 
90,628
302,698
Argenx SE ADR (a)
 
17,376
6,754,051
Aridis Pharmaceuticals, Inc. (a)(b)
 
19,230
7,642
Arrowhead Pharmaceuticals, Inc. (a)
 
63,182
2,174,093
Ars Pharmaceuticals, Inc. (a)
 
44,909
312,567
Ascendis Pharma A/S sponsored ADR (a)
 
31,251
2,717,899
Aslan Pharmaceuticals Ltd. ADR (a)
 
7,968
31,872
Assembly Biosciences, Inc. (a)
 
29,090
27,862
Astria Therapeutics, Inc. (a)
 
14,520
158,849
Atara Biotherapeutics, Inc. (a)
 
70,653
108,099
Athersys, Inc. (a)(b)
 
5,183
4,873
Atossa Therapeutics, Inc. (a)(b)
 
65,687
61,089
Atreca, Inc. (a)(b)
 
11,273
11,273
aTyr Pharma, Inc. (a)
 
16,950
38,477
Aura Biosciences, Inc. (a)
 
16,064
181,844
Aurinia Pharmaceuticals, Inc. (a)
 
76,895
688,979
Autolus Therapeutics PLC ADR (a)
 
53,736
167,119
Avalo Therapeutics, Inc. (a)
 
4,548
13,053
Avid Bioservices, Inc. (a)(b)
 
33,787
522,009
Avidity Biosciences, Inc. (a)
 
46,824
497,271
Avita Medical, Inc. (a)
 
12,445
142,122
AVROBIO, Inc. (a)(b)
 
1,470
1,617
Axcella Health, Inc. (a)(b)
 
23,744
9,303
Aziyo Biologics, Inc. (a)(b)
 
2,648
5,481
Beam Therapeutics, Inc. (a)(b)
 
40,229
1,283,305
BeiGene Ltd. ADR (a)(b)
 
24,485
5,409,471
Bellerophon Therapeutics, Inc. (a)
 
4,969
34,336
Bellicum Pharmaceuticals, Inc. (a)(b)
 
22,867
15,755
BELLUS Health, Inc. (a)(b)
 
84,292
1,231,506
Benitec Biopharma, Inc. (a)(b)
 
11,813
2,848
BeyondSpring, Inc. (a)(b)
 
20,183
20,587
Bicycle Therapeutics PLC ADR (a)
 
17,144
411,113
Bio-Path Holdings, Inc. (a)(b)
 
15,100
24,915
BioAtla, Inc. (a)(b)
 
20,287
63,904
BioCardia, Inc. (a)(b)
 
17,950
31,772
Biocept, Inc. (a)(b)
 
189
408
BioCryst Pharmaceuticals, Inc. (a)(b)
 
104,504
864,248
Biodexa Pharmaceuticals PLC ADR (a)
 
369
31
Biogen, Inc. (a)
 
81,558
24,174,607
BioLine RX Ltd. sponsored ADR (a)(b)
 
32,026
50,441
BioMarin Pharmaceutical, Inc. (a)
 
106,278
9,239,809
Biomea Fusion, Inc. (a)
 
17,536
595,523
BioNTech SE ADR
 
51,966
5,460,587
Biora Therapeutics, Inc. (a)(b)
 
1,106
4,955
BioRestorative Therapies, Inc. (a)(b)
 
3,862
20,198
BioVie, Inc. (a)(b)
 
20,890
121,998
BioXcel Therapeutics, Inc. (a)(b)
 
20,250
363,285
Black Diamond Therapeutics, Inc. (a)(b)
 
11,660
21,688
Blue Water Biotech, Inc. (a)(b)
 
3,818
3,054
bluebird bio, Inc. (a)(b)
 
49,567
166,049
Blueprint Medicines Corp. (a)
 
35,974
2,033,250
Bolt Biotherapeutics, Inc. (a)(b)
 
25,402
43,691
Bone Biologics Corp. (a)(b)
 
5,900
1,001
BrainStorm Cell Therpeutic, Inc. (a)(b)
 
23,733
67,639
BriaCell Therapeutics Corp. (a)(b)
 
7,229
42,868
BridgeBio Pharma, Inc. (a)(b)
 
93,528
1,283,204
Burning Rock Biotech Ltd. ADR (a)(b)
 
25,600
66,816
C4 Therapeutics, Inc. (a)
 
24,762
83,943
Cabaletta Bio, Inc. (a)(b)
 
15,232
153,691
Calyxt, Inc. (a)(b)
 
3,798
23,927
Candel Therapeutics, Inc. (a)
 
13,241
19,994
Capricor Therapeutics, Inc. (a)(b)
 
16,945
76,761
Cardiff Oncology, Inc. (a)(b)
 
13,765
22,162
CareDx, Inc. (a)
 
27,154
216,689
Caribou Biosciences, Inc. (a)(b)
 
29,872
131,736
Carisma Therapeutics, Inc.
 
4,628
26,241
Carisma Therapeutics, Inc. rights (a)(c)
 
92,579
1
CASI Pharmaceuticals Holdings, Inc. (a)(b)
 
22,221
62,663
Catalyst Biosciences, Inc. (a)
 
25,124
5,527
Catalyst Biosciences, Inc. rights (a)(c)
 
25,124
0
Catalyst Pharmaceutical Partners, Inc. (a)
 
57,557
664,783
Celcuity, Inc. (a)(b)
 
9,722
105,046
Celldex Therapeutics, Inc. (a)
 
25,225
802,155
Cellectar Biosciences, Inc. (a)(b)
 
5,942
9,270
Cellectis SA sponsored ADR (a)
 
10,776
20,474
Celularity, Inc. Class A (a)(b)
 
79,434
60,394
Centessa Pharmaceuticals PLC ADR (a)(b)
 
22,686
102,314
Century Therapeutics, Inc. (a)
 
33,174
105,493
Cerevel Therapeutics Holdings (a)(b)
 
89,940
2,932,044
Checkpoint Therapeutics, Inc. (a)(b)
 
4,438
11,716
Chemomab Therapeutics Ltd. ADR (a)(b)
 
11,737
18,427
Chimerix, Inc. (a)
 
52,138
71,950
Chinook Therapeutics, Inc. (a)
 
40,508
979,889
Chinook Therapeutics, Inc. rights (a)(c)
 
11,497
0
Cidara Therapeutics, Inc. (a)
 
66,465
88,398
Clementia Pharmaceuticals, Inc. rights (a)(c)
 
21,066
0
Clene, Inc. (a)(b)
 
39,010
37,848
Codiak Biosciences, Inc. (a)
 
21,826
240
Coeptis Therapeutics Holdings (a)(b)
 
2,844
5,389
Cogent Biosciences, Inc. (a)
 
39,208
460,302
Cogent Biosciences, Inc. rights (a)(c)
 
12,548
0
CohBar, Inc. (a)(b)
 
3,590
9,729
Coherus BioSciences, Inc. (a)
 
43,446
177,694
Collplant Biotechnologies Ltd. (a)
 
5,925
44,438
Comera Life Sciences Holdings, Inc. (a)(b)
 
4,547
2,319
Compass Pathways PLC ADR (a)(b)
 
13,678
100,397
Compass Therapeutics, Inc. (a)(b)
 
51,226
148,555
Concert Pharmaceuticals, Inc. rights (a)(c)
 
24,247
0
Connect Biopharma Holdings Ltd. ADR (a)(b)
 
19,032
21,696
ContraFect Corp. (a)(b)
 
303
406
Corbus Pharmaceuticals Holdings, Inc. (a)(b)
 
2,168
20,531
Corvus Pharmaceuticals, Inc. (a)(b)
 
27,371
83,208
Crinetics Pharmaceuticals, Inc. (a)
 
40,924
893,371
CRISPR Therapeutics AG (a)(b)
 
46,207
2,959,096
CTI BioPharma Corp. (a)
 
70,768
640,450
Cue Biopharma, Inc. (a)
 
20,320
81,280
Cullinan Oncology, Inc. (a)
 
22,932
235,741
CureVac NV (a)(b)
 
116,501
1,124,235
Curis, Inc. (a)
 
54,553
42,393
Cyclacel Pharmaceuticals, Inc. (a)(b)
 
10,654
6,819
Cyclerion Therapeutics, Inc. (a)
 
2,508
10,910
Cyclo Therapeutics, Inc. (a)(b)
 
6,976
8,441
Cyteir Therapeutics, Inc. (a)(b)
 
22,035
50,681
Cytokinetics, Inc. (a)(b)
 
54,647
2,059,645
CytomX Therapeutics, Inc. (a)
 
30,189
51,623
Day One Biopharmaceuticals, Inc. (a)
 
43,654
580,598
DBV Technologies SA sponsored ADR (a)(b)
 
23,666
46,149
Decibel Therapeutics, Inc. (a)
 
8,575
34,643
Deciphera Pharmaceuticals, Inc. (a)
 
39,810
537,435
Denali Therapeutics, Inc. (a)
 
78,747
2,379,734
Dermata Therapeutics, Inc. (a)
 
991
1,586
DermTech, Inc. (a)(b)
 
11,915
28,358
Design Therapeutics, Inc. (a)(b)
 
29,265
164,762
DiaMedica Therapeutics, Inc. (a)
 
42,740
116,680
Diffusion Pharmaceuticals, Inc. (a)(b)
 
2,365
8,869
Disc Medicine, Inc. (a)
 
13,212
490,562
Disc Medicine, Inc. rights (a)(c)
 
10,484
0
Dominari Holdings, Inc. (a)(b)
 
4,540
11,395
Dyadic International, Inc. (a)(b)
 
48,866
111,414
Dynavax Technologies Corp. (a)(b)
 
71,327
815,268
Dyne Therapeutics, Inc. (a)
 
27,351
356,384
Eagle Pharmaceuticals, Inc. (a)
 
7,885
163,614
Edesa Biotech, Inc. (a)(b)
 
19,777
17,997
Editas Medicine, Inc. (a)(b)
 
80,343
737,549
Effector Therapeutics, Inc. Class A (a)(b)
 
24,005
22,325
Eiger Biopharmaceuticals, Inc. (a)(b)
 
23,309
26,106
Eledon Pharmaceuticals, Inc. (a)
 
10,482
22,012
Elevation Oncology, Inc. (a)(b)
 
12,156
51,298
Eliem Therapeutics, Inc. (a)(b)
 
14,651
41,169
Enanta Pharmaceuticals, Inc. (a)
 
11,608
272,556
Enlivex Therapeutics Ltd. (a)(b)
 
10,420
27,196
Enochian Biosciences, Inc. (a)(b)
 
25,710
23,100
Ensysce Biosciences, Inc. (a)(b)
 
86
203
Entera Bio Ltd. (a)
 
17,597
13,954
Entrada Therapeutics, Inc. (a)(b)
 
17,653
202,303
EQRx, Inc. (a)
 
284,839
501,317
Equillium, Inc. (a)(b)
 
18,701
11,501
Erasca, Inc. (a)(b)
 
68,217
184,868
Erytech Pharma SA ADR (a)(b)
 
2,542
2,377
Essa Pharma, Inc. (a)
 
19,039
57,117
Eterna Therapeutics, Inc. (a)(b)
 
1,165
2,435
Evaxion Biotech A/S ADR (a)(b)
 
2,428
3,691
Evelo Biosciences, Inc. (a)
 
35,177
4,802
Evogene Ltd. (a)(b)
 
59,007
35,416
Exact Sciences Corp. (a)
 
100,779
8,221,551
Exagen, Inc. (a)
 
8,533
25,684
Exelixis, Inc. (a)
 
178,272
3,437,084
Exicure, Inc. (a)(b)
 
2,041
1,798
Exscientia Ltd. ADR (a)(b)
 
18,767
144,694
F-star Therapeutics, Inc.:
 
 
 
 rights (a)(c)
 
1,855
0
 rights (a)(c)
 
1,855
0
Fate Therapeutics, Inc. (a)(b)
 
62,224
314,231
Fennec Pharmaceuticals, Inc. (a)(b)
 
19,507
147,863
FibroGen, Inc. (a)
 
57,654
994,532
Finch Therapeutics Group, Inc. (a)
 
25,491
7,137
First Wave BioPharma, Inc. (a)
 
48
89
Flexion Therapeutics, Inc. rights (a)(c)
 
69,500
1
Foghorn Therapeutics, Inc. (a)(b)
 
23,691
149,016
Fortress Biotech, Inc. (a)(b)
 
60,011
32,286
Frequency Therapeutics, Inc. (a)
 
14,063
4,922
Fresh Tracks Therapeutics, Inc. (a)(b)
 
2,323
1,255
Fresh2 Group Ltd. sponsored ADR (a)(b)
 
3,401
14,420
Fusion Pharmaceuticals, Inc. (a)
 
25,136
128,194
G1 Therapeutics, Inc. (a)
 
21,859
55,522
Gain Therapeutics, Inc. (a)(b)
 
10,062
46,386
Galapagos NV sponsored ADR (a)
 
10,095
417,529
Galectin Therapeutics, Inc. (a)(b)
 
67,748
106,364
Galecto, Inc. (a)
 
6,022
13,128
Galera Therapeutics, Inc. (a)(b)
 
19,470
59,773
Galmed Pharmaceuticals Ltd. (a)(b)
 
1,813
8,358
Gamida Cell Ltd. (a)(b)
 
36,417
76,476
Genelux Corp. (b)
 
13,940
379,168
Generation Bio Co. (a)
 
30,848
107,968
Genetron Holdings Ltd. ADR (a)(b)
 
12,262
11,035
Genfit ADR (a)(b)
 
3,215
13,085
Genmab A/S ADR (a)(b)
 
25,385
995,346
Genprex, Inc. (a)(b)
 
35,156
30,276
GeoVax Labs, Inc. (a)(b)
 
6,138
3,806
Geron Corp. (a)
 
228,519
747,257
Gilead Sciences, Inc.
 
707,195
54,411,583
GlycoMimetics, Inc. (a)(b)
 
30,238
56,243
Gossamer Bio, Inc. (a)(b)
 
56,091
75,162
Gracell Biotechnologies, Inc. ADR (a)(b)
 
33,164
90,869
Graphite Bio, Inc. (a)(b)
 
10,956
31,115
GreenLight Biosciences Holdings PBC Class A (a)(b)
 
81,319
23,786
Greenwich Lifesciences, Inc. (a)(b)
 
7,220
78,626
Grifols SA ADR (a)
 
70,799
583,384
Gritstone Bio, Inc. (a)
 
38,068
73,471
Gt Biopharma, Inc. (a)
 
30,673
6,908
Halozyme Therapeutics, Inc. (a)
 
77,113
2,500,775
Harpoon Therapeutics, Inc. (a)(b)
 
20,157
13,707
HCW Biologics, Inc. (a)(b)
 
23,272
34,210
Heron Therapeutics, Inc. (a)(b)
 
53,573
61,073
HilleVax, Inc. (a)(b)
 
18,155
308,998
Histogen, Inc. (a)(b)
 
2,611
2,256
Homology Medicines, Inc. (a)(b)
 
29,351
28,667
Hookipa Pharma, Inc. (a)
 
14,947
19,581
Horizon Therapeutics PLC (a)
 
128,330
12,836,850
Humacyte, Inc. Class A (a)(b)
 
58,271
199,870
Humanigen, Inc. (a)(b)
 
42,206
6,647
I-Mab ADR (a)
 
34,347
106,476
Icosavax, Inc. (a)(b)
 
21,560
216,462
Ideaya Biosciences, Inc. (a)(b)
 
31,393
717,016
IGM Biosciences, Inc. (a)(b)
 
20,964
252,616
Immatics NV (a)(b)
 
33,359
329,253
Immix Biopharma, Inc. (a)(b)
 
3,185
6,434
Immucell Corp. (a)
 
2,008
9,638
Immuneering Corp. (a)(b)
 
12,929
100,200
Immunic, Inc. (a)(b)
 
24,307
40,107
ImmunityBio, Inc. (a)(b)
 
114,108
313,797
Immunocore Holdings PLC ADR (a)(b)
 
14,458
797,792
ImmunoGen, Inc. (a)
 
118,035
1,609,997
Immunome, Inc. (a)(b)
 
5,950
31,178
Immunovant, Inc. (a)
 
70,168
1,474,230
Immutep Ltd. ADR (a)(b)
 
18,722
37,631
Impel Pharmaceuticals, Inc. (a)(b)
 
15,005
18,606
Imunon, Inc. (a)
 
4,368
5,154
IMV, Inc. (a)(b)
 
4,882
354
In8bio, Inc. (a)
 
6,860
20,854
Incyte Corp. (a)
 
124,372
7,655,097
Indaptus Therapeutics, Inc. (a)(b)
 
14,123
23,020
Infinity Pharmaceuticals, Inc. (a)
 
53,051
9,019
InflaRx NV (a)(b)
 
26,327
110,310
Inhibikase Therapeutics, Inc. (a)(b)
 
19,623
13,501
Inhibrx, Inc. (a)(b)
 
22,443
531,001
Inmune Bio, Inc. (a)(b)
 
9,762
73,996
Inovio Pharmaceuticals, Inc. (a)(b)
 
144,978
86,784
Inozyme Pharma, Inc. (a)
 
19,910
119,261
Insmed, Inc. (a)
 
81,603
1,552,905
Instil Bio, Inc. (a)(b)
 
47,996
28,793
Intellia Therapeutics, Inc. (a)
 
55,719
2,076,090
Intercept Pharmaceuticals, Inc. (a)
 
26,978
284,348
Inventiva SA ADR (a)(b)
 
2,231
8,801
Invivyd, Inc. (a)(b)
 
48,492
87,286
IO Biotech, Inc. (a)(b)
 
12,730
26,097
Ionis Pharmaceuticals, Inc. (a)
 
79,115
3,235,804
Iovance Biotherapeutics, Inc. (a)
 
162,916
1,423,886
Ironwood Pharmaceuticals, Inc. Class A (a)
 
85,592
931,241
iTeos Therapeutics, Inc. (a)
 
21,888
356,337
Iveric Bio, Inc. (a)
 
73,383
2,770,208
Janux Therapeutics, Inc. (a)(b)
 
24,032
279,252
Jasper Therapeutics, Inc. (a)
 
96,591
149,716
Kalvista Pharmaceuticals, Inc. (a)
 
47,522
463,340
Kamada Ltd. (a)(b)
 
25,878
124,991
Karuna Therapeutics, Inc. (a)
 
19,413
4,398,015
Karyopharm Therapeutics, Inc. (a)(b)
 
56,050
126,673
Kazia Therapeutics Ltd. sponsored ADR (a)(b)
 
4,948
5,938
Keros Therapeutics, Inc. (a)
 
16,512
790,264
Kezar Life Sciences, Inc. (a)
 
32,480
90,294
Kineta, Inc.
 
3,022
9,096
Kineta, Inc. rights (a)(c)
 
39,785
0
Kiniksa Pharmaceuticals Ltd. (a)
 
21,394
296,521
Kinnate Biopharma, Inc. (a)
 
23,511
101,097
Kintara Therapeutics, Inc. (a)(b)
 
1,218
3,873
Kiromic BioPharma, Inc. (a)(b)
 
1,223
3,877
Kodiak Sciences, Inc. (a)
 
24,583
145,777
Kronos Bio, Inc. (a)(b)
 
13,929
23,261
Krystal Biotech, Inc. (a)
 
16,196
1,908,699
Kura Oncology, Inc. (a)
 
42,255
562,837
Kymera Therapeutics, Inc. (a)(b)
 
29,468
867,538
Lantern Pharma, Inc. (a)(b)
 
6,838
35,626
Larimar Therapeutics, Inc. (a)
 
9,372
34,583
LAVA Therapeutics NV (a)
 
11,124
21,247
Leap Therapeutics, Inc. (a)(b)
 
56,927
50,665
Legend Biotech Corp. ADR (a)
 
37,814
2,426,524
Lexicon Pharmaceuticals, Inc. (a)
 
99,564
328,561
LianBio ADR (a)
 
15,494
38,735
Liminal BioSciences, Inc. (a)
 
2,273
15,275
Lisata Therapeutics, Inc. (a)(b)
 
2,010
8,201
Lixte Biotechnology Holdings, Inc. (a)(b)
 
25,794
17,870
Longeveron, Inc. (a)(b)
 
5,000
14,800
Lumos Pharma, Inc. (a)
 
10,037
36,836
Lyell Immunopharma, Inc. (a)(b)
 
139,442
444,820
Macrogenics, Inc. (a)
 
33,170
154,904
Madrigal Pharmaceuticals, Inc. (a)
 
10,685
2,974,811
Magenta Therapeutics, Inc. (a)
 
44,600
28,874
Mainz Biomed NV (a)(b)
 
6,180
33,928
MannKind Corp. (a)(b)
 
145,163
673,556
Marker Therapeutics, Inc. (a)(b)
 
2,342
4,169
Medicenna Therapeutics Corp. (a)(b)
 
34,144
20,445
MediciNova, Inc. (a)(b)
 
25,966
55,827
MEI Pharma, Inc. (a)(b)
 
3,186
24,532
MeiraGTx Holdings PLC (a)
 
27,678
190,425
Mereo Biopharma Group PLC ADR (a)(b)
 
96,630
97,596
Merrimack Pharmaceuticals, Inc. (a)
 
5,307
66,444
Mersana Therapeutics, Inc. (a)
 
62,187
467,646
Merus BV (a)(b)
 
24,770
538,004
Mesoblast Ltd. sponsored ADR (a)(b)
 
7,548
25,512
MiMedx Group, Inc. (a)
 
60,376
353,803
Mineralys Therapeutics, Inc.
 
26,099
379,479
Minerva Neurosciences, Inc. (a)(b)
 
6,000
35,820
MiNK Therapeutics, Inc. (a)(b)
 
19,029
33,491
Mirati Therapeutics, Inc. (a)(b)
 
31,625
1,175,185
Mirum Pharmaceuticals, Inc. (a)(b)
 
18,963
497,399
Moderna, Inc. (a)
 
219,084
27,979,218
Molecular Partners AG ADR (a)
 
1,070
6,955
Molecular Templates, Inc. (a)(b)
 
52,167
24,518
Moleculin Biotech, Inc. (a)
 
15,561
9,858
Monopar Therapeutics, Inc. (a)(b)
 
13,453
13,157
Monte Rosa Therapeutics, Inc. (a)
 
24,310
179,408
Moonlake Immunotherapeutics (a)(b)
 
17,109
465,536
Morphic Holding, Inc. (a)(b)
 
25,856
1,486,720
Morphosys AG sponsored ADR (a)
 
6,994
44,832
Mustang Bio, Inc. (a)(b)
 
3,059
19,547
Myriad Genetics, Inc. (a)
 
44,051
971,765
Nanobiotix SA ADR (a)(b)
 
1,588
7,273
Natera, Inc. (a)
 
63,503
2,991,626
Neoleukin Therapeutics, Inc. (a)(b)
 
22,529
18,023
Neubase Therapeutics, Inc. (a)(b)
 
19,719
3,512
Neurobo Pharmaceuticals, Inc. (a)(b)
 
915
512
Neurobo Pharmaceuticals, Inc. rights (a)(c)
 
612
0
Neurocrine Biosciences, Inc. (a)
 
53,541
4,793,526
NewAmsterdam Pharma Co. NV (a)(b)
 
18,559
257,228
Neximmune, Inc. (a)(b)
 
11,947
3,829
NextCure, Inc. (a)
 
15,140
26,041
Nkarta, Inc. (a)(b)
 
31,469
145,387
Novavax, Inc. (a)(b)
 
44,969
362,000
NuCana PLC ADR (a)
 
18,775
15,668
Nurix Therapeutics, Inc. (a)(b)
 
35,104
355,252
Nuvalent, Inc. Class A (a)(b)
 
29,507
1,242,245
Nuvectis Pharma, Inc. (a)
 
6,558
114,765
Nymox Pharmaceutical Corp. (a)(b)
 
50,678
21,300
Ocean Biomedical, Inc. Class A (a)(b)
 
62,705
332,337
Ocugen, Inc. (a)(b)
 
495,122
227,756
Olema Pharmaceuticals, Inc. (a)
 
19,973
103,260
Omega Therapeutics, Inc. (a)(b)
 
27,098
205,674
Omniab, Inc. (c)
 
3,424
8,218
Omniab, Inc. (c)
 
3,424
7,704
OncoCyte Corp. (a)(b)
 
67,850
14,500
Oncolytics Biotech, Inc. (a)
 
34,659
56,148
Oncorus, Inc. (a)(b)
 
5,013
1,010
OncoSec Medical, Inc. (a)(b)
 
706
332
Oncternal Therapeutics, Inc. (a)
 
28,548
8,136
Oncternal Therapeutics, Inc. rights (a)(c)
 
4,319
0
OpGen, Inc. (a)(b)
 
1,305
981
Opthea Ltd. ADR (a)(b)
 
5,049
15,803
Orchard Therapeutics PLC ADR (a)
 
2,607
12,514
Organogenesis Holdings, Inc. Class A (a)
 
71,506
259,567
Organovo Holdings, Inc. (a)(b)
 
6,946
11,808
Orgenesis, Inc. (a)(b)
 
14,931
17,768
ORIC Pharmaceuticals, Inc. (a)(b)
 
18,357
92,519
Outlook Therapeutics, Inc. (a)(b)
 
106,981
160,472
Ovid Therapeutics, Inc. (a)
 
34,929
123,649
Oyster Point Pharma, Inc. rights (a)(c)
 
14,178
0
Panbela Therapeutics, Inc. (a)(b)
 
146
33
Pardes Biosciences, Inc. (a)(b)
 
30,249
57,776
Passage Bio, Inc. (a)
 
20,164
19,176
PDS Biotechnology Corp. (a)(b)
 
17,716
169,719
PepGen, Inc.
 
13,803
206,769
PharmaCyte Biotech, Inc. (a)
 
26,211
82,565
Pharming Group NV ADR (a)(b)
 
2,093
26,644
Phio Pharmaceuticals Corp. (a)(b)
 
2,856
9,996
Pieris Pharmaceuticals, Inc. (a)
 
22,483
19,063
Pluri, Inc. (a)(b)
 
25,169
21,711
Plus Therapeutics, Inc. (a)(b)
 
8,899
35,774
PMV Pharmaceuticals, Inc. (a)(b)
 
22,093
118,198
Point Biopharma Global, Inc. (a)
 
64,547
598,351
Polarityte, Inc. (a)(b)
 
4,691
1,764
Portage Biotech, Inc. (a)(b)
 
9,081
31,602
Poseida Therapeutics, Inc. (a)
 
45,001
102,152
Praxis Precision Medicines, Inc. (a)
 
30,282
26,036
Precigen, Inc. (a)
 
111,174
132,297
Precision BioSciences, Inc. (a)
 
32,101
23,755
Prelude Therapeutics, Inc. (a)(b)
 
34,715
193,710
Prime Medicine, Inc. (b)
 
53,750
737,450
ProKidney Corp. (a)(b)
 
30,445
369,602
Prometheus Biosciences, Inc. (a)
 
27,541
5,472,397
ProQR Therapeutics BV (a)(b)
 
36,293
63,150
Protagenic Therapeutics, Inc. (a)
 
5,007
9,764
Protagonist Therapeutics, Inc. (a)
 
40,655
1,059,876
Prothena Corp. PLC (a)
 
33,476
2,223,811
PTC Therapeutics, Inc. (a)
 
39,780
1,669,567
Puma Biotechnology, Inc. (a)
 
21,531
72,129
PureTech Health PLC ADR (a)(b)
 
566
14,388
Pyxis Oncology, Inc. (a)(b)
 
17,549
56,508
Qualigen Therapeutics, Inc. (a)(b)
 
4,888
4,511
Quince Therapeutics, Inc. (a)(b)
 
15,115
22,673
Radius Health, Inc. (c)
 
26,855
0
Rallybio Corp. (a)
 
18,015
128,987
RAPT Therapeutics, Inc. (a)
 
16,847
337,445
Recursion Pharmaceuticals, Inc. (a)(b)
 
105,689
926,893
Regeneron Pharmaceuticals, Inc. (a)
 
60,396
44,424,882
REGENXBIO, Inc. (a)
 
23,128
398,495
Regulus Therapeutics, Inc. (a)(b)
 
9,205
11,967
Relay Therapeutics, Inc. (a)(b)
 
70,041
780,257
Reneo Pharmaceuticals, Inc. (a)
 
13,048
104,384
RenovoRx, Inc. (a)
 
3,794
7,095
Repare Therapeutics, Inc. (a)(b)
 
26,544
281,632
Repligen Corp. (a)
 
31,171
5,234,234
Replimune Group, Inc. (a)
 
31,013
588,937
Reunion Neuroscience, Inc. (a)(b)
 
925
629
Revelation Biosciences, Inc. (a)
 
45
47
Revolution Medicines, Inc. (a)
 
53,109
1,324,007
Rezolute, Inc. (a)(b)
 
7,752
16,512
Rhythm Pharmaceuticals, Inc. (a)(b)
 
32,252
537,318
Rigel Pharmaceuticals, Inc. (a)
 
90,653
126,914
Rocket Pharmaceuticals, Inc. (a)
 
43,952
919,915
Roivant Sciences Ltd. (a)
 
439,576
3,995,746
S.A.B. Biotherapeutics, Inc. (a)(b)
 
14,671
13,057
Sage Therapeutics, Inc. (a)
 
32,980
1,632,510
Salarius Pharmaceuticals, Inc. (a)(b)
 
1,402
1,977
Salarius Pharmaceuticals, Inc. warrants 1/20/25 (a)(b)
 
122,366
1
Sana Biotechnology, Inc. (a)(b)
 
30,701
184,820
Sangamo Therapeutics, Inc. (a)
 
74,184
83,086
Sarepta Therapeutics, Inc. (a)
 
48,781
6,029,332
Savara, Inc. (a)(b)
 
71,163
195,698
Scholar Rock Holding Corp. (a)
 
36,662
213,373
Seagen, Inc. (a)
 
105,237
20,594,881
Selecta Biosciences, Inc. (a)(b)
 
116,771
137,790
Sellas Life Sciences Group, Inc. (a)(b)
 
12,014
20,604
Sensei Biotherapeutics, Inc. (a)(b)
 
16,931
24,719
Senti Biosciences, Inc. (a)(b)
 
28,123
24,858
Sera Prognostics, Inc. (a)(b)
 
16,037
51,800
Seres Therapeutics, Inc. (a)(b)
 
77,368
382,972
Shattuck Labs, Inc. (a)
 
21,179
55,277
Shuttle Pharmaceuticals Holding, Inc. (a)(b)
 
4,926
5,517
Sigilon Therapeutics, Inc. (a)
 
785
3,297
Silence Therapeutics PLC ADR (a)(b)
 
14,687
77,988
Sinovac Biotech Ltd. (a)(c)
 
27,717
179,329
Societal Cdmo, Inc. (a)(b)
 
19,350
13,545
Soleno Therapeutics, Inc. (a)(b)
 
4,007
21,117
Solid Biosciences, Inc. (a)(b)
 
4,251
26,271
Soligenix, Inc. (a)(b)
 
3,602
2,615
Spectrum Pharmaceuticals, Inc. (a)
 
67,801
72,547
Spero Therapeutics, Inc. (a)
 
16,553
28,802
SpringWorks Therapeutics, Inc. (a)(b)
 
37,448
1,025,326
Spruce Biosciences, Inc. (a)(b)
 
9,482
23,041
Stoke Therapeutics, Inc. (a)
 
30,371
340,155
Summit Therapeutics, Inc. (a)(b)
 
368,134
600,058
Sunshine Biopharma, Inc. (a)(b)
 
20,179
12,299
Surface Oncology, Inc. (a)
 
23,135
18,163
Surrozen, Inc. (a)(b)
 
16,964
10,518
Sutro Biopharma, Inc. (a)
 
41,361
185,711
Synaptogenix, Inc. (a)
 
5,004
4,203
Syndax Pharmaceuticals, Inc. (a)
 
38,393
766,708
Synlogic, Inc. (a)
 
71,644
37,613
Syros Pharmaceuticals, Inc. (a)(b)
 
6,421
24,721
T2 Biosystems, Inc. (a)(b)
 
3,228
291
Talaris Therapeutics, Inc. (a)
 
9,618
25,488
Tango Therapeutics, Inc. (a)
 
57,955
156,479
Taysha Gene Therapies, Inc. (a)
 
14,766
10,320
TCR2 Therapeutics, Inc. (a)
 
7,938
11,748
Tempest Therapeutics, Inc. (a)
 
11,414
17,463
Tenax Therapeutics, Inc. (a)
 
1,521
552
Tenaya Therapeutics, Inc. (a)
 
27,785
200,052
TG Therapeutics, Inc. (a)
 
84,648
2,254,176
Theratechnologies, Inc. (a)(b)
 
51,510
48,935
Tiziana Life Sciences Ltd. (a)
 
55,884
47,501
Tobira Therapeutics, Inc. rights (a)(c)
 
6,103
0
TONIX Pharmaceuticals Holding (a)(b)
 
2,448
4,382
TRACON Pharmaceuticals, Inc. (a)
 
18,969
10,945
TransCode Therapeutics, Inc. (a)(b)
 
851
3,574
Travere Therapeutics, Inc. (a)
 
38,619
690,894
Trevena, Inc. (a)(b)
 
7,457
8,501
TScan Therapeutics, Inc. (a)
 
12,786
29,408
Twist Bioscience Corp. (a)(b)
 
32,492
492,254
Tyra Biosciences, Inc. (a)(b)
 
23,991
347,150
Ultragenyx Pharmaceutical, Inc. (a)
 
38,924
1,921,289
Unicycive Therapeutics, Inc. (a)
 
26,109
34,464
uniQure B.V. (a)
 
25,416
490,275
United Therapeutics Corp. (a)
 
25,414
5,330,332
UNITY Biotechnology, Inc. (a)(b)
 
4,580
13,786
UroGen Pharma Ltd. (a)(b)
 
14,376
142,322
Vaccinex, Inc. (a)(b)
 
39,392
15,958
Vaccitech PLC ADR (a)(b)
 
7,880
19,227
Valneva SE ADR (a)(b)
 
359
4,125
Vanda Pharmaceuticals, Inc. (a)
 
35,063
208,625
Vascular Biogenics Ltd. (a)(b)
 
40,323
8,423
Vaxart, Inc. (a)(b)
 
167,528
204,384
Vaxcyte, Inc. (a)
 
44,411
2,199,233
Vaxxinity, Inc. Class A (a)(b)
 
60,825
108,269
VBI Vaccines, Inc. (a)(b)
 
9,359
27,796
VectivBio Holding AG (a)
 
24,647
407,908
Vera Therapeutics, Inc. (a)
 
14,729
122,987
Veracyte, Inc. (a)
 
42,321
1,095,267
Verastem, Inc. (a)
 
111,497
113,727
Vericel Corp. (a)
 
25,530
820,024
Vertex Pharmaceuticals, Inc. (a)
 
144,691
46,817,667
Verve Therapeutics, Inc. (a)(b)
 
34,834
539,230
Vigil Neuroscience, Inc. (a)(b)
 
7,791
77,910
Viking Therapeutics, Inc. (a)
 
46,434
1,019,691
Vincerx Pharma, Inc. (a)
 
9,297
17,199
Vir Biotechnology, Inc. (a)
 
76,218
2,032,734
Viracta Therapeutics, Inc. (a)(b)
 
25,757
34,257
Viridian Therapeutics, Inc. (a)
 
49,653
1,183,231
Viridian Therapeutics, Inc. rights (a)(c)
 
30,380
0
Virios Therapeutics, Inc. (a)(b)
 
3,038
5,225
VistaGen Therapeutics, Inc. (a)(b)
 
109,903
15,617
Vor Biopharma, Inc. (a)(b)
 
17,145
80,582
Voyager Therapeutics, Inc. (a)
 
22,411
255,261
vTv Therapeutics, Inc. Class A (a)(b)
 
44,768
35,367
Werewolf Therapeutics, Inc. (a)
 
15,965
50,928
Windtree Therapeutics, Inc. (a)(b)
 
381
488
X4 Pharmaceuticals, Inc. (a)
 
45,600
92,568
Xbiotech, Inc. (a)
 
15,395
78,438
Xencor, Inc. (a)
 
34,666
939,449
Xenetic Biosciences, Inc. (a)(b)
 
2,070
6,065
Xenon Pharmaceuticals, Inc. (a)
 
36,857
1,420,100
Xilio Therapeutics, Inc. (a)(b)
 
15,714
47,928
XOMA Corp. (a)(b)
 
6,585
111,945
XTL Biopharmaceuticals Ltd. ADR (a)(b)
 
8,903
10,862
Y-mAbs Therapeutics, Inc. (a)
 
17,901
145,535
Yield10 Bioscience, Inc. (a)(b)
 
7,586
21,089
YS Biopharma Co. Ltd. (a)(b)
 
13,608
20,548
Zai Lab Ltd. ADR (a)
 
38,656
1,255,933
Zentalis Pharmaceuticals, Inc. (a)
 
32,066
834,999
Zymeworks, Inc. (a)(b)
 
31,500
259,245
ZyVersa Therapeutics, Inc. Class A (a)(b)
 
4,076
1,508
 
 
 
560,453,032
Health Care Equipment & Supplies - 2.0%
 
 
 
Abiomed, Inc. (c)
 
25,491
71,120
Accelerate Diagnostics, Inc. (a)(b)
 
83,483
58,505
Accuray, Inc. (a)(b)
 
50,472
186,242
Acutus Medical, Inc. (a)
 
11,416
9,704
Aethlon Medical, Inc. (a)(b)
 
31,992
9,716
Align Technology, Inc. (a)
 
43,893
12,406,795
Alpha Tau Medical Ltd. Class A (a)
 
26,606
106,158
Alphatec Holdings, Inc. (a)
 
53,739
814,683
Angiodynamics, Inc. (a)
 
20,081
189,966
Apyx Medical Corp. (a)(b)
 
18,122
114,712
Aspira Women's Health, Inc. (a)(b)
 
4,278
13,732
Atricure, Inc. (a)
 
25,041
1,126,094
Atrion Corp.
 
1,094
569,274
Avinger, Inc. (a)(b)
 
3,056
1,655
AxoGen, Inc. (a)
 
22,322
189,737
Axonics Modulation Technologies, Inc. (a)
 
26,110
1,263,463
Beyond Air, Inc. (a)(b)
 
24,913
131,042
BioLase Technology, Inc. (a)(b)
 
4,175
340
Biomerica, Inc. (a)(b)
 
5,860
8,028
BioSig Technologies, Inc. (a)(b)
 
26,213
40,630
Bioventus, Inc. (a)(b)
 
34,854
94,280
BrainsWay Ltd. ADR (a)
 
3,457
6,067
Cerus Corp. (a)
 
93,501
200,092
Check Capital Ltd. (a)(b)
 
2,932
4,398
ClearPoint Neuro, Inc. (a)(b)
 
13,370
102,949
Co.-Diagnostics, Inc. (a)(b)
 
17,214
18,763
ConforMis, Inc. (a)(b)
 
3,067
3,404
Cue Health, Inc. (a)
 
79,656
60,658
Cutera, Inc. (a)(b)
 
10,797
181,498
CVRx, Inc. (a)(b)
 
10,458
130,934
CytoSorbents Corp. (a)(b)
 
21,655
64,315
DarioHealth Corp. (a)(b)
 
11,331
44,191
Delcath Systems, Inc. (a)(b)
 
2,322
18,483
Dentsply Sirona, Inc.
 
121,331
4,382,476
DexCom, Inc. (a)
 
218,003
25,563,032
Eargo, Inc. (a)(b)
 
10,658
50,732
EDAP TMS SA sponsored ADR (a)(b)
 
22,764
226,502
Ekso Bionics Holdings, Inc. (a)(b)
 
5,843
7,888
electroCore, Inc. (a)(b)
 
10,983
53,377
Embecta Corp.
 
34,326
949,800
ENDRA Life Sciences, Inc. (a)(b)
 
1,773
2,624
Envveno Medical Corp. (a)(b)
 
20,487
59,617
Establishment Labs Holdings, Inc. (a)(b)
 
13,987
902,441
Femasys, Inc. (a)(b)
 
6,504
4,553
Fonar Corp. (a)
 
3,366
57,626
GE Healthcare Holding LLC
 
255,880
20,345,019
Helius Medical Technologies, Inc. (U.S.) (a)(b)
 
2,717
421
Heska Corp. (a)
 
5,658
677,432
Hologic, Inc. (a)
 
140,785
11,106,529
Hyperfine, Inc. (a)(b)
 
25,802
42,315
IceCure Medical Ltd. (a)(b)
 
3,905
4,139
ICU Medical, Inc. (a)(b)
 
13,670
2,390,746
IDEXX Laboratories, Inc. (a)
 
46,487
21,605,763
Inari Medical, Inc. (a)(b)
 
30,948
1,869,259
InMode Ltd. (a)(b)
 
47,785
1,508,572
Inogen, Inc. (a)
 
13,301
140,060
Inspira Technologies Oxy BHN Ltd. (a)(b)
 
2,924
4,094
InspireMD, Inc. (a)(b)
 
14,051
25,994
Insulet Corp. (a)
 
39,308
10,780,219
Integra LifeSciences Holdings Corp. (a)
 
47,719
1,810,936
Intuitive Surgical, Inc. (a)
 
198,817
61,203,825
InVivo Therapeutics Holdings Corp. (a)(b)
 
1,757
2,267
INVO Bioscience, Inc. (a)(b)
 
4,947
1,260
IRadimed Corp.
 
7,986
375,582
iRhythm Technologies, Inc. (a)
 
16,900
1,931,163
Iridex Corp. (a)
 
7,305
15,706
Kewaunee Scientific Corp. (a)
 
1,782
27,478
KORU Medical Systems, Inc. (a)
 
31,356
114,920
Lantheus Holdings, Inc. (a)
 
38,748
3,355,189
LeMaitre Vascular, Inc. (b)
 
12,899
810,573
LENSAR, Inc. (a)
 
5,527
16,249
LivaNova PLC (a)
 
29,154
1,290,939
LogicMark, Inc. (a)(b)
 
303
842
Lucid Diagnostics, Inc. (a)(b)
 
11,733
18,655
LumiraDx Ltd. (a)(b)
 
34,946
14,328
Masimo Corp. (a)
 
29,536
4,780,106
Medigus Ltd. ADR (b)
 
510
2,264
Meihua International Medical Technologies Co. Ltd. (a)(b)
 
8,805
24,302
Merit Medical Systems, Inc. (a)
 
31,052
2,558,685
Mesa Laboratories, Inc. (b)
 
2,822
365,421
Microbot Medical, Inc. (a)(b)
 
2,681
5,255
Minerva Surgical, Inc. (a)(b)
 
7,396
1,459
Motus GI Holdings, Inc. (a)(b)
 
2,146
1,429
Nano-X Imaging Ltd. (a)(b)
 
29,795
530,053
NanoVibronix, Inc. (a)(b)
 
1,284
4,982
Nemaura Medical, Inc. (a)(b)
 
11,700
5,837
Neogen Corp. (a)(b)
 
129,217
2,260,005
Neovasc, Inc. rights (a)(c)
 
854
0
NeuroMetrix, Inc. (a)(b)
 
2,657
2,684
Neuronetics, Inc. (a)(b)
 
7,893
21,548
NeuroOne Medical Technologies Corp. (a)(b)
 
1,701
2,058
NeuroPace, Inc. (a)(b)
 
12,686
56,453
NEXGEL, Inc. (a)
 
547
1,275
Novocure Ltd. (a)(b)
 
59,205
4,251,511
NuVasive, Inc. (a)
 
29,326
1,119,080
Nyxoah SA (a)(b)
 
3,633
29,282
Omnicell, Inc. (a)
 
24,667
1,811,051
OraSure Technologies, Inc. (a)
 
41,450
208,494
Orchestra BioMed Holdings, Inc. (a)(b)
 
15,495
232,425
Orthofix International NV (a)
 
24,866
464,746
OrthoPediatrics Corp. (a)(b)
 
15,188
656,122
Outset Medical, Inc. (a)
 
25,667
534,644
PAVmed, Inc. (a)(b)
 
45,379
18,202
PetVivo Holdings, Inc. (a)(b)
 
12,298
25,580
Predictive Oncology, Inc. (a)(b)
 
6,561
21,192
Pro-Dex, Inc. (a)(b)
 
3,523
66,937
PROCEPT BioRobotics Corp. (a)
 
25,611
856,688
Profound Medical Corp. (a)(b)
 
10,870
130,984
ProSomnus, Inc. (a)(b)
 
7,965
38,471
Pulmonx Corp. (a)
 
24,714
296,815
Pulse Biosciences, Inc. (a)(b)
 
18,830
116,746
QuidelOrtho Corp. (a)
 
38,139
3,247,154
ReWalk Robotics Ltd. (a)(b)
 
29,639
18,077
Rockwell Medical Technologies, Inc. (a)(b)
 
3,194
10,604
RxSight, Inc. (a)
 
21,683
528,415
Sanara Medtech, Inc. (a)(b)
 
4,237
142,109
SeaStar Medical Holding Corp. (Class A) (a)(b)
 
3,971
2,065
Semler Scientific, Inc. (a)
 
4,084
112,269
Sensus Healthcare, Inc. (a)(b)
 
10,687
28,748
Shockwave Medical, Inc. (a)
 
20,174
5,549,666
SI-BONE, Inc. (a)
 
17,331
436,395
Sientra, Inc. (a)(b)
 
3,100
5,146
Sight Sciences, Inc. (a)
 
24,595
235,866
Silk Road Medical, Inc. (a)(b)
 
19,105
576,780
Sintx Technologies, Inc. (a)
 
211
310
SmileDirectClub, Inc. (a)(b)
 
44,592
15,835
Staar Surgical Co. (a)(b)
 
26,676
1,547,742
STRATA Skin Sciences, Inc. (a)
 
17,447
15,615
Surgalign Holdings, Inc. (a)(b)
 
11,452
9,288
SurModics, Inc. (a)
 
7,764
142,314
Tactile Systems Technology, Inc. (a)(b)
 
12,519
263,149
Talis Biomedical Corp. (a)
 
13,579
6,659
Tandem Diabetes Care, Inc. (a)
 
35,812
930,754
Tela Bio, Inc. (a)
 
7,936
80,392
Thermogenesis Holdings, Inc. (a)(b)
 
146
190
TransMedics Group, Inc. (a)
 
17,684
1,284,919
Treace Medical Concepts, Inc. (a)
 
28,866
767,836
Trinity Biotech PLC sponsored ADR (a)
 
5,165
4,803
UFP Technologies, Inc. (a)
 
5,073
784,438
Utah Medical Products, Inc.
 
2,529
236,436
Varex Imaging Corp. (a)
 
23,722
522,833
Venus Concept, Inc. (a)(b)
 
1,875
4,069
ViewRay, Inc. (a)
 
126,726
69,826
Vivani Medical, Inc. (a)(b)
 
3,026
3,964
Zimvie, Inc. (a)
 
17,620
175,848
Zynex, Inc. (a)(b)
 
24,118
226,227
 
 
 
231,482,297
Health Care Providers & Services - 0.4%
 
 
 
23andMe Holding Co. Class A (a)(b)
 
182,416
350,239
Acadia Healthcare Co., Inc. (a)
 
50,937
3,597,680
Accolade, Inc. (a)(b)
 
37,420
450,537
AdaptHealth Corp. (a)
 
75,766
794,028
Addus HomeCare Corp. (a)
 
8,720
786,108
Aesthetic Medical International Holdings Group Ltd. ADR (a)(b)
 
2,491
2,117
AirSculpt Technologies, Inc. (b)
 
29,506
249,031
Akumin, Inc. (a)(b)
 
36,627
14,497
Alignment Healthcare, Inc. (a)
 
103,822
609,435
Amedisys, Inc. (a)(b)
 
18,157
1,378,661
Apollo Medical Holdings, Inc. (a)(b)
 
31,352
991,350
Assure Holdings Corp. (a)
 
31
30
Aveanna Healthcare Holdings, Inc. (a)
 
100,162
118,191
BIMI International Medical, Inc. (a)(b)
 
357
343
Biodesix, Inc. (a)(b)
 
16,804
23,526
CareMax, Inc. Class A (a)(b)
 
57,146
150,294
Castle Biosciences, Inc. (a)
 
13,646
333,372
Centogene NV (a)(b)
 
11,156
8,936
Clover Health Investments Corp. (a)(b)
 
296,263
250,905
Corvel Corp. (a)
 
10,115
1,976,876
Cosmos Health, Inc. (a)(b)
 
1,781
6,091
Cross Country Healthcare, Inc. (a)
 
22,341
569,696
DocGo, Inc. Class A (a)
 
55,906
500,359
ETAO International Co. Ltd. (a)(b)
 
1,605
724
EUDA Health Holdings Ltd. (a)(b)
 
2,778
3,695
Fulgent Genetics, Inc. (a)
 
15,751
626,417
G Medical Innovations Holdings Ltd. (a)(b)
 
1,112
434
GeneDx Holdings Corp. Class A (a)(b)
 
5,082
38,217
Great Elm Group, Inc. (a)
 
7,056
14,324
Greenbrook TMS, Inc. (a)(b)
 
16,163
9,948
Guardant Health, Inc. (a)
 
59,938
1,757,382
HealthEquity, Inc. (a)
 
48,065
2,633,962
Henry Schein, Inc. (a)
 
77,434
5,722,373
IMAC Holdings, Inc. (a)(b)
 
54,807
7,092
Innovage Holding Corp. (a)(b)
 
77,714
523,015
LifeStance Health Group, Inc. (a)(b)
 
209,488
1,715,707
Modivcare, Inc. (a)(b)
 
7,758
348,567
MSP Recovery, Inc. (a)(b)
 
13,433
8,449
MSP Recovery, Inc. warrants 5/20/27 (a)(b)
 
1,585,094
4,280
National Research Corp. Class A
 
15,135
679,562
NeoGenomics, Inc. (a)
 
71,021
1,220,141
Novo Integrated Sciences, Inc. (a)
 
12,127
1,601
Nutex Health, Inc. (a)(b)
 
307,423
133,821
Ontrak, Inc. (a)(b)
 
10,232
4,604
Opko Health, Inc. (a)(b)
 
430,736
598,723
Option Care Health, Inc. (a)
 
102,132
2,813,737
P3 Health Partners, Inc. Class A (a)(b)
 
55,233
223,694
Patterson Companies, Inc.
 
54,157
1,418,372
Pennant Group, Inc. (a)
 
17,279
207,348
PetIQ, Inc. Class A (a)(b)
 
15,095
192,159
Precipio, Inc. (a)(b)
 
61,940
35,925
Premier, Inc.
 
68,207
1,705,175
Prenetics Global Ltd. (a)(b)
 
44,743
40,269
Privia Health Group, Inc. (a)
 
62,434
1,557,728
Progyny, Inc. (a)(b)
 
56,927
2,120,531
Psychemedics Corp.
 
4,592
21,766
Quipt Home Medical Corp. (a)
 
18,355
89,940
R1 RCM, Inc. (a)
 
234,912
3,817,320
RadNet, Inc. (a)
 
35,037
1,013,971
Star Equity Holdings, Inc. (a)(b)
 
11,004
11,224
Surgery Partners, Inc. (a)
 
68,818
2,579,299
Talkspace, Inc. Class A (a)(b)
 
79,242
84,789
The Ensign Group, Inc.
 
31,601
2,800,165
The Joint Corp. (a)
 
8,305
117,765
The Oncology Institute, Inc. (a)(b)
 
32,634
13,951
Viemed Healthcare, Inc. (a)
 
19,429
185,158
Virax Biolabs Group Ltd. (b)(d)
 
5,416
2,102
Vivos Therapeutics, Inc. (a)(b)
 
36,452
13,910
 
 
 
50,281,638
Health Care Technology - 0.1%
 
 
 
Akili, Inc. (a)(b)
 
34,561
40,436
Augmedix, Inc. (a)
 
8,640
31,968
Better Therapeutics, Inc. (a)(b)
 
6,986
4,891
Biotricity, Inc. (a)(b)
 
31,571
21,784
CareCloud, Inc. (a)
 
13,011
36,561
Certara, Inc. (a)
 
90,887
1,888,632
Computer Programs & Systems, Inc. (a)
 
10,575
252,320
Definitive Healthcare Corp. (a)(b)
 
59,328
577,855
Forian, Inc. (a)(b)
 
18,658
44,593
GoodRx Holdings, Inc. (a)
 
46,684
253,494
Health Catalyst, Inc. (a)
 
27,691
311,801
HealthStream, Inc.
 
16,614
382,454
HTG Molecular Diagnostics (a)(b)
 
776
1,653
iCAD, Inc. (a)(b)
 
17,375
22,414
iSpecimen, Inc. (a)
 
5,334
6,828
Lifemd, Inc. (a)(b)
 
11,075
21,596
Nextgen Healthcare, Inc. (a)
 
39,057
608,117
OptimizeRx Corp. (a)
 
10,957
153,836
Renalytix AI PLC ADR (a)(b)
 
4,865
11,919
Schrodinger, Inc. (a)
 
32,559
1,089,099
SCWorx, Corp. (a)(b)
 
21,155
5,331
Sharecare, Inc. Class A (a)
 
191,907
285,941
Simulations Plus, Inc. (b)
 
11,532
509,599
SOPHiA GENETICS SA (a)(b)
 
25,124
117,078
Streamline Health Solutions, Inc. (a)
 
19,282
28,923
Tabula Rasa HealthCare, Inc. (a)(b)
 
16,205
86,049
Trxade Health, Inc. (a)(b)
 
15,392
4,310
Veradigm, Inc. (a)(b)
 
66,307
781,096
 
 
 
7,580,578
Life Sciences Tools & Services - 0.5%
 
 
 
10X Genomics, Inc. (a)
 
53,766
2,820,564
AbCellera Biologics, Inc. (a)(b)
 
162,374
1,131,747
Adaptive Biotechnologies Corp. (a)
 
87,891
611,721
Akoya Biosciences, Inc. (a)
 
25,075
141,172
Alpha Teknova, Inc. (a)
 
16,055
61,651
Applied DNA Sciences, Inc. (a)(b)
 
15,383
16,921
Azenta, Inc. (a)
 
41,417
1,791,285
Bio-Techne Corp.
 
87,933
7,192,040
BioLife Solutions, Inc. (a)(b)
 
22,958
536,069
BioNano Genomics, Inc. (a)(b)
 
155,696
107,726
Bruker Corp.
 
82,993
5,734,816
Champions Oncology, Inc. (a)
 
10,958
53,694
ChromaDex, Inc. (a)(b)
 
42,495
59,918
Codexis, Inc. (a)
 
35,046
77,452
Compugen Ltd. (a)(b)
 
27,170
27,713
CryoPort, Inc. (a)
 
26,414
486,282
Cytek Biosciences, Inc. (a)(b)
 
77,112
602,245
Evotec OAI AG ADR (a)
 
9,752
106,004
Genetic Technologies Ltd. ADR (a)(b)
 
2,511
2,405
Harvard Bioscience, Inc. (a)
 
25,302
141,438
ICON PLC (a)
 
45,874
9,772,538
Illumina, Inc. (a)
 
90,180
17,733,897
ImmunoPrecise Antibodies Ltd. (a)(b)
 
17,484
55,249
Inotiv, Inc. (a)(b)
 
12,964
78,821
Maravai LifeSciences Holdings, Inc. (a)
 
75,470
969,035
MaxCyte, Inc. (a)
 
54,747
223,368
Medpace Holdings, Inc. (a)
 
17,464
3,614,524
Miromatrix Medical, Inc. (a)(b)
 
10,203
9,693
Nanostring Technologies, Inc. (a)
 
22,753
134,015
Nautilus Biotechnology, Inc. (a)
 
73,031
208,869
Olink Holding AB ADR (a)(b)
 
18,467
359,737
OmniAb, Inc. (a)
 
46,694
201,718
Pacific Biosciences of California, Inc. (a)
 
133,667
1,654,797
Personalis, Inc. (a)
 
23,807
42,853
Phenomex, Inc. (a)
 
63,423
44,396
Quanterix Corp. (a)
 
18,705
366,805
Quantum-Si, Inc. (a)(b)
 
64,799
97,846
Quoin Pharmaceuticals Ltd.:
 
 
 
 ADR (a)(b)(e)
 
1,151
490
 rights (a)(c)
 
3,438,400
34
Rapid Micro Biosystems, Inc. (a)
 
21,522
22,598
Science 37 Holdings, Inc. (a)(b)
 
82,595
21,177
Seer, Inc. (a)
 
35,353
130,099
Singular Genomics Systems, Inc. (a)(b)
 
25,471
26,872
SomaLogic, Inc. Class A (a)
 
130,594
395,700
Sotera Health Co. (a)
 
159,442
2,246,538
Standard BioTools, Inc. (a)
 
41,862
98,376
Syneos Health, Inc. (a)
 
57,615
2,396,784
Telesis Bio, Inc. (a)(b)
 
4,784
7,654
 
 
 
62,617,346
Pharmaceuticals - 0.7%
 
 
 
9 Meters Biopharma, Inc. (a)(b)
 
6,852
4,796
A Menarini Industrie Farmaceut rights (a)(c)
 
32,407
0
Acasti Pharma, Inc. (a)(b)
 
18,348
9,908
AcelRx Pharmaceuticals, Inc. (a)(b)
 
7,485
7,455
Acer Therapeutics, Inc. (a)(b)
 
14,284
12,713
Aclaris Therapeutics, Inc. (a)
 
38,620
322,477
Adamis Pharmaceuticals Corp. (a)(b)
 
1,251
2,615
Adial Pharmaceuticals, Inc. (a)(b)
 
16,546
4,352
Agile Therapeutics, Inc. (a)(b)
 
48
182
Akari Therapeutics PLC sponsored ADR (a)(b)
 
30,264
5,354
Alimera Sciences, Inc. (a)(b)
 
5,507
15,144
Altamira Therapeutics Ltd. (a)(b)
 
943
783
Amphastar Pharmaceuticals, Inc. (a)
 
29,456
1,306,963
Amryt Pharma PLC:
 
 
 
 rights (a)(c)
 
160,470
2
 rights (a)(c)
 
160,470
2
Amylyx Pharmaceuticals, Inc. (a)
 
38,285
945,257
AN2 Therapeutics, Inc. (a)(b)
 
5,024
28,185
Anebulo Pharmaceuticals, Inc. (a)(b)
 
4,108
9,284
Angion Biomedica Corp. (a)(b)
 
16,608
16,276
ANI Pharmaceuticals, Inc. (a)
 
9,565
431,764
Aquestive Therapeutics, Inc. (a)(b)
 
39,828
92,003
Artelo Biosciences, Inc. (a)(b)
 
3,253
5,693
Arvinas Holding Co. LLC (a)
 
31,478
687,165
Assertio Holdings, Inc. (a)(b)
 
29,212
184,912
AstraZeneca PLC sponsored ADR
 
345,741
25,266,752
atai Life Sciences NV (a)(b)
 
117,226
209,835
Atea Pharmaceuticals, Inc. (a)
 
43,830
174,882
Athira Pharma, Inc. (a)
 
16,877
46,749
Aurora Cannabis, Inc. (a)(b)
 
148,904
75,777
Avadel Pharmaceuticals PLC sponsored ADR (a)(b)
 
40,528
561,313
Avenue Therapeutics, Inc. (a)(b)
 
1,272
1,374
Axsome Therapeutics, Inc. (a)(b)
 
24,669
1,820,079
Baudax Bio, Inc. (a)(b)
 
444
233
Belite Bio, Inc. ADR (a)(b)
 
5,895
97,209
Biofrontera, Inc. (a)(b)
 
10,901
5,123
Biondvax Pharmaceuticals Ltd. ADR (a)(b)
 
1,376
2,436
Biote Corp. Class A (a)(b)
 
5,866
32,087
Bright Green Corp. (a)(b)
 
89,677
92,367
Calliditas Therapeutics AB ADR (a)(b)
 
5,831
99,477
Cara Therapeutics, Inc. (a)
 
34,753
110,515
Cardiol Therapeutics, Inc. (a)(b)
 
52,435
35,525
Cassava Sciences, Inc. (a)(b)
 
22,322
506,933
China SXT Pharmaceuticals, Inc. (a)(b)
 
1,333
270
CinCor Pharma, Inc. rights (a)(c)
 
24,312
0
Citius Pharmaceuticals, Inc. (a)(b)
 
75,361
87,419
Clearside Biomedical, Inc. (a)
 
38,079
41,125
Clever Leaves Holdings, Inc. (a)(b)
 
14,276
3,563
CNS Pharmaceuticals, Inc. (a)(b)
 
1,358
2,499
Cocrystal Pharma, Inc. (a)(b)
 
4,223
9,122
Cognition Therapeutics, Inc. (a)
 
8,935
18,317
Collegium Pharmaceutical, Inc. (a)(b)
 
23,387
516,151
Context Therapeutics, Inc. (a)(b)
 
2,231
1,941
Corcept Therapeutics, Inc. (a)
 
62,375
1,465,189
CorMedix, Inc. (a)(b)
 
22,697
109,173
Cronos Group, Inc. (a)(b)
 
260,717
456,255
Cumberland Pharmaceuticals, Inc. (a)(b)
 
11,327
18,236
CymaBay Therapeutics, Inc. (a)
 
58,261
523,184
Dare Bioscience, Inc. (a)
 
29,994
30,294
DICE Therapeutics, Inc. (a)(b)
 
27,657
874,238
Dova Pharmaceuticals, Inc. rights (a)(c)
 
23,572
0
Durect Corp. (a)(b)
 
13,906
85,522
Edgewise Therapeutics, Inc. (a)(b)
 
33,836
342,420
Elanco Animal Health, Inc. rights (a)(c)
 
45,364
0
Eloxx Pharmaceuticals, Inc. (a)(b)
 
2,954
19,880
Enliven Therapeutics, Inc. (a)(b)
 
2,051
37,533
Enliven Therapeutics, Inc. rights (a)(c)
 
8,204
0
Enveric Biosciences, Inc. (a)(b)
 
96
402
Esperion Therapeutics, Inc. (a)(b)
 
48,336
65,737
Eton Pharmaceuticals, Inc. (a)(b)
 
19,371
76,709
Evoke Pharma, Inc. (a)(b)
 
4,486
7,312
Evolus, Inc. (a)(b)
 
29,762
269,346
Eyenovia, Inc. (a)
 
21,508
61,083
Eyepoint Pharmaceuticals, Inc. (a)(b)
 
15,491
93,721
Fulcrum Therapeutics, Inc. (a)(b)
 
37,833
102,906
GH Research PLC (a)(b)
 
29,429
329,605
Gri Bio, Inc. (a)(b)
 
318
1,905
Harmony Biosciences Holdings, Inc. (a)
 
33,782
1,168,182
Harrow Health, Inc. (a)(b)
 
22,258
419,786
Hepion Pharmaceuticals, Inc. (a)(b)
 
2,007
19,267
HEXO Corp. (a)
 
5,765
5,557
High Tide, Inc. (a)(b)
 
46,134
59,974
Hoth Therapeutics, Inc. (a)(b)
 
1,988
3,141
HUTCHMED China Ltd. sponsored ADR (a)
 
22,305
267,660
Ikena Oncology, Inc. (a)
 
27,112
174,872
Incannex Healthcare Ltd. ADR (a)
 
489
929
InMed Pharmaceuticals, Inc. (a)
 
556
739
Innoviva, Inc. (a)(b)
 
42,389
571,828
InterCure Ltd. (a)(b)
 
14,148
27,447
Intra-Cellular Therapies, Inc. (a)
 
53,306
3,165,310
Ipsen SA (c)
 
103,469
1
Iterum Therapeutics PLC (a)(b)
 
6,139
7,060
Jaguar Health, Inc. (a)(b)
 
527
350
Jazz Pharmaceuticals PLC (a)
 
36,182
4,637,085
Kala Pharmaceuticals, Inc. (a)(b)
 
790
11,297
Landos Biopharma, Inc. (a)(b)
 
2,305
6,362
Lexaria Bioscience Corp. (a)(b)
 
2,740
2,035
Ligand Pharmaceuticals, Inc.:
 
 
 
 Class B (a)
 
11,014
771,861
 General CVR (a)(c)
 
1,518
8
 Glucagon CVR (a)(c)
 
1,518
5
 rights (a)(c)
 
1,518
11
 TR Beta CVR (a)(c)
 
1,518
271
Lipocine, Inc. (a)(b)
 
3,603
16,574
Liquidia Corp. (a)
 
36,922
299,807
Longboard Pharmaceuticals, Inc. (a)
 
6,573
45,551
Lyra Therapeutics, Inc. (a)(b)
 
10,575
27,178
Marinus Pharmaceuticals, Inc. (a)
 
20,303
144,354
MediWound Ltd. (a)(b)
 
2,691
24,650
Milestone Pharmaceuticals, Inc. (a)(b)
 
17,576
69,249
Mind Medicine (MindMed), Inc. (a)(b)
 
34,366
121,656
MyMD Pharmaceuticals, Inc. (a)(b)
 
21,161
36,820
Nabriva Therapeutics PLC (a)(b)
 
1,709
2,649
Nektar Therapeutics (a)
 
33,166
19,240
NGM Biopharmaceuticals, Inc. (a)
 
63,741
193,135
NLS Pharmaceutics Ltd. (a)(b)
 
14,362
14,793
Novan, Inc. (a)(b)
 
10,162
13,820
NRX Pharmaceuticals, Inc. (a)(b)
 
30,907
21,635
Nutriband, Inc. (a)(b)
 
6,718
18,878
Ocular Therapeutix, Inc. (a)(b)
 
35,651
228,166
Oculis Holding AG (a)(b)
 
1,100
12,650
Ocuphire Pharma, Inc. (a)(b)
 
34,766
134,197
Omeros Corp. (a)(b)
 
40,138
248,856
Onconova Therapeutics, Inc. (a)(b)
 
33,198
38,842
Opiant Pharmaceuticals, Inc. rights (a)(c)
 
3,728
0
OptiNose, Inc. (a)(b)
 
56,631
70,789
Oramed Pharmaceuticals, Inc. (a)(b)
 
18,130
73,245
Pacira Biosciences, Inc. (a)
 
26,424
1,004,905
PainReform Ltd. (a)(b)
 
19,107
8,858
Palisade Bio, Inc. (a)(b)
 
1,306
1,724
Palisade Bio, Inc. rights (a)(c)
 
29,628
0
Paratek Pharmaceuticals, Inc. (a)(b)
 
29,676
45,404
PaxMedica, Inc. (b)
 
2,979
3,902
Petros Pharmaceuticals, Inc. (a)(b)
 
674
1,570
Pharvaris BV (a)(b)
 
18,643
159,398
Phathom Pharmaceuticals, Inc. (a)(b)
 
21,720
255,427
Phibro Animal Health Corp. Class A
 
16,621
221,059
Pliant Therapeutics, Inc. (a)
 
30,478
659,239
PolyPid Ltd. (a)(b)
 
12,545
4,767
Procaps Group SA (a)(b)
 
21,223
96,565
Processa Pharmaceuticals, Inc. (a)(b)
 
11,057
6,855
ProPhase Labs, Inc. (b)
 
11,262
106,876
Pulmatrix, Inc. (a)
 
2,220
6,038
Purple Biotech Ltd. ADR (a)(b)
 
12,666
22,292
Qilian International Holding Group Ltd. (b)
 
23,641
22,695
Rain Oncology, Inc. (a)(b)
 
10,662
11,835
Rani Therapeutics Holdings, Inc. (a)(b)
 
14,915
60,853
Reata Pharmaceuticals, Inc. (a)(b)
 
18,956
1,706,988
RedHill Biopharma Ltd. sponsored ADR (a)(b)
 
1,040
2,413
Regencell Bioscience Holdings Ltd. (a)(b)
 
6,816
138,092
Relmada Therapeutics, Inc. (a)
 
14,221
40,388
Revance Therapeutics, Inc. (a)
 
47,886
1,463,396
Reviva Pharmaceuticals Holdings, Inc. (a)(b)
 
12,478
76,241
Royalty Pharma PLC
 
249,891
8,181,431
RVL Pharmaceuticals PLC (a)(b)
 
45,207
37,974
Sanofi SA sponsored ADR
 
166,560
8,497,891
Satsuma Pharmaceuticals, Inc. (a)
 
19,951
20,949
Scilex Holding Co. (a)(b)
 
83,438
496,456
Scilex Holding Co.
 
39,285
210,371
scPharmaceuticals, Inc. (a)(b)
 
18,268
194,006
SCYNEXIS, Inc. (a)(b)
 
18,298
45,745
Seelos Therapeutics, Inc. (a)(b)
 
84,689
78,871
Seelos Therapeutics, Inc. rights (a)(b)(c)
 
2,932
0
SenesTech, Inc. (a)(b)
 
1,582
1,835
SIGA Technologies, Inc. (b)
 
42,115
236,265
Sol-Gel Technologies Ltd. (a)(b)
 
13,406
47,323
Sonoma Pharmaceuticals, Inc. (a)(b)
 
4,975
4,776
Supernus Pharmaceuticals, Inc. (a)
 
32,482
1,076,453
Tarsus Pharmaceuticals, Inc. (a)
 
17,259
289,088
Terns Pharmaceuticals, Inc. (a)(b)
 
26,112
277,048
TFF Pharmaceuticals, Inc. (a)
 
10,670
4,908
TherapeuticsMD, Inc. (a)(b)
 
2,275
9,441
Theravance Biopharma, Inc. (a)(b)
 
43,005
480,796
Theseus Pharmaceuticals, Inc. (a)(b)
 
21,027
153,077
Third Harmonics Bio, Inc. (b)
 
17,293
82,833
Tilray Brands, Inc. Class 2 (a)(b)
 
370,726
619,112
Titan Pharmaceuticals, Inc. (a)(b)
 
19,257
14,712
Trevi Therapeutics, Inc. (a)(b)
 
21,600
46,656
Universe Pharmaceuticals, Inc. (a)(b)
 
8,802
5,017
Ventyx Biosciences, Inc. (a)(b)
 
31,061
1,070,673
Verona Pharma PLC ADR (a)
 
32,790
705,641
Verrica Pharmaceuticals, Inc. (a)(b)
 
20,418
115,770
Viatris, Inc.
 
686,122
6,278,016
Virpax Pharmaceuticals, Inc. (a)(b)
 
6,419
5,038
Vyne Therapeutics, Inc. (a)(b)
 
1,680
10,567
WAVE Life Sciences (a)(b)
 
49,083
194,369
Xeris Biopharma Holdings, Inc. (a)(b)
 
76,277
195,269
Xeris Biopharma Holdings, Inc. rights (a)(c)
 
39,901
0
Zevra Therapeutics, Inc. (a)(b)
 
18,495
93,215
Zynerba Pharmaceuticals, Inc. (a)(b)
 
21,768
7,271
 
 
 
87,997,423
TOTAL HEALTH CARE
 
 
1,000,412,314
INDUSTRIALS - 4.8%
 
 
 
Aerospace & Defense - 0.2%
 
 
 
A2Z Smart Technologies Corp. (a)(b)
 
9,144
17,008
AeroVironment, Inc. (a)
 
14,029
1,310,449
AerSale Corp. (a)
 
32,388
486,468
Aerwins Technology, Inc. Class A (a)(b)
 
2,112
1,225
Astra Space, Inc. Class A (a)(b)
 
107,445
38,669
Astronics Corp. (a)
 
11,489
182,675
Axon Enterprise, Inc. (a)
 
40,217
7,758,261
Byrna Technologies, Inc. (a)(b)
 
14,709
68,691
Draganfly, Inc. (a)(b)
 
18,003
15,123
EHang Holdings Ltd. ADR (a)(b)
 
18,331
183,493
Elbit Systems Ltd. (b)
 
25,289
5,218,132
Innovative Solutions & Support, Inc. (a)
 
6,779
44,470
Intuitive Machines, Inc. Class A (a)(b)
 
52,949
363,230
Kratos Defense & Security Solutions, Inc. (a)
 
68,797
903,993
Leonardo DRS, Inc. (a)
 
147,137
2,221,769
Lilium NV (a)(b)
 
18,161
19,069
Mercury Systems, Inc. (a)
 
33,713
1,368,411
Momentus, Inc. Class A (a)(b)
 
35,057
11,793
Rocket Lab U.S.A., Inc. Class A (a)(b)
 
282,570
1,294,171
Satellogic, Inc. Class A (a)(b)
 
49,366
108,605
TAT Technologies Ltd. (a)
 
4,899
31,623
VirTra, Inc. (a)
 
1,810
14,136
Woodward, Inc.
 
33,738
3,556,323
 
 
 
25,217,787
Air Freight & Logistics - 0.2%
 
 
 
Addentax Group Corp. (a)(b)
 
14,985
10,939
Air T, Inc. (a)(b)
 
1,316
33,729
Air Transport Services Group, Inc. (a)
 
43,309
723,260
C.H. Robinson Worldwide, Inc. (b)
 
66,256
6,263,842
Expeditors International of Washington, Inc.
 
89,532
9,876,275
Forward Air Corp.
 
15,781
1,535,018
Freight Technologies, Inc. (a)(b)
 
761
913
Freightos Ltd. (a)
 
10,007
19,514
Hub Group, Inc. Class A (a)
 
18,738
1,378,367
 
 
 
19,841,857
Building Products - 0.1%
 
 
 
AAON, Inc.
 
31,699
2,745,450
American Woodmark Corp. (a)
 
8,946
532,287
Apogee Enterprises, Inc.
 
10,769
397,484
Applied UV, Inc. (a)
 
861
1,662
Caesarstone Sdot-Yam Ltd.
 
30,851
143,149
CSW Industrials, Inc.
 
8,472
1,200,652
DIRTT Environmental Solutions Ltd. (a)(b)
 
44,471
16,454
Gibraltar Industries, Inc. (a)
 
18,047
943,858
Intelligent Living Application Group, Inc. (b)
 
8,624
9,141
Molekule Group, Inc. (a)(b)
 
11,410
20,424
UFP Industries, Inc.
 
34,558
2,698,980
View, Inc. Class A (a)(b)
 
117,562
18,328
 
 
 
8,727,869
Commercial Services & Supplies - 0.6%
 
 
 
ACV Auctions, Inc. Class A (a)
 
72,728
1,239,285
Aqua Metals, Inc. (a)(b)
 
36,541
37,637
Aurora Innovation, Inc. (a)
 
237,890
335,425
Bridger Aerospace Group Holdings, Inc. (a)(b)
 
30,894
196,177
Casella Waste Systems, Inc. Class A (a)
 
27,982
2,522,857
CECO Environmental Corp. (a)
 
21,695
233,438
Cimpress PLC (a)
 
15,021
717,703
Cintas Corp.
 
56,561
26,704,711
Copart, Inc. (a)
 
265,905
23,290,619
Driven Brands Holdings, Inc. (a)
 
94,370
2,343,207
Fuel Tech, Inc. (a)
 
7,428
10,102
Greenwave Technology Solutions, Inc. (a)(b)
 
7,560
5,897
Guardforce AI Co. Ltd. (a)
 
119
747
Healthcare Services Group, Inc.
 
46,535
628,688
Heritage-Crystal Clean, Inc. (a)
 
13,663
453,065
Interface, Inc.
 
29,819
206,646
Kimball International, Inc. Class B
 
34,877
428,987
Knightscope, Inc. Class A (a)(b)
 
8,793
3,355
LanzaTech Global, Inc. (a)(b)
 
1,196
3,516
Liquidity Services, Inc. (a)
 
22,490
340,274
Matthews International Corp. Class A
 
14,831
570,994
Millerknoll, Inc.
 
40,332
546,499
Odyssey Marine Exploration, Inc. (a)(b)
 
6,411
22,439
Performant Financial Corp. (a)
 
31,795
75,672
Perma-Fix Environmental Services, Inc. (a)(b)
 
9,998
107,978
PyroGenesis Canada, Inc. (a)(b)
 
105,149
80,986
Quest Resource Holding Corp. (a)
 
7,646
41,288
Quhuo Ltd. ADR (a)(b)
 
348
626
Sentage Holdings, Inc. (a)
 
347
781
Smart Powerr Corp. (a)(b)
 
2,863
5,526
SP Plus Corp. (a)
 
13,740
500,273
Stericycle, Inc. (a)
 
51,587
2,174,392
Tetra Tech, Inc.
 
29,711
4,084,371
TOMI Environmental Solutions, Inc. (a)
 
8,765
4,418
Virco Manufacturing Co. (a)
 
950
3,620
VSE Corp.
 
7,604
357,616
 
 
 
68,279,815
Construction & Engineering - 0.1%
 
 
 
Bowman Consulting Group Ltd. (a)
 
5,507
149,185
Capitalworks Emerging Markets Acquisition Corp. (a)(b)
 
2,441
25,533
Concrete Pumping Holdings, Inc. (a)
 
28,584
198,373
Construction Partners, Inc. Class A (a)
 
27,271
754,589
Great Lakes Dredge & Dock Corp. (a)
 
35,442
224,702
IES Holdings, Inc. (a)
 
12,297
583,124
iSun, Inc. (a)(b)
 
10,234
5,424
Limbach Holdings, Inc. (a)
 
6,648
138,478
Matrix Service Co. (a)
 
12,262
66,337
MYR Group, Inc. (a)
 
9,722
1,239,555
Northwest Pipe Co. (a)
 
7,033
186,796
Orbital Infrastructure Group I (a)(b)
 
871
1,725
QualTek Services, Inc. Class A (a)(b)
 
22,514
2,017
Safe & Green Holdings Corp. (a)(b)
 
5,721
4,377
Sterling Construction Co., Inc. (a)
 
17,918
825,482
Willscot Mobile Mini Holdings (a)
 
118,659
5,111,830
 
 
 
9,517,527
Electrical Equipment - 0.2%
 
 
 
ADS-TEC Energy PLC (a)(b)
 
14,709
88,401
Advent Technologies Holdings, Inc. Class A (a)(b)
 
25,238
20,698
Allied Motion Technologies, Inc.
 
8,863
300,722
American Superconductor Corp. (a)
 
23,972
112,429
Array Technologies, Inc. (a)
 
86,006
1,906,753
Asia Pacific Wire & Cable Corp. Ltd. (a)(b)
 
107,599
177,538
Ballard Power Systems, Inc. (a)(b)
 
164,663
688,291
Beam Global (a)(b)
 
6,808
80,879
Blink Charging Co. (a)(b)
 
27,952
188,117
Broadwind, Inc. (a)(b)
 
9,566
35,873
Capstone Turbine Corp. (a)(b)
 
5,108
5,874
CBAK Energy Technology, Inc. (a)(b)
 
60,126
55,316
Dragonfly Energy Holdings Corp. (a)(b)
 
11,655
30,769
Encore Wire Corp. (b)
 
10,517
1,721,317
Energous Corp. (a)
 
89,434
26,821
Energy Focus, Inc. (a)(b)
 
4,115
1,722
Enovix Corp. (a)(b)
 
87,094
1,155,737
Eos Energy Enterprises, Inc. (a)(b)
 
29,681
65,595
Fluence Energy, Inc. (a)(b)
 
65,638
1,627,822
Flux Power Holdings, Inc. (a)(b)
 
15,492
53,447
FTC Solar, Inc. (a)(b)
 
47,794
131,911
FuelCell Energy, Inc. (a)(b)
 
225,259
477,549
Fusion Fuel Green PLC Class A (a)(b)
 
4,794
15,485
Ideal Power, Inc. (a)(b)
 
6,424
70,664
LSI Industries, Inc.
 
17,145
199,396
NeoVolta, Inc. (a)(b)
 
13,952
41,437
Nextracker, Inc. Class A (b)
 
23,421
895,853
Nuvve Holding Corp. (a)(b)
 
16,407
8,532
Orion Energy Systems, Inc. (a)(b)
 
14,347
21,162
Pineapple Energy, Inc. (a)
 
1,083
1,430
Pineapple Energy, Inc. rights (a)(c)
 
1,083
0
Pioneer Power Solutions, Inc. (a)(b)
 
9,793
53,764
Plug Power, Inc. (a)(b)
 
330,675
2,751,216
Polar Power, Inc. (a)(b)
 
8,285
11,185
Powell Industries, Inc.
 
6,368
366,160
Preformed Line Products Co.
 
3,095
475,732
Shoals Technologies Group, Inc. (a)
 
72,406
1,700,817
SKYX Platforms Corp. (a)(b)
 
58,672
184,817
SunPower Corp. (a)(b)
 
97,348
1,031,889
Sunrun, Inc. (a)(b)
 
120,249
2,121,192
Sunworks, Inc. (a)(b)
 
14,202
19,883
TPI Composites, Inc. (a)(b)
 
21,435
228,497
Tritium DCFC Ltd. (a)(b)
 
101,080
117,253
Ultralife Corp. (a)
 
11,042
46,487
Vicor Corp. (a)
 
18,628
1,031,060
 
 
 
20,347,492
Ground Transportation - 0.8%
 
 
 
ArcBest Corp.
 
13,772
1,153,818
Avis Budget Group, Inc. (a)(b)
 
23,196
3,892,057
Covenant Transport Group, Inc. Class A
 
6,293
240,204
CSX Corp.
 
1,161,535
35,624,278
Daseke, Inc. (a)
 
34,313
205,878
FTAI Infrastructure LLC
 
42,306
137,495
Grab Holdings Ltd. (a)(b)
 
2,094,176
6,240,644
Heartland Express, Inc.
 
44,050
687,180
Hertz Global Holdings, Inc. (a)(b)
 
186,743
2,928,130
J.B. Hunt Transport Services, Inc.
 
57,936
9,673,574
Landstar System, Inc.
 
20,130
3,530,399
Lyft, Inc. (a)
 
201,969
1,821,760
Marten Transport Ltd.
 
47,473
1,004,054
Micromobility.Com, Inc. (a)(b)
 
1,711
585
MingZhu Logistics Holdings Ltd. (a)(b)
 
2,711
3,280
Old Dominion Freight Lines, Inc.
 
62,106
19,280,187
P.A.M. Transportation Services, Inc. (a)
 
14,004
366,345
Patriot Transportation Holding, Inc. (a)
 
1,759
15,233
Saia, Inc. (a)
 
15,012
4,265,810
Swvl Holdings Corp. Class A (a)(b)
 
5,907
7,088
TuSimple Holdings, Inc. (a)(b)
 
113,475
229,220
Universal Logistics Holdings, Inc.
 
15,843
420,632
Werner Enterprises, Inc.
 
37,001
1,625,084
Yellow Corp. (a)(b)
 
25,553
32,452
 
 
 
93,385,387
Industrial Conglomerates - 0.6%
 
 
 
Gaucho Group Holdings, Inc. (a)(b)
 
832
487
Honeywell International, Inc.
 
379,898
72,788,457
Icahn Enterprises LP
 
192,630
4,347,659
 
 
 
77,136,603
Machinery - 0.4%
 
 
 
Agrify Corp. (a)(b)
 
1,129
203
Astec Industries, Inc.
 
13,267
489,022
Berkshire Grey, Inc. Class A (a)(b)
 
116,912
162,508
Blue Bird Corp. (a)
 
16,718
423,968
Columbus McKinnon Corp. (NY Shares)
 
16,265
593,347
Commercial Vehicle Group, Inc. (a)
 
21,200
207,972
Eastern Co. (b)
 
4,547
74,071
Energy Recovery, Inc. (a)
 
35,074
835,112
Franklin Electric Co., Inc.
 
25,745
2,341,765
FreightCar America, Inc. (a)(b)
 
32,845
92,294
Greenland Technologies Holding Corp. (a)(b)
 
5,467
9,677
GreenPower Motor Co., Inc. (a)(b)
 
11,083
25,491
Hillman Solutions Corp. Class A (a)
 
118,272
958,003
Hurco Companies, Inc.
 
4,416
92,957
Hydrofarm Holdings Group, Inc. (a)(b)
 
45,713
41,923
Hyzon Motors, Inc. Class A (a)(b)
 
134,771
74,124
Ideanomics, Inc. (a)(b)
 
232,089
9,748
JE Cleantech Holdings Ltd. (a)(b)
 
7,504
4,845
Kornit Digital Ltd. (a)
 
26,015
584,037
L.B. Foster Co. Class A (a)
 
5,419
71,802
Laser Photonics Corp. (b)
 
2,853
8,388
Lincoln Electric Holdings, Inc.
 
32,427
5,501,565
LiqTech International, Inc. (a)(b)
 
1,854
6,304
Manitex International, Inc. (a)
 
14,236
64,987
Microvast Holdings, Inc. (a)(b)
 
170,830
211,829
Middleby Corp. (a)
 
29,825
3,936,900
Nauticus Robotics, Inc. (a)(b)
 
6,031
11,760
Nikola Corp. (a)(b)
 
277,385
173,088
NN, Inc. (a)(b)
 
23,071
40,605
Nordson Corp.
 
32,070
6,989,015
Nxu, Inc. (a)(b)
 
6,484
3,177
Omega Flex, Inc. (b)
 
6,379
664,500
PACCAR, Inc.
 
290,661
19,991,664
Park-Ohio Holdings Corp. (b)
 
7,033
110,910
Perma-Pipe International Holdings, Inc. (a)
 
5,390
55,625
Proterra, Inc. Class A (a)(b)
 
125,619
134,412
Sarcos Technology and Robotics Corp. Class A (a)(b)
 
75,604
29,493
Shyft Group, Inc. (The)
 
20,942
492,346
Symbotic, Inc. (a)(b)
 
35,622
1,174,814
Taylor Devices, Inc. (a)
 
1,759
32,717
Twin Disc, Inc. (a)
 
9,749
109,579
Urban-Gro, Inc. (a)(b)
 
1,561
1,920
Vicinity Motor Corp. (a)(b)
 
64,732
55,100
voxeljet AG ADR (a)
 
2,769
5,400
Westport Fuel Systems, Inc. (a)(b)
 
72,395
51,089
Xos, Inc. Class A (a)(b)
 
97,889
40,918
 
 
 
46,990,974
Marine Transportation - 0.0%
 
 
 
Capital Product Partners LP
 
9,277
120,694
Caravelle International Group (a)(b)
 
20,088
12,254
Castor Maritime, Inc. (a)(b)
 
49,703
22,550
EuroDry Ltd. (a)(b)
 
3,499
47,796
Euroseas Ltd. (b)
 
5,072
102,657
Golden Ocean Group Ltd. (b)
 
114,916
811,307
Grindrod Shipping Holdings Ltd. (b)
 
9,738
69,237
Pangaea Logistics Solutions Ltd.
 
29,549
169,611
Pyxis Tankers, Inc. (a)(b)
 
10,640
42,454
Seanergy Martime Holdings Corp. (b)
 
7,208
29,192
Star Bulk Carriers Corp. (b)
 
58,306
998,782
Toro Corp. (a)(b)
 
4,970
15,208
United Maritime Corp. (b)
 
608
1,642
 
 
 
2,443,384
Passenger Airlines - 0.2%
 
 
 
Allegiant Travel Co. (a)
 
10,764
1,049,382
American Airlines Group, Inc. (a)
 
360,724
5,331,501
Blade Air Mobility, Inc. (a)(b)
 
44,231
142,866
Frontier Group Holdings, Inc. (a)
 
120,000
987,600
Hawaiian Holdings, Inc. (a)
 
31,196
249,880
JetBlue Airways Corp. (a)
 
186,955
1,276,903
Mesa Air Group, Inc. (a)
 
19,225
31,529
Ryanair Holdings PLC sponsored ADR (a)
 
55,908
5,874,813
SkyWest, Inc. (a)(b)
 
28,361
848,278
Sun Country Airlines Holdings, Inc. (a)
 
31,435
590,978
United Airlines Holdings, Inc. (a)
 
184,658
8,764,792
 
 
 
25,148,522
Professional Services - 1.2%
 
 
 
Asure Software, Inc. (a)
 
12,380
146,208
Automatic Data Processing, Inc.
 
233,852
48,872,729
Barrett Business Services, Inc.
 
3,985
334,740
Concentrix Corp.
 
29,301
2,569,698
Conduent, Inc. (a)
 
123,383
373,850
CoStar Group, Inc. (a)
 
228,207
18,119,636
CRA International, Inc.
 
4,701
435,642
CSG Systems International, Inc.
 
17,738
851,069
DLH Holdings Corp. (a)
 
6,805
71,861
Exela Technologies, Inc. (a)(b)
 
862
4,439
ExlService Holdings, Inc. (a)
 
18,501
2,792,541
Exponent, Inc.
 
28,889
2,638,143
First Advantage Corp. (a)(b)
 
84,804
1,145,702
Forrester Research, Inc. (a)
 
10,756
308,697
Headhunter Group PLC ADR (a)(c)
 
16,914
46,036
Heidrick & Struggles International, Inc.
 
10,143
245,968
Hirequest, Inc. (b)
 
6,993
162,517
Hudson Global, Inc. (a)
 
1,914
37,151
Huron Consulting Group, Inc. (a)
 
11,971
973,003
IBEX Ltd. (a)
 
11,244
230,277
ICF International, Inc.
 
10,225
1,145,098
Innodata, Inc. (a)
 
13,207
133,787
Kelly Services, Inc. Class A (non-vtg.)
 
24,091
421,111
Kforce, Inc.
 
10,845
624,564
LegalZoom.com, Inc. (a)
 
111,440
1,247,014
NV5 Global, Inc. (a)
 
8,747
792,653
Paychex, Inc.
 
202,818
21,281,693
Paycor HCM, Inc. (a)(b)
 
97,696
2,148,335
Paylocity Holding Corp. (a)
 
30,781
5,317,418
Professional Diversity Network, Inc. (a)(b)
 
2,796
10,681
RCM Technologies, Inc. (a)
 
6,964
112,886
Recruiter.com Group, Inc. (a)(b)
 
7,704
1,724
Red Violet, Inc. (a)
 
8,743
172,412
Resources Connection, Inc.
 
22,136
338,238
ShiftPixy, Inc. (a)(b)
 
5,720
11,726
SS&C Technologies Holdings, Inc.
 
141,808
7,793,768
Steel Connect, Inc. (a)
 
32,364
27,267
Sterling Check Corp. (a)(b)
 
57,207
774,011
Sunrise New Energy Co. Ltd. (a)(b)
 
8,860
17,277
TaskUs, Inc. (a)(b)
 
14,716
159,669
Ttec Holdings, Inc.
 
26,494
840,390
Upwork, Inc. (a)
 
70,469
577,846
Verisk Analytics, Inc.
 
87,675
19,210,469
Verra Mobility Corp. (a)
 
88,691
1,563,622
Where Food Comes From, Inc. (a)(b)
 
2,480
34,745
Willdan Group, Inc. (a)
 
8,506
141,710
 
 
 
145,260,021
Trading Companies & Distributors - 0.2%
 
 
 
Beacon Roofing Supply, Inc. (a)
 
36,275
2,319,424
Distribution Solutions Group I (a)
 
13,506
608,445
DXP Enterprises, Inc. (a)
 
11,146
356,338
Euro Tech Holdings Co. Ltd. (a)(b)
 
4,600
7,268
Fastenal Co.
 
320,369
17,251,871
FTAI Aviation Ltd.
 
59,349
1,664,739
Gd Culture Group Ltd. (a)
 
590
2,897
H&E Equipment Services, Inc.
 
19,545
702,838
Hudson Technologies, Inc. (a)
 
23,239
203,109
iPower, Inc. (a)(b)
 
20,826
12,287
Karat Packaging, Inc.
 
10,117
161,265
Lavoro Ltd. Class A (a)(b)
 
2,118
12,390
McGrath RentCorp.
 
12,871
1,143,074
Rush Enterprises, Inc.:
 
 
 
 Class A
 
25,714
1,344,071
 Class B (b)
 
6,706
390,222
Td Holdings, Inc. (a)
 
11,672
7,762
Titan Machinery, Inc. (a)
 
11,661
294,440
Transcat, Inc. (a)
 
4,527
382,667
Willis Lease Finance Corp. (a)
 
3,418
132,789
Xometry, Inc. (a)(b)
 
26,019
476,148
 
 
 
27,474,044
Transportation Infrastructure - 0.0%
 
 
 
Grupo Aeroportuario Norte S.A.B. de CV ADR
 
2,078
171,747
Singularity Future Technology Ltd. (a)(b)
 
11,251
5,684
 
 
 
177,431
TOTAL INDUSTRIALS
 
 
569,948,713
INFORMATION TECHNOLOGY - 46.5%
 
 
 
Communications Equipment - 1.2%
 
 
 
ADTRAN Holdings, Inc. (b)
 
42,564
379,245
Applied Optoelectronics, Inc. (a)(b)
 
20,141
44,713
AudioCodes Ltd.
 
17,081
146,384
Aviat Networks, Inc. (a)
 
6,448
197,438
CalAmp Corp. (a)
 
18,255
32,129
Cambium Networks Corp. (a)
 
14,493
227,250
Casa Systems, Inc. (a)(b)
 
32,303
33,918
Ceragon Networks Ltd. (a)(b)
 
40,973
73,342
Cisco Systems, Inc.
 
2,316,313
115,051,267
Clearfield, Inc. (a)(b)
 
8,271
323,479
ClearOne, Inc. (a)(b)
 
10,289
23,459
CommScope Holding Co., Inc. (a)
 
117,050
486,928
COMSovereign Holding Corp. (a)(b)
 
203
327
Comtech Telecommunications Corp.
 
12,600
144,648
Digi International, Inc. (a)
 
19,090
686,286
DZS, Inc. (a)(b)
 
49,902
298,913
EMCORE Corp. (a)
 
20,355
15,185
Ericsson (B Shares) sponsored ADR (b)
 
184,390
951,452
Extreme Networks, Inc. (a)
 
71,064
1,463,918
F5, Inc. (a)
 
33,582
4,956,032
Franklin Wireless Corp. (a)
 
9,420
33,064
Genasys, Inc. (a)(b)
 
20,513
53,129
Gilat Satellite Networks Ltd. (a)(b)
 
24,237
127,002
Harmonic, Inc. (a)
 
60,290
1,061,707
Infinera Corp. (a)(b)
 
138,900
680,610
Inseego Corp. (a)(b)
 
52,527
56,204
Ituran Location & Control Ltd.
 
10,985
250,897
KVH Industries, Inc. (a)
 
10,763
96,221
Lantronix, Inc. (a)(b)
 
15,008
66,485
Lumentum Holdings, Inc. (a)
 
38,886
2,057,069
Minim, Inc. (a)(b)
 
566
2,326
NETGEAR, Inc. (a)
 
18,625
261,309
NetScout Systems, Inc. (a)(b)
 
41,313
1,260,873
Ondas Holdings, Inc. (a)(b)
 
18,652
16,177
PCTEL, Inc.
 
11,312
54,071
Radware Ltd. (a)
 
27,195
534,654
Ribbon Communications, Inc. (a)
 
100,851
280,366
Silicom Ltd. (a)
 
4,848
178,309
Siyata Mobile, Inc. (a)(b)
 
19,350
1,740
Tessco Technologies, Inc. (a)
 
10,061
89,241
UTStarcom Holdings Corp. (a)
 
12,236
48,210
ViaSat, Inc. (a)(b)
 
44,110
1,967,747
Viavi Solutions, Inc. (a)
 
125,363
1,233,572
Vislink Technologies, Inc. (a)(b)
 
1,268
7,253
 
 
 
135,954,549
Electronic Equipment, Instruments & Components - 0.6%
 
 
 
908 Devices, Inc. (a)(b)
 
25,319
220,528
Advanced Energy Industries, Inc.
 
21,207
2,081,467
AEye, Inc. Class A (a)(b)
 
77,692
15,826
Airgain, Inc. (a)
 
4,073
23,012
Akoustis Technologies, Inc. (a)(b)
 
42,555
134,474
Alpine 4 Holdings, Inc. (a)(b)
 
12,412
32,644
Arbe Robotics Ltd. (a)(b)
 
30,506
68,333
Astrotech Corp. (a)(b)
 
1,228
14,122
Avnet, Inc.
 
53,317
2,337,417
Bel Fuse, Inc.:
 
 
 
 Class A
 
1,125
51,998
 Class B (non-vtg.)
 
5,258
258,641
Bonso Electronic International, Inc. (a)(b)
 
5,325
14,990
CDW Corp.
 
75,867
13,025,605
Cemtrex, Inc. (a)(b)
 
862
8,198
Cepton, Inc. (a)(b)
 
81,091
36,467
ClearSign Combustion Corp. (a)(b)
 
16,057
24,567
Climb Global Solutions, Inc.
 
3,243
152,259
Coda Octopus Group, Inc. (a)(b)
 
4,103
42,958
Cognex Corp.
 
98,483
5,412,626
CPS Technologies Corp. (a)(b)
 
4,893
14,434
Daktronics, Inc. (a)
 
31,984
201,179
Data I/O Corp. (a)
 
15,054
65,184
Deswell Industries, Inc.
 
1,758
4,694
Digital Ally, Inc. (a)(b)
 
1,160
4,304
ePlus, Inc. (a)
 
14,724
727,218
Evolv Technologies Holdings, Inc. (a)
 
82,187
489,835
FARO Technologies, Inc. (a)(b)
 
11,137
168,057
Flex Ltd. (a)
 
254,596
6,464,192
Focus Universal, Inc. (b)
 
37,564
62,732
Frequency Electronics, Inc.
 
5,274
34,545
Hollysys Automation Technologies Ltd. (a)(b)
 
35,132
553,680
Identiv, Inc. (a)
 
10,328
75,085
IDEX Biometrics ASA ADR (a)
 
440
2,253
Innoviz Technologies Ltd. (a)(b)
 
78,745
231,510
Insight Enterprises, Inc. (a)(b)
 
19,371
2,619,347
Integrated Media Technology Ltd. (a)(b)
 
3,824
1,935
Interlink Electronics, Inc. (a)(b)
 
2,544
25,135
IPG Photonics Corp. (a)
 
27,488
3,036,599
Iteris, Inc. (a)
 
22,008
101,017
Itron, Inc. (a)
 
24,868
1,684,310
KEY Tronic Corp. (a)
 
6,057
33,011
Kimball Electronics, Inc. (a)
 
15,945
395,436
LightPath Technologies, Inc. Class A (a)
 
12,016
17,183
Lightwave Logic, Inc. (a)(b)
 
60,149
445,704
Littelfuse, Inc.
 
13,952
3,572,270
Luna Innovations, Inc. (a)(b)
 
21,826
201,236
MicroVision, Inc. (a)(b)
 
87,687
411,252
Movella Holdings, Inc. (a)(b)
 
17,794
42,528
Napco Security Technologies, Inc. (b)
 
23,668
880,213
National Instruments Corp.
 
72,866
4,211,655
Nayax Ltd. (a)
 
18,600
318,432
Neonode, Inc. (a)(b)
 
4,962
40,291
nLIGHT, Inc. (a)
 
33,320
481,807
Novanta, Inc. (a)
 
19,813
3,281,033
OSI Systems, Inc. (a)
 
9,960
1,185,340
PC Connection, Inc.
 
15,743
707,963
Plexus Corp. (a)
 
16,563
1,501,933
Powerfleet, Inc. (a)
 
19,674
61,580
Presto Automation, Inc. (a)(b)
 
14,322
38,956
Rail Vision Ltd. (a)(b)
 
6,227
3,863
Red Cat Holdings, Inc. (a)(b)
 
30,119
27,709
Research Frontiers, Inc. (a)(b)
 
10,936
19,029
RF Industries Ltd. (a)
 
2,448
10,869
Richardson Electronics Ltd.
 
7,825
129,817
Sanmina Corp. (a)
 
31,715
1,682,164
ScanSource, Inc. (a)
 
13,234
380,610
Senstar Technologies Ltd. (a)
 
12,188
16,698
SMX Security Matters PLC (a)(b)
 
3,529
3,600
Sobr Safe, Inc. (a)(b)
 
5,319
8,830
Sono-Tek Corp. (a)(b)
 
2,629
14,433
Supercom Ltd. (a)(b)
 
894
966
Tempo Automation Holdings, Inc. Class A (a)(b)
 
15,037
4,061
Tingo Group, Inc. (a)(b)
 
91,949
261,135
Trimble, Inc. (a)
 
139,242
6,498,424
TROOPS, Inc. (a)(b)
 
52,367
178,571
TTM Technologies, Inc. (a)
 
56,839
778,694
Wrap Technologies, Inc. (a)(b)
 
38,058
40,722
Zebra Technologies Corp. Class A (a)
 
29,057
7,629,496
 
 
 
76,040,891
IT Services - 0.6%
 
 
 
AgileThought, Inc. Class A (a)(b)
 
21,017
15,763
Akamai Technologies, Inc. (a)
 
88,918
8,191,126
Alithya Group, Inc. (a)
 
36,580
61,820
Amdocs Ltd.
 
67,943
6,398,192
Backblaze, Inc. Class A (a)(b)
 
3,198
13,400
BigCommerce Holdings, Inc. (a)
 
42,950
342,312
Brightcove, Inc. (a)
 
26,601
111,192
Chindata Group Holdings Ltd. ADR (a)
 
69,326
395,158
Ciso Global, Inc. (a)(b)
 
82,667
14,194
CLPS, Inc. (b)
 
5,050
6,666
Cognizant Technology Solutions Corp. Class A
 
289,460
18,088,355
Computer Task Group, Inc. (a)(b)
 
17,316
120,693
Crexendo, Inc.
 
12,457
20,305
CSP, Inc.
 
2,765
34,065
CXApp, Inc.:
 
 
 
 Class A (a)(b)
 
28,670
352,641
 Class C
 
238
2,635
Cyxtera Technologies, Inc. Class A (a)(b)
 
95,891
15,534
Data Storage Corp. (a)(b)
 
23,206
43,627
Edgio, Inc. (a)
 
115,599
59,557
Formula Systems (1985) Ltd. ADR (b)
 
193
13,452
GDS Holdings Ltd. ADR (a)(b)
 
49,637
484,457
Grid Dynamics Holdings, Inc. (a)
 
99,879
958,838
Hackett Group, Inc. (b)
 
16,264
315,359
Hub Cyber Security Ltd. (a)(b)
 
3,799
2,253
Information Services Group, Inc.
 
25,958
132,386
Inpixon (a)(b)
 
689
138
Kingsoft Cloud Holdings Ltd. ADR (a)(b)
 
68,164
304,011
Microalgo, Inc. (a)(b)
 
39,101
90,323
MongoDB, Inc. Class A (a)
 
38,646
11,353,808
Okta, Inc. (a)
 
85,473
7,769,496
Perficient, Inc. (a)
 
20,170
1,542,400
PFSweb, Inc. (a)
 
12,193
52,674
Rackspace Technology, Inc. (a)(b)
 
141,850
221,286
Research Solutions, Inc. (a)
 
4,834
10,103
Taoping, Inc. (a)(b)
 
3,739
2,617
The Glimpse Group, Inc. (a)(b)
 
3,147
15,546
Thoughtworks Holding, Inc. (a)
 
184,167
1,517,536
Tucows, Inc. (a)(b)
 
6,556
203,892
VeriSign, Inc. (a)
 
59,497
13,286,870
Vnet Group, Inc. ADR (a)(b)
 
74,174
190,627
WaveDancer, Inc. (a)
 
2,165
801
Wix.com Ltd. (a)
 
32,415
2,470,671
 
 
 
75,226,779
Semiconductors & Semiconductor Equipment - 13.5%
 
 
 
ACM Research, Inc. (a)
 
28,563
288,772
Advanced Micro Devices, Inc. (a)
 
907,246
107,245,550
AEHR Test Systems (a)(b)
 
14,540
480,111
Allegro MicroSystems LLC (a)(b)
 
111,129
4,370,704
Alpha & Omega Semiconductor Ltd. (a)
 
13,730
380,184
Ambarella, Inc. (a)
 
21,826
1,578,456
Amkor Technology, Inc.
 
136,705
3,387,550
Amtech Systems, Inc. (a)
 
9,588
85,333
Analog Devices, Inc.
 
287,231
51,038,076
Applied Materials, Inc.
 
479,100
63,864,030
Ascent Solar Technologies, Inc. (a)(b)
 
22,041
2,502
ASML Holding NV (depository receipt)
 
49,872
36,053,965
Atomera, Inc. (a)(b)
 
13,904
127,639
Axcelis Technologies, Inc. (a)
 
19,189
3,023,227
AXT, Inc. (a)
 
21,623
73,734
Broadcom, Inc.
 
234,960
189,838,282
Camtek Ltd. (a)(b)
 
23,975
692,638
Canadian Solar, Inc. (a)(b)
 
35,996
1,504,633
CEVA, Inc. (a)
 
12,199
305,219
ChipMOS TECHNOLOGIES, Inc. sponsored ADR
 
3,922
100,325
Cirrus Logic, Inc. (a)
 
32,816
2,549,147
Cohu, Inc. (a)
 
26,895
1,031,154
Credo Technology Group Holding Ltd. (a)(b)
 
84,458
1,133,426
CVD Equipment Corp. (a)(b)
 
4,263
27,752
Diodes, Inc. (a)
 
25,728
2,311,404
Enphase Energy, Inc. (a)
 
76,496
13,301,124
Entegris, Inc.
 
84,220
8,864,155
Everspin Technologies, Inc. (a)
 
13,033
111,823
First Solar, Inc. (a)
 
59,922
12,161,769
FormFactor, Inc. (a)
 
42,470
1,328,886
GlobalFoundries, Inc. (a)(b)
 
307,619
17,943,416
GSI Technology, Inc. (a)(b)
 
15,609
90,376
Himax Technologies, Inc. sponsored ADR (b)
 
59,577
409,890
Ichor Holdings Ltd. (a)
 
15,188
460,196
Impinj, Inc. (a)(b)
 
13,887
1,421,196
indie Semiconductor, Inc. (a)(b)
 
78,627
746,957
Intel Corp.
 
2,325,585
73,116,392
KLA Corp.
 
78,300
34,686,117
Kopin Corp. (a)
 
49,279
106,935
Kulicke & Soffa Industries, Inc. (b)
 
33,199
1,755,563
Lam Research Corp.
 
76,699
47,300,273
Lattice Semiconductor Corp. (a)
 
77,203
6,277,376
MACOM Technology Solutions Holdings, Inc. (a)
 
41,657
2,492,338
Marvell Technology, Inc.
 
481,174
28,143,867
Maxeon Solar Technologies Ltd. (a)(b)
 
27,787
772,201
MaxLinear, Inc. Class A (a)
 
42,983
1,255,533
Meta Materials, Inc. (a)(b)
 
192,868
40,502
Microchip Technology, Inc.
 
310,121
23,339,706
Micron Technology, Inc.
 
612,055
41,742,151
MKS Instruments, Inc. (b)
 
37,952
3,693,109
Monolithic Power Systems, Inc.
 
26,156
12,814,086
Navitas Semiconductor Corp. (a)(b)
 
100,637
860,446
Nova Ltd. (a)(b)
 
15,784
1,704,514
NVE Corp.
 
2,373
212,075
NVIDIA Corp.
 
1,395,982
528,155,830
NXP Semiconductors NV (b)
 
146,264
26,195,882
onsemi (a)
 
243,625
20,367,050
PDF Solutions, Inc. (a)
 
23,680
1,000,480
Peraso, Inc. (a)(b)
 
20,260
19,788
Photronics, Inc. (a)
 
36,838
782,071
Pixelworks, Inc. (a)(b)
 
37,111
65,686
POET Technologies, Inc. (a)(b)
 
3,990
17,556
Power Integrations, Inc. (b)
 
33,245
2,872,368
Qorvo, Inc. (a)
 
58,332
5,673,370
Qualcomm, Inc.
 
632,156
71,692,812
QuickLogic Corp. (a)(b)
 
2,338
14,016
Rambus, Inc. (a)
 
62,796
4,016,432
Rigetti Computing, Inc. Class A (a)(b)
 
72,424
67,992
SemiLEDs Corp. (a)(b)
 
4,500
11,565
Semtech Corp. (a)
 
36,094
784,684
Silicon Laboratories, Inc. (a)(b)
 
19,443
2,735,047
Silicon Motion Tech Corp. sponsored ADR
 
19,713
1,207,224
SiTime Corp. (a)
 
11,495
1,139,959
SkyWater Technology, Inc. (a)(b)
 
21,008
215,332
Skyworks Solutions, Inc.
 
89,365
9,250,171
SMART Global Holdings, Inc. (a)
 
25,906
584,957
SolarEdge Technologies, Inc. (a)
 
31,414
8,947,650
SPI Energy Co. Ltd. sponsored ADR (a)
 
11,554
13,749
Synaptics, Inc. (a)
 
22,741
1,956,636
Teradyne, Inc.
 
87,553
8,771,935
Texas Instruments, Inc.
 
511,785
88,989,176
Tower Semiconductor Ltd. (a)
 
61,684
2,414,312
Transphorm, Inc. (a)
 
7,137
28,048
Ultra Clean Holdings, Inc. (a)
 
25,361
869,375
Universal Display Corp.
 
26,158
3,853,858
Veeco Instruments, Inc. (a)(b)
 
28,870
704,717
WiSA Technologies, Inc. (a)(b)
 
510
627
WISeKey International Holding Ltd. ADR (a)(b)
 
695
1,327
 
 
 
1,602,068,467
Software - 16.9%
 
 
 
8x8, Inc. (a)
 
66,663
271,985
Absolute Software Corp.
 
25,866
289,958
ACI Worldwide, Inc. (a)
 
65,286
1,489,174
Adeia, Inc.
 
60,469
593,201
Adobe, Inc. (a)
 
259,186
108,285,319
Agilysys, Inc. (a)
 
14,089
1,047,376
Agora, Inc. ADR (a)
 
52,617
144,171
Alarm.com Holdings, Inc. (a)
 
28,485
1,430,517
Alarum Technologies Ltd. ADR (a)(b)
 
2,487
7,461
Alkami Technology, Inc. (a)
 
54,588
818,820
Allot Ltd. (a)(b)
 
21,262
57,407
Altair Engineering, Inc. Class A (a)(b)
 
28,825
2,113,737
American Software, Inc. Class A
 
20,292
258,317
Amplitude, Inc. (a)
 
16,277
158,538
ANSYS, Inc. (a)
 
49,154
15,905,743
AppFolio, Inc. (a)
 
11,991
1,716,512
Appian Corp. Class A (a)(b)
 
24,732
1,059,272
Applied Digital Corp. (a)
 
60,991
510,495
AppLovin Corp. (a)(b)
 
160,428
4,012,304
Argo Blockchain PLC ADR (a)(b)
 
2,693
3,232
Arqit Quantum, Inc. (a)(b)
 
67,275
95,531
Arteris, Inc. (a)
 
17,296
120,380
Aspen Technology, Inc. (a)
 
36,789
6,030,453
Atlassian Corp. PLC (a)(b)
 
86,301
15,602,358
Auddia, Inc. (a)(b)
 
4,309
1,810
AudioEye, Inc. (a)(b)
 
8,256
50,279
Aurora Mobile Ltd. ADR (a)(b)
 
47,465
14,714
Authid, Inc. (a)(b)
 
12,623
8,584
Autodesk, Inc. (a)
 
121,053
24,136,758
AvePoint, Inc. (a)(b)
 
117,943
779,603
Aware, Inc. (a)
 
13,849
21,881
Baijiayun Group Ltd. (a)(b)
 
4,935
35,236
Bentley Systems, Inc. Class B
 
154,645
7,543,583
Bio-Key International, Inc. (a)(b)
 
10,259
8,002
Bit Digital, Inc. (a)(b)
 
5,626
19,072
Bit Origin Ltd. (a)(b)
 
1,005
2,221
Bitfarms Ltd. (a)(b)
 
218,197
261,836
Blackbaud, Inc. (a)
 
30,083
2,206,889
BlackLine, Inc. (a)
 
35,053
1,825,210
Braze, Inc. (a)
 
29,733
984,460
Bridgeline Digital, Inc. (a)(b)
 
2,527
2,603
BSQUARE Corp. (a)
 
7,925
9,193
BTCS, Inc. (a)
 
2,315
2,801
BTCS, Inc. Series V (c)
 
2,315
0
Cadence Design Systems, Inc. (a)
 
154,169
35,599,164
CCC Intelligent Solutions Holdings, Inc. Class A (a)(b)
 
350,865
3,838,463
Cellebrite DI Ltd. (a)(b)
 
109,618
632,496
Cerence, Inc. (a)
 
27,389
781,134
Check Point Software Technologies Ltd. (a)
 
70,022
8,739,446
Cipher Mining, Inc. (a)(b)
 
155,211
394,236
Cleanspark, Inc. (a)(b)
 
20,735
88,953
Cognyte Software Ltd. (a)
 
61,289
304,606
CommVault Systems, Inc. (a)
 
24,432
1,702,666
Confluent, Inc. (a)
 
84,849
2,693,107
Consensus Cloud Solutions, Inc. (a)
 
11,285
411,338
Couchbase, Inc. (a)(b)
 
23,156
475,161
Crowdstrike Holdings, Inc. (a)
 
122,930
19,684,781
Cvent Holding Corp. (a)(b)
 
280,207
2,378,957
CyberArk Software Ltd. (a)
 
22,061
3,413,499
Cyngn, Inc. (a)(b)
 
11,100
11,100
Datadog, Inc. Class A (a)
 
165,459
15,703,714
Datasea, Inc. (a)(b)
 
16,136
14,845
DatChat, Inc. (a)(b)
 
11,224
4,119
Dave, Inc. (a)(b)
 
2,237
11,990
Descartes Systems Group, Inc. (a)
 
47,707
3,689,182
Digihost Technology, Inc. (a)
 
8,997
13,585
Digimarc Corp. (a)(b)
 
15,142
467,282
Digital Turbine, Inc. (a)(b)
 
52,403
478,963
Docebo, Inc. (a)
 
18,504
631,356
DocuSign, Inc. (a)
 
112,854
6,364,966
Domo, Inc. Class B (a)
 
23,964
322,316
Dropbox, Inc. Class A (a)
 
149,709
3,446,301
Duos Technologies Group, Inc. (a)(b)
 
2,223
11,360
Ebix, Inc. (b)
 
17,007
338,779
eGain Communications Corp. (a)
 
24,943
180,837
Embark Technology, Inc. (a)(b)
 
7,450
20,786
Everbridge, Inc. (a)
 
25,015
600,860
EverCommerce, Inc. (a)(b)
 
111,483
1,324,418
Expensify, Inc. (a)
 
37,779
261,431
Five9, Inc. (a)
 
39,358
2,601,957
Fortinet, Inc. (a)
 
439,842
30,054,404
Freshworks, Inc. (a)
 
89,881
1,416,525
Gen Digital, Inc.
 
366,595
6,430,076
GitLab, Inc. (a)(b)
 
49,563
1,831,848
Gorilla Technology Group, Inc. (a)(b)
 
41,258
76,327
Greenidge Generation Holdings, Inc. (a)(b)
 
641
1,513
HashiCorp, Inc. (a)
 
44,894
1,541,660
HIVE Blockchain Technologies Ltd. (a)(b)
 
35,232
114,152
Hut 8 Mining Corp. (a)(b)
 
143,401
309,746
Infobird Co. Ltd. (a)(b)
 
464
566
Intapp, Inc. (a)
 
34,418
1,454,849
Intellicheck, Inc. (a)(b)
 
10,166
23,890
InterDigital, Inc. (b)
 
17,923
1,488,326
Intrusion, Inc. (a)(b)
 
13,441
20,968
Intuit, Inc.
 
157,983
66,213,835
Iris Energy Ltd. (a)(b)
 
30,475
108,796
Jamf Holding Corp. (a)(b)
 
67,210
1,235,320
JFrog Ltd. (a)
 
57,353
1,397,119
Kaltura, Inc. (a)(b)
 
70,000
119,700
Karooooo Ltd. (b)
 
18,218
419,196
Kaspien Holdings, Inc. (a)(b)
 
939
263
Latch, Inc. (a)
 
25,259
25,259
LivePerson, Inc. (a)
 
50,042
184,155
Livevox Holdings, Inc. (a)
 
69,123
190,779
Magic Software Enterprises Ltd.
 
31,025
370,128
Manhattan Associates, Inc. (a)
 
35,415
6,424,989
Marathon Digital Holdings, Inc. (a)(b)
 
69,576
681,149
Marin Software, Inc. (a)(b)
 
14,390
10,203
Materialise NV ADR (a)
 
14,271
133,006
Matterport, Inc. (a)(b)
 
86,119
255,773
Mawson Infrastructure Group, Inc. (a)(b)
 
5,882
15,293
Mercurity Fintech Holding, Inc. sponsored ADR (a)
 
10,072
23,770
MicroCloud Hologram, Inc. (a)(b)
 
28,830
72,940
Microsoft Corp.
 
4,202,151
1,379,944,367
MicroStrategy, Inc. Class A (a)(b)
 
5,348
1,613,117
Mitek Systems, Inc. (a)
 
28,300
294,886
MMTEC, Inc. (a)(b)
 
62,271
47,102
Momentive Global, Inc. (a)
 
80,549
761,188
Monday.com Ltd. (a)
 
25,605
4,614,021
My Size, Inc. (a)(b)
 
3,464
4,191
nCino, Inc. (a)(b)
 
64,312
1,767,937
Near Intelligence, Inc. (a)(b)
 
13,665
24,460
NetSol Technologies, Inc. (a)
 
6,495
14,419
Nextnav, Inc. (a)(b)
 
54,893
141,624
NICE Ltd. sponsored ADR (a)
 
28,784
5,927,777
Nisun International Enterprise (a)(b)
 
1,122
4,140
Nutanix, Inc. Class A (a)
 
131,081
3,882,619
Oblong, Inc. (a)(b)
 
1,687
2,834
Onespan, Inc. (a)
 
27,480
416,047
Open Text Corp. (b)
 
153,133
6,373,395
Opera Ltd. ADR (b)
 
20,330
319,994
Otonomo Technologies Ltd. (a)(b)
 
42,044
16,818
Pagaya Technologies Ltd. Class A (a)(b)
 
72,529
78,331
Palo Alto Networks, Inc. (a)
 
170,554
36,394,518
Park City Group, Inc. (b)
 
11,886
95,445
Pegasystems, Inc.
 
49,771
2,406,926
Phunware, Inc. (a)(b)
 
56,490
33,442
Porch Group, Inc. Class A (a)(b)
 
62,174
87,665
Powerbridge Technologies Co. Ltd. (a)(b)
 
44,173
2,540
Progress Software Corp.
 
24,678
1,480,680
PTC, Inc. (a)
 
65,301
8,776,454
Qualtrics International, Inc. (a)
 
102,187
1,847,541
Qualys, Inc. (a)
 
22,000
2,777,720
Quantum Computing, Inc. (a)(b)
 
20,196
23,629
Radcom Ltd. (a)(b)
 
13,668
131,213
Rapid7, Inc. (a)
 
31,975
1,525,847
Rekor Systems, Inc. (a)(b)
 
22,727
37,727
Remark Holdings, Inc. (a)(b)
 
7,793
9,430
Rimini Street, Inc. (a)
 
115,012
529,055
Riot Platforms, Inc. (a)(b)
 
107,353
1,288,236
SAI.TECH Global Corp. Class A (a)(b)
 
7,507
11,711
Sapiens International Corp. NV
 
29,953
744,033
SeaChange International, Inc. (a)
 
725
5,981
SecureWorks Corp. (a)
 
11,955
96,477
Semantix, Inc. (a)(b)
 
23,554
52,761
Sigma Additive Solutions, Inc. (a)(b)
 
14,199
5,159
SilverSun Technologies, Inc. (A Shares) (a)
 
910
2,885
Smith Micro Software, Inc. (a)(b)
 
26,575
32,156
Soluna Holdings, Inc. (a)(b)
 
5,272
870
SoundHound AI, Inc. (a)(b)
 
87,055
265,518
SoundThinking, Inc. (a)
 
9,121
232,494
Sphere 3D Corp. (a)
 
22,706
7,025
Splunk, Inc. (a)
 
91,875
9,122,269
SpringBig Holdings, Inc. (a)(b)
 
23,342
7,231
Sprout Social, Inc. (a)
 
27,210
1,178,465
SPS Commerce, Inc. (a)
 
19,954
3,108,833
Stronghold Digital Mining, Inc. Class A (a)(b)
 
1,018
6,373
SunCar Technology Group, Inc. Class A (a)(b)
 
7,095
305,440
Synchronoss Technologies, Inc. (a)
 
64,975
62,376
Synopsys, Inc. (a)
 
85,787
39,029,654
Telos Corp. (a)
 
39,309
126,182
Tenable Holdings, Inc. (a)
 
62,120
2,546,299
TeraWulf, Inc. (a)(b)
 
67,452
101,178
TeraWulf, Inc. rights (a)(c)
 
946
0
Upland Software, Inc. (a)
 
21,178
59,510
Varonis Systems, Inc. (a)
 
63,549
1,670,068
Verb Technology Co., Inc. (a)(b)
 
1,547
2,259
Verint Systems, Inc. (a)
 
35,965
1,290,424
Veritone, Inc. (a)(b)
 
18,574
73,182
Vertex, Inc. Class A (a)
 
29,998
659,356
Viant Technology, Inc. (a)
 
11,166
51,364
WalkMe Ltd. (a)
 
49,858
494,093
WeTrade Group, Inc. (b)
 
88,233
3,979
Workday, Inc. Class A (a)
 
117,477
24,903,949
Xunlei Ltd. sponsored ADR (a)
 
24,768
33,189
Zenvia, Inc. (a)(b)
 
1,673
1,338
ZeroFox Holdings, Inc. (a)(b)
 
6,028
6,209
Zoom Video Communications, Inc. Class A (a)
 
138,494
9,297,102
Zscaler, Inc. (a)
 
81,217
11,003,279
 
 
 
2,010,519,679
Technology Hardware, Storage & Peripherals - 13.7%
 
 
 
Apple, Inc.
 
8,939,168
1,584,467,500
Astro-Med, Inc. (a)
 
3,663
58,425
Avid Technology, Inc. (a)
 
25,039
600,936
Borqs Technologies, Inc. (a)(b)
 
7,860
1,702
Boxlight Corp. (a)(b)
 
32,673
9,168
Canaan, Inc. ADR (a)(b)
 
92,287
188,265
CompoSecure, Inc. (a)(b)
 
34,716
239,193
Corsair Gaming, Inc. (a)
 
59,540
1,174,129
CPI Card Group (a)
 
5,860
155,935
Ebang International Holdings, Inc. Class A (a)(b)
 
1,980
12,712
Immersion Corp.
 
18,807
133,154
Intevac, Inc. (a)
 
22,851
113,798
Logitech International SA (b)
 
91,997
5,873,088
Movano, Inc. (a)(b)
 
16,621
16,579
Nano Dimension Ltd. ADR (a)(b)
 
155,866
375,637
NetApp, Inc.
 
124,125
8,235,694
One Stop Systems, Inc. (a)(b)
 
8,505
21,348
Quantum Corp. (a)(b)
 
39,121
43,033
Seagate Technology Holdings PLC
 
115,833
6,961,563
Socket Mobile, Inc. (a)(b)
 
1,296
1,737
Sonim Technologies, Inc. (a)(b)
 
7,078
7,290
Stratasys Ltd. (a)
 
34,957
508,624
Super Micro Computer, Inc. (a)
 
29,455
6,596,447
Transact Technologies, Inc. (a)
 
6,575
47,274
Turtle Beach Corp. (a)
 
8,432
95,956
Western Digital Corp. (a)
 
176,324
6,829,029
Xerox Holdings Corp.
 
89,618
1,260,925
 
 
 
1,624,029,141
TOTAL INFORMATION TECHNOLOGY
 
 
5,523,839,506
MATERIALS - 0.3%
 
 
 
Chemicals - 0.1%
 
 
 
Advanced Emissions Solutions, Inc. (a)
 
9,725
14,004
Alto Ingredients, Inc. (a)(b)
 
38,730
77,847
Amyris, Inc. (a)(b)
 
171,916
145,028
Balchem Corp.
 
17,894
2,212,235
Bioceres Crop Solutions Corp. (a)(b)
 
29,815
355,693
Bon Natural Life Ltd. (a)
 
4,398
3,167
CN Energy Group, Inc. (a)(b)
 
8,671
1,778
Crown ElectroKinetics Corp. (a)
 
5,276
775
Diversey Holdings Ltd. (a)(b)
 
193,314
1,610,306
Gulf Resources, Inc. (a)
 
8,302
24,076
Hawkins, Inc.
 
11,982
562,435
Innospec, Inc.
 
14,671
1,355,014
Loop Industries, Inc. (a)(b)
 
23,631
71,129
Methanex Corp.
 
40,908
1,671,910
Northern Technologies International Corp.
 
5,689
64,286
Origin Materials, Inc. Class A (a)(b)
 
78,046
330,135
PureCycle Technologies, Inc. (a)(b)
 
96,800
666,952
Save Foods, Inc. (a)(b)
 
6,151
4,218
 
 
 
9,170,988
Construction Materials - 0.0%
 
 
 
ReTo Eco-Solutions, Inc. (a)(b)
 
2,244
3,186
Smith-Midland Corp. (a)(b)
 
2,305
37,249
United States Lime & Minerals, Inc.
 
3,255
590,522
 
 
 
630,957
Containers & Packaging - 0.0%
 
 
 
Eightco Holdings, Inc. (a)(b)
 
149
265
Pactiv Evergreen, Inc.
 
104,568
734,067
TriMas Corp.
 
23,430
593,013
 
 
 
1,327,345
Metals & Mining - 0.2%
 
 
 
5E Advanced Materials, Inc. (a)(b)
 
24,267
68,918
Adamas One Corp. (b)
 
5,283
4,226
Algoma Steel Group, Inc.
 
59,470
407,370
American Lithium Corp. (a)(b)
 
110,010
202,418
Ascent Industries Co. (a)
 
7,726
73,397
Century Aluminum Co. (a)(b)
 
49,517
388,213
China Natural Resources, Inc. (a)(b)
 
2,427
4,878
Ferroglobe PLC (a)
 
105,632
458,443
Haynes International, Inc.
 
8,044
349,270
Huadi International Group Co. Ltd. (a)(b)
 
7,169
33,049
Hycroft Mining Holding Corp. (a)(b)
 
125,396
42,133
ioneer Ltd. ADR (a)
 
1,836
16,451
Kaiser Aluminum Corp. (b)
 
9,286
560,874
Largo, Inc. (a)(b)
 
35,869
135,585
NioCorp Developments Ltd. (a)(b)
 
20,572
110,883
Olympic Steel, Inc. (b)
 
7,458
311,894
Perpetua Resources Corp. (a)
 
34,563
157,953
Piedmont Lithium, Inc. (a)(b)
 
9,399
514,783
Ramaco Resources, Inc.
 
27,313
202,389
Royal Gold, Inc.
 
37,338
4,623,938
Schnitzer Steel Industries, Inc. Class A
 
15,466
425,470
Sigma Lithium Corp. (a)(b)
 
58,171
2,188,393
Snow Lake Resources Ltd. (a)(b)
 
4,113
10,612
SSR Mining, Inc. (b)
 
119,238
1,761,145
Steel Dynamics, Inc.
 
98,361
9,039,376
TMC the metals Co., Inc. (a)(b)
 
144,842
99,955
U.S. Gold Corp. (a)(b)
 
1,706
6,773
Universal Stainless & Alloy Products, Inc. (a)
 
7,722
93,745
 
 
 
22,292,534
Paper & Forest Products - 0.0%
 
 
 
Mercer International, Inc. (SBI) (b)
 
37,097
321,260
TOTAL MATERIALS
 
 
33,743,084
REAL ESTATE - 0.9%
 
 
 
Equity Real Estate Investment Trusts (REITs) - 0.7%
 
 
 
Creative Media & Community Trust Corp.
 
12,011
62,097
Diversified Healthcare Trust (SBI)
 
142,959
194,424
Equinix, Inc.
 
52,048
38,804,386
Gaming & Leisure Properties
 
143,527
6,909,390
Gladstone Commercial Corp.
 
18,518
216,475
Gladstone Land Corp. (b)
 
24,626
389,337
Global Self Storage, Inc.
 
5,948
29,621
Host Hotels & Resorts, Inc.
 
400,949
6,655,753
Indus Realty Trust, Inc.
 
7,899
527,653
Industrial Logistics Properties Trust
 
41,417
74,965
Lamar Advertising Co. Class A
 
47,671
4,284,669
Medalist Diversified (REIT), Inc.
 
1,616
8,581
Necessity Retail (REIT), Inc./The
 
86,334
551,674
Office Properties Income Trust
 
35,609
257,809
Phillips Edison & Co., Inc.
 
65,268
1,893,425
Potlatch Corp.
 
48,129
2,239,442
Presidio Property Trust, Inc.:
 
 
 
 Class A (b)
 
6,016
5,174
 Class A warrants 1/24/27 (a)
 
6,016
199
Regency Centers Corp.
 
95,000
5,345,650
Retail Opportunity Investments Corp.
 
70,063
854,769
Sabra Health Care REIT, Inc.
 
132,435
1,491,218
SBA Communications Corp. Class A
 
60,523
13,422,791
Service Properties Trust
 
89,889
737,989
Sotherly Hotels, Inc. (a)
 
4,274
7,821
Uniti Group, Inc.
 
129,373
481,268
Wheeler REIT, Inc. (a)
 
15,634
11,256
 
 
 
85,457,836
Real Estate Management & Development - 0.2%
 
 
 
Alset, Inc. (a)
 
2,169
4,338
Altisource Portfolio Solutions SA (a)(b)
 
12,106
56,414
Appreciate Holdings, Inc. (a)(b)
 
12,250
3,919
Avalon GloboCare Corp. (a)(b)
 
4,894
8,956
Colliers International Group, Inc. (b)
 
24,605
2,288,265
Comstock Holding Companies, Inc. (a)
 
4,017
15,144
eXp World Holdings, Inc. (b)
 
84,627
1,302,410
Fathom Holdings, Inc. (a)(b)
 
7,329
45,880
FirstService Corp.
 
25,390
3,685,105
Flj Group Ltd. ADR (a)(b)
 
4,737
1,753
FRP Holdings, Inc. (a)
 
6,217
328,320
Green Giant, Inc. (a)(b)
 
20,468
46,667
Gyrodyne LLC (a)
 
1,080
9,774
InterGroup Corp. (a)(b)
 
986
35,457
MDJM Ltd. (a)(b)
 
4,594
7,350
Newmark Group, Inc.
 
93,901
537,114
Opendoor Technologies, Inc. (a)(b)
 
345,111
911,093
Redfin Corp. (a)(b)
 
58,457
572,294
Stratus Properties, Inc.
 
5,346
116,436
The Real Brokerage, Inc. (a)(b)
 
43,591
55,796
The RMR Group, Inc.
 
7,911
170,324
Ucommune International Ltd. (a)(b)
 
2,354
1,648
Zillow Group, Inc.:
 
 
 
 Class A (a)
 
25,600
1,146,624
 Class C (a)(b)
 
107,305
4,894,181
 
 
 
16,245,262
TOTAL REAL ESTATE
 
 
101,703,098
UTILITIES - 0.9%
 
 
 
Electric Utilities - 0.9%
 
 
 
Alliant Energy Corp.
 
139,857
7,197,041
American Electric Power Co., Inc.
 
301,591
25,068,244
Constellation Energy Corp.
 
183,939
15,454,555
Evergy, Inc.
 
129,697
7,502,971
Exelon Corp.
 
557,522
22,105,747
MGE Energy, Inc.
 
22,792
1,635,554
Otter Tail Corp. (b)
 
23,594
1,750,911
Via Renewables, Inc. Class A, (b)
 
1,462
15,380
Xcel Energy, Inc.
 
311,472
20,336,007
 
 
 
101,066,410
Gas Utilities - 0.0%
 
 
 
RGC Resources, Inc.
 
5,446
112,732
Independent Power and Renewable Electricity Producers - 0.0%
 
 
 
Atlantica Sustainable Infrastructure PLC (b)
 
70,020
1,692,383
Eco Wave Power Global AB ADR (a)
 
1,986
5,978
Enlight Renewable Energy Ltd.
 
61,900
1,145,150
Montauk Renewables, Inc. (a)(b)
 
85,373
592,489
ReNew Energy Global PLC (a)(b)
 
161,158
881,534
VivoPower International PLC (a)(b)
 
27,588
15,336
 
 
 
4,332,870
Multi-Utilities - 0.0%
 
 
 
NorthWestern Energy Corp.
 
28,847
1,632,452
Water Utilities - 0.0%
 
 
 
Artesian Resources Corp. Class A
 
6,205
307,148
Cadiz, Inc. (a)(b)
 
30,070
157,567
Consolidated Water Co., Inc.
 
10,783
210,484
Global Water Resources, Inc.
 
13,586
158,684
Middlesex Water Co.
 
10,525
856,314
Pure Cycle Corp. (a)
 
13,933
135,429
York Water Co.
 
8,284
351,324
 
 
 
2,176,950
TOTAL UTILITIES
 
 
109,321,414
 
TOTAL COMMON STOCKS
  (Cost $5,441,394,693)
 
 
 
11,797,306,692
 
 
 
 
Nonconvertible Preferred Stocks - 0.0%
 
 
Shares
Value ($)
 
CONSUMER DISCRETIONARY - 0.0%
 
 
 
Hotels, Restaurants & Leisure - 0.0%
 
 
 
FAT Brands, Inc.
 
1,005
15,276
ENERGY - 0.0%
 
 
 
Oil, Gas & Consumable Fuels - 0.0%
 
 
 
Imperial Petroleum, Inc.
 
816
16,312
INFORMATION TECHNOLOGY - 0.0%
 
 
 
Software - 0.0%
 
 
 
SRAX, Inc. (a)(c)
 
9,776
0
 
TOTAL NONCONVERTIBLE PREFERRED STOCKS
  (Cost $29,165)
 
 
 
31,588
 
 
 
 
U.S. Treasury Obligations - 0.0%
 
 
Principal
Amount (f)
 
Value ($)
 
U.S. Treasury Bills, yield at date of purchase 4.65% 6/29/23 (g)
 
  (Cost $4,982,257)
 
 
5,000,000
4,980,366
 
 
 
 
Money Market Funds - 4.1%
 
 
Shares
Value ($)
 
Fidelity Cash Central Fund 5.14% (h)
 
62,864,868
62,877,441
Fidelity Securities Lending Cash Central Fund 5.14% (h)(i)
 
423,341,480
423,383,815
 
TOTAL MONEY MARKET FUNDS
  (Cost $486,261,256)
 
 
486,261,256
 
 
 
 
 
TOTAL INVESTMENT IN SECURITIES - 103.5%
  (Cost $5,932,667,371)
 
 
 
12,288,579,902
NET OTHER ASSETS (LIABILITIES) - (3.5)%  
(414,629,838)
NET ASSETS - 100.0%
11,873,950,064
 
 
 
Futures Contracts  
 
Number
of contracts
Expiration
Date
Notional
Amount ($)
 
Value ($)
 
Unrealized
Appreciation/
(Depreciation) ($)
 
Purchased
 
 
 
 
 
 
 
 
 
 
 
Equity Index Contracts
 
 
 
 
 
CME E-mini NASDAQ 100 Index Contracts (United States)
265
Jun 2023
75,792,650
8,430,311
8,430,311
 
 
 
 
 
 
The notional amount of futures purchased as a percentage of Net Assets is 0.6%
 
 
 
Legend
 
(a)
Non-income producing
 
(b)
Security or a portion of the security is on loan at period end.
 
(c)
Level 3 security
 
(d)
Security exempt from registration under Rule 144A of the Securities Act of 1933.  These securities may be resold in transactions exempt from registration, normally to qualified institutional buyers. At the end of the period, the value of these securities amounted to $1,166,216 or 0.0% of net assets.
 
(e)
Affiliated company
 
(f)
Amount is stated in United States dollars unless otherwise noted.
 
(g)
Security or a portion of the security was pledged to cover margin requirements for futures contracts. At period end, the value of securities pledged amounted to $4,404,636.
 
(h)
Affiliated fund that is generally available only to investment companies and other accounts managed by Fidelity Investments. The rate quoted is the annualized seven-day yield of the fund at period end. A complete unaudited listing of the fund's holdings as of its most recent quarter end is available upon request. In addition, each Fidelity Central Fund's financial statements are available on the SEC's website or upon request.
 
(i)
Investment made with cash collateral received from securities on loan.
 
 
 
 
Affiliated Central Funds
 
Fiscal year to date information regarding the Fund's investments in Fidelity Central Funds, including the ownership percentage, is presented below.
 
 
Affiliate
Value,
beginning
of period ($)
Purchases ($)
Sales
Proceeds ($)
Dividend
Income ($)
Realized
Gain (loss) ($)
Change in
Unrealized
appreciation
(depreciation) ($)
Value,
end
of period ($)
% ownership,
end
of period
Fidelity Cash Central Fund 5.14%
19,033,988
232,473,694
188,630,241
840,432
-
-
62,877,441
0.2%
Fidelity Securities Lending Cash Central Fund 5.14%
468,589,806
513,260,336
558,466,327
8,425,183
-
-
423,383,815
1.5%
Total
487,623,794
745,734,030
747,096,568
9,265,615
-
-
486,261,256
 
 
 
 
 
 
 
 
 
 
Amounts in the dividend income column in the above table include any capital gain distributions from underlying funds, which are presented in the corresponding line item in the Statement of Operations, if applicable.
 
Amounts in the dividend income column for Fidelity Securities Lending Cash Central Fund represents the income earned on investing cash collateral, less rebates paid to borrowers and any lending agent fees associated with the loan, plus any premium payments received for lending certain types of securities.
 
Amounts included in the purchases and sales proceeds columns may include in-kind transactions, if applicable.
 
Other Affiliated Issuers
An affiliated company is a company in which the Fund has ownership of at least 5% of the voting securities. Fiscal year to date transactions with companies which are or were affiliates are presented in the table below. Certain corporate actions, such as mergers, are excluded from the amounts in this table if applicable. A dash in the Value end of period ($) column means either the issuer is no longer held at period end, or the issuer is held at period end but is no longer an affiliate.
Affiliate
Value,
beginning
of period ($)
Purchases ($)
Sales
Proceeds ($)
Dividend
Income ($)
Realized
Gain (loss) ($)
Change in
Unrealized
appreciation
(depreciation) ($)
Value,
end
of period ($)
Quoin Pharmaceuticals Ltd. ADR
1,922
-
-
-
-
(1,432)
490
Total
1,922
-
-
-
-
(1,432)
490
 
 
 
Amounts included in the purchases and sales proceeds columns may include in-kind transactions, if applicable.
 
Investment Valuation
 
The following is a summary of the inputs used, as of May 31, 2023, involving the Fund's assets and liabilities carried at fair value. The inputs or methodology used for valuing securities may not be an indication of the risk associated with investing in those securities. For more information on valuation inputs, and their aggregation into the levels used below, please refer to the Investment Valuation section in the accompanying Notes to Financial Statements.
 
Valuation Inputs at Reporting Date:
Description
Total ($)
Level 1 ($)
Level 2 ($)
Level 3 ($)
  Investments in Securities:
 
 
 
 
 Equities:
 
 
 
 
Communication Services
1,720,719,259
1,719,259,290
-
1,459,969
Consumer Discretionary
1,629,374,223
1,628,940,671
-
433,552
Consumer Staples
518,140,872
518,121,639
612
18,621
Energy
76,030,235
76,030,235
-
-
Financials
514,105,562
514,019,884
-
85,678
Health Care
1,000,412,314
999,867,314
248,003
296,997
Industrials
569,948,713
569,902,677
-
46,036
Information Technology
5,523,839,506
5,523,836,871
2,635
-
Materials
33,743,084
33,743,084
-
-
Real Estate
101,703,098
101,703,098
-
-
Utilities
109,321,414
109,321,414
-
-
 U.S. Government and Government Agency Obligations
4,980,366
-
4,980,366
-
  Money Market Funds
486,261,256
486,261,256
-
-
 Total Investments in Securities:
12,288,579,902
12,281,007,433
5,231,616
2,340,853
  Derivative Instruments:
 
 
 
 
 Assets
 
 
 
 
Futures Contracts
8,430,311
8,430,311
-
-
  Total Assets
8,430,311
8,430,311
-
-
 Total Derivative Instruments:
8,430,311
8,430,311
-
-
 
Value of Derivative Instruments
 
The following table is a summary of the Fund's value of derivative instruments by primary risk exposure as of May 31, 2023. For additional information on derivative instruments, please refer to the Derivative Instruments section in the accompanying Notes to Financial Statements.
 
Primary Risk Exposure / Derivative Type                                                                                                                                                                                   
 
Value
Asset ($)
Liability ($)
Equity Risk
 
 
Futures Contracts (a)  
8,430,311
0
Total Equity Risk
8,430,311
0
Total Value of Derivatives
8,430,311
0
 
(a)Reflects gross cumulative appreciation (depreciation) on futures contracts as presented in the Schedule of Investments. In the Statement of Assets and Liabilities, the period end daily variation margin is included in receivable or payable for daily variation margin on futures contracts, and the net cumulative appreciation (depreciation) is included in Total accumulated earnings (loss).
 
 
 
Financial Statements   (Unaudited)
Statement of Assets and Liabilities
 
 
 
May 31, 2023
(Unaudited)
 
 
 
 
 
Assets
 
 
 
 
Investment in securities, at value  (including  securities loaned of $400,441,148) - See accompanying schedule:
 
 
 
 
Unaffiliated issuers (cost $5,446,204,379)
$
11,802,318,156
 
 
Fidelity Central Funds (cost $486,261,256)
486,261,256
 
 
Other affiliated issuers (cost $201,736)
490
 
 
 
 
 
 
 
 
 
 
 
 
Total Investment in Securities (cost $5,932,667,371)
 
 
$
12,288,579,902
Cash
 
 
55,960
Foreign currency held at value (cost $302)
 
 
299
Receivable for investments sold
 
 
21,764
Receivable for fund shares sold
 
 
10,735,041
Dividends receivable
 
 
9,001,574
Distributions receivable from Fidelity Central Funds
 
 
1,680,098
Prepaid expenses
 
 
2,049
Receivable from investment adviser for expense reductions
 
 
505,770
Other receivables
 
 
13,813
  Total assets
 
 
12,310,596,270
Liabilities
 
 
 
 
Payable for fund shares redeemed
$
9,508,513
 
 
Accrued management fee
2,279,120
 
 
Payable for daily variation margin on futures contracts
499,144
 
 
Other affiliated payables
957,966
 
 
Other payables and accrued expenses
93,282
 
 
Collateral on securities loaned
423,308,181
 
 
  Total Liabilities
 
 
 
436,646,206
Net Assets  
 
 
$
11,873,950,064
Net Assets consist of:
 
 
 
 
Paid in capital
 
 
$
5,660,397,054
Total accumulated earnings (loss)
 
 
 
6,213,553,010
Net Assets
 
 
$
11,873,950,064
Net Asset Value , offering price and redemption price per share ($11,873,950,064 ÷ 72,543,639 shares)
 
 
$
163.68
 
Statement of Operations
 
 
 
Six months ended
May 31, 2023
(Unaudited)
Investment Income
 
 
 
 
Dividends
 
 
$
49,615,652
Interest  
 
 
92,222
Income from Fidelity Central Funds (including $8,425,183 from security lending)
 
 
9,265,615
 Total Income
 
 
 
58,973,489
Expenses
 
 
 
 
Management fee
$
12,810,198
 
 
Transfer agent fees
5,337,582
 
 
Accounting fees
50,000
 
 
Custodian fees and expenses
84,442
 
 
Independent trustees' fees and expenses
34,133
 
 
Registration fees
52,318
 
 
Audit
42,250
 
 
Legal
(1,142,275)
 
 
Interest
11,916
 
 
Miscellaneous
29,970
 
 
 Total expenses before reductions
 
17,310,534
 
 
 Expense reductions
 
(2,962,715)
 
 
 Total expenses after reductions
 
 
 
14,347,819
Net Investment income (loss)
 
 
 
44,625,670
Realized and Unrealized Gain (Loss)
 
 
 
 
Net realized gain (loss) on:
 
 
 
 
 Investment Securities:
 
 
 
 
   Unaffiliated issuers  
 
(78,373,015)
 
 
 Foreign currency transactions
 
5
 
 
 Futures contracts
 
1,556,433
 
 
Total net realized gain (loss)
 
 
 
(76,816,577)
Change in net unrealized appreciation (depreciation) on:
 
 
 
 
 Investment Securities:
 
 
 
 
   Unaffiliated issuers
 
1,411,495,191
 
 
   Affiliated issuers
 
(1,432)
 
 
 Assets and liabilities in foreign currencies
 
1,402
 
 
 Futures contracts
 
5,874,736
 
 
Total change in net unrealized appreciation (depreciation)
 
 
 
1,417,369,897
Net gain (loss)
 
 
 
1,340,553,320
Net increase (decrease) in net assets resulting from operations
 
 
$
1,385,178,990
Statement of Changes in Net Assets
 
 
Six months ended
May 31, 2023
(Unaudited)
 
Year ended
November 30, 2022
Increase (Decrease) in Net Assets
 
 
 
 
Operations
 
 
 
Net investment income (loss)
$
44,625,670
$
83,909,292
Net realized gain (loss)
 
(76,816,577)
 
 
(72,368,382)
 
Change in net unrealized appreciation (depreciation)
 
1,417,369,897
 
(3,626,296,386)
 
Net increase (decrease) in net assets resulting from operations
 
1,385,178,990
 
 
(3,614,755,476)
 
Distributions to shareholders
 
(83,603,942)
 
 
(66,552,817)
 
Share transactions
 
 
 
 
Proceeds from sales of shares
 
717,170,837
 
2,272,549,827
  Reinvestment of distributions
 
76,959,005
 
 
61,977,740
 
Cost of shares redeemed
 
(884,551,005)
 
(2,068,342,097)
  Net increase (decrease) in net assets resulting from share transactions
 
(90,421,163)
 
 
266,185,470
 
Total increase (decrease) in net assets
 
1,211,153,885
 
 
(3,415,122,823)
 
 
 
 
 
 
Net Assets
 
 
 
 
Beginning of period
 
10,662,796,179
 
14,077,919,002
 
End of period
$
11,873,950,064
$
10,662,796,179
 
 
 
 
 
Other Information
 
 
 
 
Shares
 
 
 
 
Sold
 
4,868,055
 
13,957,177
  Issued in reinvestment of distributions
 
589,951
 
 
312,168
 
Redeemed
 
(6,082,456)
 
(12,859,134)
Net increase (decrease)
 
(624,450)
 
1,410,211
 
 
 
 
 
 
Financial Highlights
Fidelity® Nasdaq Composite Index® Fund
 
 
Six months ended
(Unaudited) May 31, 2023  
 
Years ended November 30, 2022  
 
2021    
 
2020  
 
2019  
 
2018    
  Selected Per-Share Data  
 
 
 
 
 
 
 
 
 
 
 
 
  Net asset value, beginning of period
$
145.73
$
196.19
$
154.09
$
113.58
$
96.86
$
90.92
  Income from Investment Operations
 
 
 
 
 
 
 
 
 
 
 
 
     Net investment income (loss) A,B
 
.61
 
1.16
 
1.00
 
1.04
 
1.12
 
.89
     Net realized and unrealized gain (loss)
 
18.50
 
(50.70)
 
42.19
 
44.44
 
17.26
 
5.71
  Total from investment operations
 
19.11  
 
(49.54)  
 
43.19  
 
45.48  
 
18.38
 
6.60
  Distributions from net investment income
 
(1.16)
 
(.92)
 
(1.09)
 
(1.11) C
 
(.81)
 
(.64)
  Distributions from net realized gain
 
-
 
-
 
-
 
(3.86) C
 
(.85)
 
(.02)
     Total distributions
 
(1.16)
 
(.92)
 
(1.09)
 
(4.97)
 
(1.66)
 
(.66)
  Net asset value, end of period
$
163.68
$
145.73
$
196.19
$
154.09
$
113.58
$
96.86
 Total Return   D,E
 
13.32%
 
(25.37)%
 
28.18%
 
41.63%
 
19.55%
 
7.30%
 Ratios to Average Net Assets B,F,G
 
 
 
 
 
 
 
 
 
 
 
 
    Expenses before reductions
 
.34% H,I
 
.36%
 
.35%
 
.35%
 
.35%
 
.40%
    Expenses net of fee waivers, if any
 
.28% H,I
 
.31%
 
.29%
 
.29%
 
.29%
 
.29%
    Expenses net of all reductions
 
.28% H,I
 
.31%
 
.29%
 
.29%
 
.29%
 
.29%
    Net investment income (loss)
 
.82% H,I
 
.73%
 
.56%
 
.84%
 
1.10%
 
.90%
 Supplemental Data
 
 
 
 
 
 
 
 
 
 
 
 
    Net assets, end of period (000 omitted)
$
11,873,950
$
10,662,796
$
14,077,919
$
10,165,899
$
7,154,288
$
6,002,333
    Portfolio turnover rate J
 
3% I
 
4%
 
7%
 
17%
 
6%
 
15%
 
A Calculated based on average shares outstanding during the period.
 
B Net investment income (loss) is affected by the timing of the declaration of dividends by any underlying mutual funds or exchange-traded funds (ETFs). Net investment income (loss) of any mutual funds or ETFs is not included in the Fund's net investment income (loss) ratio.
 
C The amount shown reflects reclassifications related to book to tax differences that were made in the year shown.
 
D Total returns for periods of less than one year are not annualized.
 
E Total returns would have been lower if certain expenses had not been reduced during the applicable periods shown.
 
F Fees and expenses of any underlying mutual funds or exchange-traded funds (ETFs) are not included in the Fund's expense ratio. The Fund indirectly bears its proportionate share of these expenses. For additional expense information related to investments in Fidelity Central Funds, please refer to the "Investments in Fidelity Central Funds" note found in the Notes to Financial Statements section of the most recent Annual or Semi-Annual report.
 
G Expense ratios reflect operating expenses of the class. Expenses before reductions do not reflect amounts reimbursed, waived, or reduced through arrangements with the investment adviser, brokerage services, or other offset arrangements, if applicable, and do not represent the amount paid by the class during periods when reimbursements, waivers or reductions occur.
 
H Legal expenses are not annualized.
 
I Annualized.
 
J Amount does not include the portfolio activity of any underlying mutual funds or exchange-traded funds (ETFs).
 
For the period ended May 31, 2023
 
1. Organization.
Fidelity Nasdaq Composite Index Fund (the Fund) is a fund of Fidelity Concord Street Trust (the Trust) and is authorized to issue an unlimited number of shares.   Share transactions on the Statement of Changes in Net Assets may contain exchanges between affiliated funds. The Trust is registered under the Investment Company Act of 1940, as amended (the 1940 Act), as an open-end management investment company organized as a Massachusetts business trust. The Fund may operate as a non-diversified fund, as defined under the 1940 Act, to the approximate extent the Index is non-diversified.
 
2. Investments in Fidelity Central Funds.
Funds may invest in Fidelity Central Funds, which are open-end investment companies generally available only to other investment companies and accounts managed by the investment adviser and its affiliates. The Schedule of Investments lists any Fidelity Central Funds held as an investment as of period end, but does not include the underlying holdings of each Fidelity Central Fund. An investing fund indirectly bears its proportionate share of the expenses of the underlying Fidelity Central Funds.
 
Based on its investment objective, each Fidelity Central Fund may invest or participate in various investment vehicles or strategies that are similar to those of the investing fund. These strategies are consistent with the investment objectives of the investing fund and may involve certain economic risks which may cause a decline in value of each of the Fidelity Central Funds and thus a decline in the value of the investing fund.
 
Fidelity Central Fund
Investment Manager
Investment Objective
Investment Practices
Expense Ratio A
Fidelity Money Market Central Funds
Fidelity Management & Research Company LLC (FMR)
Each fund seeks to obtain a high level of current income consistent with the preservation of capital and liquidity.
Short-term Investments
Less than .005%
 
A Expenses expressed as a percentage of average net assets and are as of each underlying Central Fund's most recent annual or semi-annual shareholder report.
 
A complete unaudited list of holdings for each Fidelity Central Fund is available upon request or at the Securities and Exchange Commission website at www.sec.gov. In addition, the financial statements of the Fidelity Central Funds which contain the significant accounting policies (including investment valuation policies) of those funds, and are not covered by the Report of Independent Registered Public Accounting Firm, are available on the Securities and Exchange Commission website or upon request.
 
3. Significant Accounting Policies.
The Fund is an investment company and applies the accounting and reporting guidance of the Financial Accounting Standards Board (FASB) Accounting Standards Codification Topic 946 Financial Services - Investment Companies . The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP), which require management to make certain estimates and assumptions at the date of the financial statements. Actual results could differ from those estimates. Subsequent events, if any, through the date that the financial statements were issued have been evaluated in the preparation of the financial statements. The Fund's Schedule of Investments lists any underlying mutual funds or exchange-traded funds (ETFs) but does not include the underlying holdings of these funds. The following summarizes the significant accounting policies of the Fund:
 
Investment Valuation. Investments are valued as of 4:00 p.m. Eastern time on the last calendar day of the period. The Board of Trustees (the Board) has designated the Fund's investment adviser as the valuation designee responsible for the fair valuation function and performing fair value determinations as needed. The investment adviser has established a Fair Value Committee (the Committee) to carry out the day-to-day fair valuation responsibilities and has adopted policies and procedures to govern the fair valuation process and the activities of the Committee. In accordance with these fair valuation policies and procedures, which have been approved by the Board, the Fund attempts to obtain prices from one or more third party pricing services or brokers to value its investments. When current market prices, quotations or currency exchange rates are not readily available or reliable, investments will be fair valued in good faith by the Committee, in accordance with the policies and procedures. Factors used in determining fair value vary by investment type and may include market or investment specific events, transaction data, estimated cash flows, and market observations of comparable investments. The frequency that the fair valuation procedures are used cannot be predicted and they may be utilized to a significant extent. The Committee manages the Fund's fair valuation practices and maintains the fair valuation policies and procedures. The Fund's investment adviser reports to the Board information regarding the fair valuation process and related material matters.
 
The Fund categorizes the inputs to valuation techniques used to value its investments into a disclosure hierarchy consisting of three levels as shown below:
 
Level 1 - unadjusted quoted prices in active markets for identical investments
Level 2 - other significant observable inputs (including quoted prices for similar investments, interest rates, prepayment speeds, etc.)
Level 3 - unobservable inputs (including the Fund's own assumptions based on the best information available)
 
Valuation techniques used to value the Fund's investments by major category are as follows:
 
Equity securities, including restricted securities, for which market quotations are readily available, are valued at the last reported sale price or official closing price as reported by a third party pricing service on the primary market or exchange on which they are traded and are categorized as Level 1 in the hierarchy. In the event there were no sales during the day or closing prices are not available, securities are valued at the last quoted bid price or may be valued using the last available price and are generally categorized as Level 2 in the hierarchy. For foreign equity securities, when market or security specific events arise, comparisons to the valuation of American Depositary Receipts (ADRs), futures contracts, ETFs and certain indexes as well as quoted prices for similar securities may be used and would be categorized as Level 2 in the hierarchy. For equity securities, including restricted securities, where observable inputs are limited, assumptions about market activity and risk are used and these securities may be categorized as Level 3 in the hierarchy.
 
Debt securities, including restricted securities, are valued based on evaluated prices received from third party pricing services or from brokers who make markets in such securities. U.S. government and government agency obligations are valued by pricing services who utilize matrix pricing which considers yield or price of bonds of comparable quality, coupon, maturity and type or by broker-supplied prices. When independent prices are unavailable or unreliable, debt securities may be valued utilizing pricing methodologies which consider similar factors that would be used by third party pricing services. Debt securities are generally categorized as Level 2 in the hierarchy but may be Level 3 depending on the circumstances.
 
Futures contracts are valued at the settlement price established each day by the board of trade or exchange on which they are traded and are categorized as Level 1 in the hierarchy. Investments in open-end mutual funds, including the Fidelity Central Funds, are valued at their closing net asset value (NAV) each business day and are categorized as Level 1 in the hierarchy.
 
Changes in valuation techniques may result in transfers in or out of an assigned level within the disclosure hierarchy. The aggregate value of investments by input level as of May 31, 2023 is included at the end of the Fund's Schedule of Investments.
 
Foreign Currency. Certain Funds may use foreign currency contracts to facilitate transactions in foreign-denominated securities. Gains and losses from these transactions may arise from changes in the value of the foreign currency or if the counterparties do not perform under the contracts' terms.
 
Foreign-denominated assets, including investment securities, and liabilities are translated into U.S. dollars at the exchange rates at period end. Purchases and sales of investment securities, income and dividends received, and expenses denominated in foreign currencies are translated into U.S. dollars at the exchange rate in effect on the transaction date.
 
The effects of exchange rate fluctuations on investments are included with the net realized and unrealized gain (loss) on investment securities. Other foreign currency transactions resulting in realized and unrealized gain (loss) are disclosed separately.
 
Investment Transactions and Income. For financial reporting purposes, the Fund's investment holdings and NAV include trades executed through the end of the last business day of the period. The NAV per share for processing shareholder transactions is calculated as of the close of business of the New York Stock Exchange (NYSE), normally 4:00 p.m. Eastern time and includes trades executed through the end of the prior business day. Gains and losses on securities sold are determined on the basis of identified cost   and include proceeds received from litigation. Commissions paid to certain brokers with whom the investment adviser, or its affiliates, places trades on behalf of a fund include an amount in addition to trade execution, which may be rebated back to a fund. Any such rebates are included in net realized gain (loss) on investments in the Statement of Operations. Dividend income is recorded on the ex-dividend date, except for certain dividends from foreign securities where the ex-dividend date may have passed, which are recorded as soon as the Fund is informed of the ex-dividend date. Non-cash dividends included in dividend income, if any, are recorded at the fair market value of the securities received. Income and capital gain distributions from Fidelity Central Funds, if any, are recorded on the ex-dividend date. Certain distributions received by the Fund represent a return of capital or capital gain. The Fund determines the components of these distributions subsequent to the ex-dividend date, based upon receipt of tax filings or other correspondence relating to the underlying investment. These distributions are recorded as a reduction of cost of investments and/or as a realized gain. Interest income is accrued as earned and includes coupon interest and amortization of premium and accretion of discount on debt securities as applicable. Investment income is recorded net of foreign taxes withheld where recovery of such taxes is uncertain. Funds may file withholding tax reclaims in certain jurisdictions to recover a portion of amounts previously withheld. Any withholding tax reclaims income is included in the Statement of Operations in dividends. Any receivables for withholding tax reclaims are included in the Statement of Assets and Liabilities in dividends receivable.
 
Expenses. Expenses directly attributable to a fund are charged to that fund. Expenses attributable to more than one fund are allocated among the respective funds on the basis of relative net assets or other appropriate methods. Expenses included in the accompanying financial statements reflect the expenses of that fund and do not include any expenses associated with any underlying mutual funds or exchange-traded funds. Although not included in a fund's expenses, a fund indirectly bears its proportionate share of these expenses through the net asset value of each underlying mutual fund or exchange-traded fund. Expense estimates are accrued in the period to which they relate and adjustments are made when actual amounts are known.
 
Income Tax Information and Distributions to Shareholders. Each year, the Fund intends to qualify as a regulated investment company under Subchapter M of the Internal Revenue Code, including distributing substantially all of its taxable income and realized gains. As a result, no provision for U.S. Federal income taxes is required. The Fund files a U.S. federal tax return, in addition to state and local tax returns as required. The Fund's federal income tax returns are subject to examination by the Internal Revenue Service (IRS) for a period of three fiscal years after they are filed. State and local tax returns may be subject to examination for an additional fiscal year depending on the jurisdiction.   Foreign taxes are provided for based on the Fund's understanding of the tax rules and rates that exist in the foreign markets in which it invests.
 
Distributions are declared and recorded on the ex-dividend date. Income and capital gain distributions are determined in accordance with income tax regulations, which may differ from GAAP.
 
Capital accounts within the financial statements are adjusted for permanent book-tax differences. These adjustments have no impact on net assets or the results of operations. Capital accounts are not adjusted for temporary book-tax differences which will reverse in a subsequent period.
 
Book-tax differences are primarily due to   futures contracts, foreign currency transactions, passive foreign investment companies (PFIC), partnerships, capital loss carryforwards and   losses deferred due to wash sales.
 
As of period end, the cost and unrealized appreciation (depreciation) in securities, and derivatives if applicable, for federal income tax purposes were as follows:
 
Gross unrealized appreciation
$7,122,047,002
Gross unrealized depreciation
(786,193,611)
Net unrealized appreciation (depreciation)
$6,335,853,391
Tax cost
$5,961,156,822
 
Capital loss carryforwards are only available to offset future capital gains of the Fund to the extent provided by regulations and may be limited. The capital loss carryforward information presented below, including any applicable limitation, is estimated as of prior fiscal period end and is subject to adjustment.
 
Short-term
$(91,242,778)
Long-term
(1,968,709)
Total capital loss carryforward
$(93,211,487)
 
Restricted Securities (including Private Placements). Funds may invest in securities that are subject to legal or contractual restrictions on resale. These securities generally may be resold in transactions exempt from registration or to the public if the securities are registered. Disposal of these securities may involve time-consuming negotiations and expense, and prompt sale at an acceptable price may be difficult. Information regarding restricted securities held at period end is included at the end of the Schedule of Investments, if applicable.
 
4. Derivative Instruments.
Risk Exposures and the Use of Derivative Instruments. The Fund's investment objectives allow for various types of derivative instruments, including futures contracts. Derivatives are investments whose value is primarily derived from underlying assets, indices or reference rates and may be transacted on an exchange or over-the-counter (OTC). Derivatives may involve a future commitment to buy or sell a specified asset based on specified terms, to exchange future cash flows at periodic intervals based on a notional principal amount, or for one party to make one or more payments upon the occurrence of specified events in exchange for periodic payments from the other party.
 
Derivatives were used to increase returns and to manage exposure to certain risks as defined below. The success of any strategy involving derivatives depends on analysis of numerous economic factors, and if the strategies for investment do not work as intended, the objectives may not be achieved.
 
Derivatives were used to increase or decrease exposure to the following risk(s):
 
 
 
 
Equity Risk
Equity risk relates to the fluctuations in the value of financial instruments as a result of changes in market prices (other than those arising from interest rate risk or foreign exchange risk), whether caused by factors specific to an individual investment, its issuer, or all factors affecting all instruments traded in a market or market segment.
 
 
 
Funds are also exposed to additional risks from investing in derivatives, such as liquidity risk and counterparty credit risk. Liquidity risk is the risk that a fund will be unable to close out the derivative in the open market in a timely manner. Counterparty credit risk is the risk that the counterparty will not be able to fulfill its obligation to a fund. Counterparty credit risk related to exchange-traded contracts may be mitigated by the protection provided by the exchange on which they trade.
 
Investing in derivatives may involve greater risks than investing in the underlying assets directly and, to varying degrees, may involve risk of loss in excess of any initial investment and collateral received and amounts recognized in the Statement of Assets and Liabilities. In addition, there may be the risk that the change in value of the derivative contract does not correspond to the change in value of the underlying instrument.
 
Futures Contracts. A futures contract is an agreement between two parties to buy or sell a specified underlying instrument for a fixed price at a specified future date. Futures contracts were used to manage exposure to the stock market.
 
Upon entering into a futures contract, a fund is required to deposit either cash or securities (initial margin) with a clearing broker in an amount equal to a certain percentage of the face value of the contract. Futures contracts are marked-to-market daily and subsequent daily payments are made or received by a fund depending on the daily fluctuations in the value of the futures contracts and are recorded as unrealized appreciation or (depreciation). This receivable and/or payable, if any, is included in daily variation margin on futures contracts in the Statement of Assets and Liabilities. Realized gain or (loss) is recorded upon the expiration or closing of a futures contract. The net realized gain (loss) and change in net unrealized appreciation (depreciation) on futures contracts during the period is presented in the Statement of Operations.
 
Any open futures contracts at period end are presented in the Schedule of Investments under the caption "Futures Contracts". The notional amount at value reflects each contract's exposure to the underlying instrument or index at period end, and is representative of volume of activity during the period unless an average notional amount is presented. Any securities deposited to meet initial margin requirements are identified in the Schedule of Investments. Any cash deposited to meet initial margin requirements is presented as segregated cash with brokers for derivative instruments in the Statement of Assets and Liabilities.
 
5. Purchases and Sales of Investments.
Purchases and sales of securities, other than short-term securities and in-kind transactions, as applicable, are noted in the table below.
 
 
Purchases ($)
Sales ($)
Fidelity Nasdaq Composite Index Fund
143,481,747
272,242,525
 
6. Fees and Other Transactions with Affiliates.
Management Fee. Fidelity Management & Research Company LLC (the investment adviser) and its affiliates provide the Fund with investment management related services for which the Fund pays a monthly management fee that is based on an annual rate of .24% of the Fund's average net assets.
 
Sub-Adviser. Geode Capital Management, LLC (Geode), serves as sub-adviser for the Fund. Geode provides discretionary investment advisory services to the Fund and is paid by the investment adviser for providing these services.
 
Transfer Agent Fees. Fidelity Investments Institutional Operations Company LLC (FIIOC), an affiliate of the investment adviser, is the Fund's transfer, dividend disbursing and shareholder servicing agent. FIIOC receives an asset-based fee of .10% of the Fund's average net assets. FIIOC pays for typesetting, printing and mailing of shareholder reports, except proxy statements.
 
Accounting Fees. Fidelity Service Company, Inc. (FSC), an affiliate of the investment adviser, maintains the Fund's accounting records. The accounting fee is based on the level of average net assets for each month. For the period, the fees were equivalent to the following annualized rates:
 
 
% of Average Net Assets
Fidelity Nasdaq Composite Index Fund
- A
 
A Amount represents less than .005%.
 
Interfund Lending Program. Pursuant to an Exemptive Order issued by the Securities and Exchange Commission (the SEC), the Fund, along with other registered investment companies having management contracts with Fidelity Management & Research Company LLC (FMR), or other affiliated entities of FMR, may participate in an interfund lending program. This program provides an alternative credit facility allowing the Fund to borrow from, or lend money to, other participating affiliated funds. At period end, there were no interfund loans outstanding. Activity in this program during the period for which loans were outstanding was as follows:
 
 
Borrower or Lender
Average Loan Balance
Weighted Average Interest Rate
Interest Expense
Fidelity Nasdaq Composite Index Fund
Borrower
$32,955,667
4.34%
$11,916
 
Interfund Trades. Funds may purchase from or sell securities to other Fidelity Funds under procedures adopted by the Board. The procedures have been designed to ensure these interfund trades are executed in accordance with Rule 17a-7 of the 1940 Act. Any interfund trades are included within the respective purchases and sales amounts shown in the Purchases and Sales of Investments note. During the period, there were no interfund trades.
 
7. Committed Line of Credit.
Certain Funds participate with other funds managed by the investment adviser or an affiliate in a $4.25 billion credit facility (the "line of credit") to be utilized for temporary or emergency purposes to fund shareholder redemptions or for other short-term liquidity purposes. The participating funds have agreed to pay commitment fees on their pro-rata portion of the line of credit, which are reflected in Miscellaneous expenses on the Statement of Operations, and are listed below. During the period, there were no borrowings on this line of credit.
 
 
 
Amount
Fidelity Nasdaq Composite Index Fund
$10,158
 
8. Security Lending.
Funds lend portfolio securities from time to time in order to earn additional income. Lending agents are used, including National Financial Services (NFS), an affiliate of the investment adviser. Pursuant to a securities lending agreement, NFS will receive a fee, which is capped at 9.9% of a fund's daily lending revenue, for its services as lending agent. A fund may lend securities to certain qualified borrowers, including NFS. On the settlement date of the loan, a fund receives collateral (in the form of U.S. Treasury obligations, letters of credit and/or cash) against the loaned securities and maintains collateral in an amount not less than 100% of the market value of the loaned securities during the period of the loan. The market value of the loaned securities is determined at the close of business of a fund and any additional required collateral is delivered to a fund on the next business day. A fund or borrower may terminate the loan at any time, and if the borrower defaults on its obligation to return the securities loaned because of insolvency or other reasons, a fund may apply collateral received from the borrower against the obligation. A fund may experience delays and costs in recovering the securities loaned. Any cash collateral received is invested in the Fidelity Securities Lending Cash Central Fund. Any loaned securities are identified as such in the Schedule of Investments, and the value of loaned securities and cash collateral at period end, as applicable, are presented in the Statement of Assets and Liabilities. Security lending income represents the income earned on investing cash collateral, less rebates paid to borrowers and any lending agent fees associated with the loan, plus any premium payments received for lending certain types of securities. Security lending income is presented in the Statement of Operations as a component of income from Fidelity Central Funds. Affiliated security lending activity, if any, was as follows:
 
 
Total Security Lending Fees Paid to NFS
Security Lending Income From Securities Loaned to NFS
Value of Securities Loaned to NFS at Period End
Fidelity Nasdaq Composite Index Fund
$884,133
$256,925
$4,483,325
 
9. Expense Reductions.
The investment adviser contractually agreed to reimburse the Fund to the extent annual operating expenses exceeded .29% of average net assets. This reimbursement will remain in place through March 31, 2024. Some expenses, for example the compensation of the independent Trustees, and certain miscellaneous expenses such as proxy and shareholder meeting expenses, are excluded from this reimbursement. During the period this reimbursement reduced the Fund's expenses by $2,956,113.
 
Through arrangements with the Fund's custodian, credits realized as a result of certain uninvested cash balances were used to reduce the Fund's expenses by $6,602.
 
10. Other.
A fund's organizational documents provide former and current trustees and officers with a limited indemnification against liabilities arising in connection with the performance of their duties to the fund. In the normal course of business, a fund may also enter into contracts that provide general indemnifications. A fund's maximum exposure under these arrangements is unknown as this would be dependent on future claims that may be made against a fund. The risk of material loss from such claims is considered remote.
 
11. Risk and Uncertainties.
Many factors affect a fund's performance. Developments that disrupt global economies and financial markets, such as pandemics, epidemics, outbreaks of infectious diseases, war, terrorism, and environmental disasters, may significantly affect a fund's investment performance. The effects of these developments to a fund will be impacted by the types of securities in which a fund invests, the financial condition, industry, economic sector, and geographic location of an issuer, and a fund's level of investment in the securities of that issuer. Significant concentrations in security types, issuers, industries, sectors, and geographic locations may magnify the factors that affect a fund's performance.
As a shareholder, you incur two types of costs: (1) transaction costs, which may include sales charges (loads) on purchase payments or redemption proceeds, as applicable and (2) ongoing costs, which generally include management fees, distribution and/or service (12b-1) fees and other Fund expenses. This Example is intended to help you understand your ongoing costs (in dollars) of investing in a fund and to compare these costs with the ongoing costs of investing in other mutual funds.
 
The Example is based on an investment of $1,000 invested at the beginning of the period and held for the entire period (December 1, 2022 to May 31, 2023).
 
Actual Expenses
The first line of the accompanying table provides information about actual account values and actual expenses. You may use the information in this line, together with the amount you invested, to estimate the expenses that you paid over the period. Simply divide your account value by $1,000.00 (for example, an $8,600 account value divided by $1,000.00 = 8.6), then multiply the result by the number in the first line for a class/Fund under the heading entitled "Expenses Paid During Period" to estimate the expenses you paid on your account during this period. If any fund is a shareholder of any underlying mutual funds or exchange-traded funds (ETFs) (the Underlying Funds), such fund indirectly bears its proportional share of the expenses of the Underlying Funds in addition to the direct expenses incurred presented in the table. These fees and expenses are not included in the annualized expense ratio used to calculate the expense estimate in the table below.
 
Hypothetical Example for Comparison Purposes
The second line of the accompanying table provides information about hypothetical account values and hypothetical expenses based on the actual expense ratio and an assumed rate of return of 5% per year before expenses, which is not the actual return. The hypothetical account values and expenses may not be used to estimate the actual ending account balance or expenses you paid for the period. You may use this information to compare the ongoing costs of investing in the Fund and other funds. To do so, compare this 5% hypothetical example with the 5% hypothetical examples that appear in the shareholder reports of the other funds. If any fund is a shareholder of any Underlying Funds, such fund indirectly bears its proportional share of the expenses of the Underlying Funds in addition to the direct expenses as presented in the table. These fees and expenses are not included in the annualized expense ratio used to calculate the expense estimate in the table below.
Please note that the expenses shown in the table are meant to highlight your ongoing costs only and do not reflect any transaction costs. Therefore, the second line of the table is useful in comparing ongoing costs only, and will not help you determine the relative total costs of owning different funds. In addition, if these transactional costs were included, your costs would have been higher.
 
 
 
 
 
Annualized Expense Ratio- A
 
Beginning Account Value December 1, 2022
 
Ending Account Value May 31, 2023
 
Expenses Paid During Period- C December 1, 2022 to May 31, 2023
 
 
 
 
 
 
 
 
 
 
Fidelity® Nasdaq Composite Index® Fund
 
 
 
.28%
 
 
 
 
 
 
Actual
 
 
 
 
 
$ 1,000
 
$ 1,133.20
 
$ 1.49
Hypothetical- B
 
 
 
 
 
$ 1,000
 
$ 1,023.54
 
$ 1.41
 
A   Annualized expense ratio reflects expenses net of applicable fee waivers.
 
B   5% return per year before expenses
 
C   Expenses are equal to the annualized expense ratio, multiplied by the average account value over the period, multiplied by 182/ 365 (to reflect the one-half year period). The fees and expenses of any Underlying Funds are not included in each annualized expense ratio.
 
 
 
 
Board Approval of Investment Advisory Contracts
 
Fidelity Nasdaq Composite Index Fund
 
At its May 2023 meeting, the Board of Trustees, including the Independent Trustees (together, the Board), voted to continue the management contract with Fidelity Management & Research Company LLC (FMR), and the sub-advisory agreements and sub-subadvisory agreements, in each case, where applicable (together, the Advisory Contracts) for the fund, including the fund's sub-advisory agreement with Geode Capital Management, LLC, for two months from June 1, 2023 through July 31, 2023. The Board determined that it will consider the annual renewal of the fund's Advisory Contracts for a full one year period in July 2023, following its review of additional materials provided by FMR.  
 
The Board considered that the approval of the fund's Advisory Contracts will not result in any changes in (i) the investment process or strategies employed in the management of the fund's assets; (ii) the fees and expenses paid by shareholders; (iii) the nature, extent or quality of services provided under the fund's Advisory Contracts; or (iv) the day-to-day management of the fund or the persons primarily responsible for such management. The Board also considered that since its last approval of the fund's Advisory Contracts, FMR had provided additional information on the fund in support of the annual contract renewal process, including competitive analyses on total expenses and management fees and in-depth reviews of fund performance and fund profitability information. The Board concluded that the fund's Advisory Contracts are fair and reasonable, and that the fund's Advisory Contracts should be renewed, without modification, through July 31, 2023, with the understanding that the Board will consider the annual renewal for a full one year period in July 2023.
 
In connection with its consideration of future renewals of the fund's Advisory Contracts, the Board will consider: (i) the nature, extent and quality of services provided to the fund, including shareholder and administrative services and investment performance; (ii) the competitiveness of the management fee and total expenses for the fund; (iii) the costs of the services and profitability, including the revenues earned and the expenses incurred in conducting the business of developing, marketing, distributing, managing, administering, and servicing the fund and its shareholders, to the extent applicable; and (iv) whether there have been economies of scale in respect of the Fidelity funds, whether the Fidelity funds (including the fund) have appropriately benefited from any such economies of scale, and whether there is the potential for realization of any further economies.
 
Based on its evaluation of all of the conclusions noted above, and after considering all factors it believed relevant, the Board ultimately concluded that the fund's management fee structure is fair and reasonable, and that the continuation of the fund's Advisory Contracts should be approved for two months from June 1, 2023 through July 31, 2023.
 
The Securities and Exchange Commission adopted Rule 22e-4 under the Investment Company Act of 1940 (the Liquidity Rule) to promote effective liquidity risk management throughout the open-end investment company industry, thereby reducing the risk that funds will be unable to meet their redemption obligations and mitigating dilution of the interests of fund shareholders.
The Fund has adopted and implemented a liquidity risk management program (the Program) reasonably designed to assess and manage the Fund's liquidity risk and to comply with the requirements of the Liquidity Rule. The Fund's Board of Trustees (the Board) has designated the Fund's investment adviser as administrator of the Program. The Fidelity advisers have established a Liquidity Risk Management Committee (the LRM Committee) to manage the Program for each of the Fidelity Funds. The LRM Committee monitors the adequacy and effectiveness of implementation of the Program and on a periodic basis assesses each Fund's liquidity risk based on a variety of factors including (1) the Fund's investment strategy, (2) portfolio liquidity and cash flow projections during normal and reasonably foreseeable stressed conditions, (3) shareholder redemptions, (4) borrowings and other funding sources and (5) certain factors specific to ETFs including the effect of the Fund's prices and spreads, market participants, and basket compositions on the overall liquidity of the Fund's portfolio, as applicable.
In accordance with the Program, each of the Fund's portfolio investments is classified into one of four defined liquidity categories based on a determination of a reasonable expectation for how long it would take to convert the investment to cash (or sell or dispose of the investment) without significantly changing its market value.
  • Highly liquid investments - cash or convertible to cash within three business days or less
  • Moderately liquid investments - convertible to cash in three to seven calendar days
  • Less liquid investments - can be sold or disposed of, but not settled, within seven calendar days
  • Illiquid investments - cannot be sold or disposed of within seven calendar days
Liquidity classification determinations take into account a variety of factors including various market, trading and investment-specific considerations, as well as market depth, and generally utilize analysis from a third-party liquidity metrics service.
The Liquidity Rule places a 15% limit on a fund's illiquid investments and requires funds that do not primarily hold assets that are highly liquid investments to determine and maintain a minimum percentage of the fund's net assets to be invested in highly liquid investments (highly liquid investment minimum or HLIM).  The Program includes provisions reasonably designed to comply with the 15% limit on illiquid investments and for determining, periodically reviewing and complying with the HLIM requirement as applicable.
At a recent meeting of the Fund's Board of Trustees, the LRM Committee provided a written report to the Board pertaining to the operation, adequacy, and effectiveness of the Program for the period December 1, 2021 through November 30, 2022.  The report concluded that the Program is operating effectively and is reasonably designed to assess and manage the Fund's liquidity risk.  
 
1.795567.119
EIF-SANN-0723


Item 2.

Code of Ethics


Not applicable.

 

Item 3.

Audit Committee Financial Expert


Not applicable.


Item 4.

Principal Accountant Fees and Services


Not applicable.


Item 5.

Audit Committee of Listed Registrants


Not applicable.


Item 6.  

Investments


(a)

Not applicable.


(b)

Not applicable


Item 7.

Disclosure of Proxy Voting Policies and Procedures for Closed-End Management Investment Companies


Not applicable.


Item 8.

Portfolio Managers of Closed-End Management Investment Companies


Not applicable.


Item 9.  

Purchase of Equity Securities by Closed-End Management Investment Company and Affiliated Purchasers


Not applicable.


Item 10.

Submission of Matters to a Vote of Security Holders


There were no material changes to the procedures by which shareholders may recommend nominees to the Fidelity Concord Street Trusts Board of Trustees.


Item 11.

Controls and Procedures


(a)(i)  The President and Treasurer and the Chief Financial Officer have concluded that the Fidelity Concord Street Trusts (the Trust) disclosure controls and procedures (as



defined in Rule 30a-3(c) under the Investment Company Act) provide reasonable assurances that material information relating to the Trust is made known to them by the appropriate persons, based on their evaluation of these controls and procedures as of a date within 90 days of the filing date of this report.


(a)(ii)  There was no change in the Trusts internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act) that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the Trusts internal control over financial reporting.


Item 12.

Disclosure of Securities Lending Activities for Closed-End Management

Investment Companies


Not applicable.



Item 13.

Exhibits


(a)

(1)

Not applicable.

(a)

(2)

Certification pursuant to Rule 30a-2(a) under the Investment Company Act of 1940 (17 CFR 270.30a-2(a)) is filed and attached hereto as Exhibit 99.CERT.

(a)

(3)

Not applicable.

(b)


Certification pursuant to Rule 30a-2(b) under the Investment Company Act of 1940 (17 CFR 270.30a-2(b)) is furnished and attached hereto as Exhibit 99.906CERT.




SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Fidelity Concord Street Trust



By:

/s/Stacie M. Smith


Stacie M. Smith


President and Treasurer



Date:

July 20, 2023


Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.



By:

/s/Stacie M. Smith


Stacie M. Smith


President and Treasurer



Date:

July 20, 2023



By:

/s/John J. Burke III


John J. Burke III


Chief Financial Officer



Date:

July 20, 2023

 






EX-99.CERT 2 ex99cert.htm EX99CERT.HTM Form of Certification required from Principal Executive Officer and Principal Financial Officer in connection with each Form N

                                                       Exhibit EX-99.CERT

     

I, Stacie M. Smith, certify that:



1.

I have reviewed this report on Form N-CSR of Fidelity Concord Street Trust;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the financial statements are required to include a statement of cash flows) of the registrant as of, and for, the periods presented in this report;

4.

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report based upon such evaluation; and

d.

Disclosed in this report any change in the registrant s internal control over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant s internal control over financial reporting; and





5.

The registrant's other certifying officer(s) and I have disclosed to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.



Date:

 July 20, 2023

/s/Stacie M. Smith

Stacie M. Smith

President and Treasurer









I, John J. Burke III, certify that:

1.

I have reviewed this report on Form N-CSR of Fidelity Concord Street Trust;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the financial statements are required to include a statement of cash flows) of the registrant as of, and for, the periods presented in this report;

4.

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report based upon such evaluation; and

d.

Disclosed in this report any change in the registrant s internal control over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant s internal control over financial reporting; and

5.

The registrant's other certifying officer(s) and I have disclosed to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):





a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.



Date:

July 20, 2023

/s/John J. Burke III

John J. Burke III

Chief Financial Officer















EX-99.906 CERT 3 ex99906cert.htm EX99906CERT.HTM Exhibit 99

Exhibit EX-99.906CERT





Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code)



In connection with the attached Report of Fidelity Concord Street Trust (the Trust ) on Form N-CSR to be filed with the Securities and Exchange Commission (the Report ), each of the undersigned officers of the Trust does hereby certify that, to the best of such officer s knowledge:



1.

The Report fully complies with the requirements of 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Trust as of, and for, the periods presented in the Report.



Dated: July 20, 2023





/s/Stacie M. Smith

Stacie M. Smith

President and Treasurer





 

Dated: July 20, 2023





/s/John J. Burke III

John J. Burke III

Chief Financial Officer







A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Trust and will be retained by the Trust and furnished to the Securities and Exchange Commission or its staff upon request.







GRAPHIC 4 img90917_1.jpg IMG90917_1.JPG begin 644 img90917_1.jpg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end GRAPHIC 5 img90917_4.jpg IMG90917_4.JPG begin 644 img90917_4.jpg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end GRAPHIC 6 img90917_2.jpg IMG90917_2.JPG begin 644 img90917_2.jpg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end GRAPHIC 7 img90917_6.jpg IMG90917_6.JPG begin 644 img90917_6.jpg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end